<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000147" GROUP_ID="DEMENTIA" ID="913499081216140354" MERGED_FROM="" MODIFIED="2010-06-10 16:21:59 +0200" MODIFIED_BY="Sue Marcus" REVIEW_NO="8" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2010-06-10 16:21:59 +0200" MODIFIED_BY="Sue Marcus">
<TITLE>Nimodipine for primary degenerative, mixed and vascular dementia</TITLE>
<CONTACT MODIFIED="2010-06-10 16:21:59 +0200" MODIFIED_BY="Sue Marcus"><PERSON ID="8725" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jess</FIRST_NAME><LAST_NAME>López-Arrieta</LAST_NAME><POSITION>Responsable del Servicio de Geriatría y de la Unidad de Memoria</POSITION><EMAIL_1>pdarrieta@wanadoo.es</EMAIL_1><EMAIL_2>jlopezar.hgugm@salud.madrid.org</EMAIL_2><ADDRESS><DEPARTMENT>Geriatric Department</DEPARTMENT><ORGANISATION>Hospital Universitario La Paz-Cantoblanco</ORGANISATION><ADDRESS_1>Ctra de Colmenar km 14,500</ADDRESS_1><CITY>Madrid</CITY><ZIP>28049</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 915 86 76 14</PHONE_1><PHONE_2>+ 34 610 926 479</PHONE_2><FAX_1>+34 915 86 75 82</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-06-10 16:21:59 +0200" MODIFIED_BY="Sue Marcus"><PERSON ID="7198" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Jacqueline</FIRST_NAME><LAST_NAME>Birks</LAST_NAME><SUFFIX>MA (Cantab) MSc (Oxon) C Stat</SUFFIX><POSITION>NIHR Senior Medical Statistician</POSITION><EMAIL_1>jacqueline.birks@csm.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Statistics in Medicine</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Wolfson College</ADDRESS_1><ADDRESS_2>Linton Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6UD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 (0)1865 284403</PHONE_1></ADDRESS></PERSON><PERSON ID="8725" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jess</FIRST_NAME><LAST_NAME>López-Arrieta</LAST_NAME><POSITION>Responsable del Servicio de Geriatría y de la Unidad de Memoria</POSITION><EMAIL_1>pdarrieta@wanadoo.es</EMAIL_1><EMAIL_2>jlopezar.hgugm@salud.madrid.org</EMAIL_2><ADDRESS><DEPARTMENT>Geriatric Department</DEPARTMENT><ORGANISATION>Hospital Universitario La Paz-Cantoblanco</ORGANISATION><ADDRESS_1>Ctra de Colmenar km 14,500</ADDRESS_1><CITY>Madrid</CITY><ZIP>28049</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 915 86 76 14</PHONE_1><PHONE_2>+ 34 610 926 479</PHONE_2><FAX_1>+34 915 86 75 82</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-06-10 14:40:00 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="25" MONTH="5" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="3" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="25" MONTH="11" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2010-05-19 15:18:25 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-05-19 15:18:06 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>An update search was performed for this review on 26 March 2010. No new studies were identified for inclusion within the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-05-19 15:18:25 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-05-19 15:18:21 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>An update search of January 2008 identified six studies for consideration by the authors.<BR/>
<BR/>A new RCT has been included (Pantoni 2005) although there is insufficient data to add data from this study to the meta-analysis. There are now 15 studies included. In this update five new trials have been excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-05-19 15:18:25 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="4" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-06-10 15:17:21 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Evidence of some short-term benefit of nimodipine for people with dementia</TITLE>
<SUMMARY_BODY>
<P>The efficacy of nimodipine, a calcium channel blocker, has been tested in randomized controlled trials for the treatment of dementia, particularly Alzheimer's disease and multi-infarct dementia, the commonest forms of dementia in older people. The rationale for its use is to restrict the influx of calcium ions into neurons, and, by vasodilatation, to improve blood flow to the brain. This review found evidence of some short-term benefit attributable to nimodipine, mainly in measures of cognitive function and global impression, but not in activities on daily living, for patients with degenerative and multi-infarct dementia, and mixed dementia. Nimodipine is well tolerated with a low rate of adverse effects similar to that associated with placebo. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-06-10 15:15:47 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Dementia is an age-associated syndrome most commonly due to Alzheimer's disease (AD) and/or cerebrovascular disease. </P>
<P>Calcium has an important role in regulating brain functions. Calcium ions link membrane excitation to subsequent intracellular molecular responses. Age-associated changes in calcium homoeostasis have possible repercussions on higher cortical functions. Nimodipine is an isopropyl calcium channel blocker which readily crosses the blood-brain barrier. Its primary action is to reduce the number of open calcium channels in cell membranes, thus restricting influx of calcium ions into cells.</P>
<P>The usefulness of nimodipine in patients with Alzheimer's disease and vascular dementia and unspecified dementia is still controversial. In spite of the uncertainties about its efficacy in dementia, nimodipine is currently frequently prescribed for cognitive impairment and dementia in several continental European countries. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the clinical efficacy of nimodipine for the manifestations of dementia, in unclassified disease and in the major subtypes - Alzheimer's disease, cerebrovascular disease, and mixed Alzheimer's and cerebrovascular disease.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-06-10 15:15:47 +0100" MODIFIED_BY="[Empty name]">
<P>We searched <A HREF="http://www.medicine.ox.ac.uk/alois">ALOIS</A> - the Cochrane Dementia and Cognitive Improvement Group&#8217;s Specialized Register on 26 March 2010 using the term: nimodipine</P>
<P>The search of August 2005 identified two studies which were excluded. The search of January 2008 identified six new studies for consideration, only one met the inclusion criteria for this meta-analysis although the data were difficult to interpret and they were not included in this update (Pantoni 2005). The latest search of March 2010 identified no new studies for inclusion within the review. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All unconfounded, double-blind, randomized trials in which treatment with nimodipine was administered for more than a day and compared with placebo in patients with dementia, of unclassified type or attributable to Alzheimer's disease, cerebrovascular disease, or mixed Alzheimer's and cerebrovascular disease.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted independently by the reviewers and the odds ratio (95% CI) or the average difference (95% CI) were estimated. Both intention-to-treat and on-treatment results were extracted.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-10-13 13:44:42 +0100" MODIFIED_BY="Helen Collins">
<P>Fifteen trials were included which tested two treatment regimes, 90 and 180 mg/day of nimodipine for 12, 24 weeks and 52 weeks. Two trials included only patients with Alzheimer's disease (AD), 10 trials included only patients with cerebrovascular dementia (CVD), and three trials included patients with AD, CVD and mixed disease. Available outcome data from nine trials (2492 patients) cover the domains of cognitive function, activities of daily living, global clinical state, safety and tolerability. By pooling available data from all trials, whatever the diagnosis of the patients included, this review found benefit associated with nimodipine (90 mg/day at 12 weeks) compared with placebo on the SCAG scale (WMD -7.59, 95% CI -9.87 to -5.31, P&lt;0.00001), on clinical global impression (WMD -0.87, 95% CI -1.07 to -0.67, P&lt;0.00001) and cognitive function (SMD 0.61, 95% CI 0.42 to 0.81, P&lt;0.00001) but not on scales assessing activities of daily living. When the AD trials and the VD trials were pooled separately, similar significant results were found for the 90 mg/day dose of nimodipine at 12 weeks.</P>
<P>Drop-out rates were low in the trials, affecting similar proportions of treatment and placebo groups. Nimodipine is well tolerated with a low rate of adverse effects similar to that associated with placebo. There were slightly more adverse cerebrovascular events, and adverse events due to blood problems, associated with placebo than with nimodipine, and adverse autonomic events were slightly more common with nimodipine than with placebo.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Nimodipine can be of some benefit in the treatment of patients with features of dementia due to unclassified disease or to Alzheimer's disease, cerebrovascular disease, or mixed Alzheimer's and cerebrovascular disease. It appears to be well tolerated with few side effects. Data were not available from several trials, a total of more than 500 patients. A meta-analysis of individual patient data from all trials is desirable. Dementia is a chronic disorder and the short-term benefits of nimodipine demonstrated in the trials reviewed do not justify its use as a long-term anti-dementia drug. New research must focus on longer term outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-06-10 15:17:21 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-13 13:45:31 +0100" MODIFIED_BY="Helen Collins">
<P>Dementia is an age-associated condition and Alzheimer's disease (AD) and cerebrovascular disease are its commonest causes. Over the years 1975 to 2000, the world population increased by a quarter to around six billion people. Increases in older age groups have been disproportionately large ranging from 68% in the 65 to 74 age group, 84% at ages 75 to 79, to 92% for people over 80 years of age.</P>
<P>Calcium has a pervasive role in regulating brain functions (e.g. plasticity, glucose metabolism, neurotransmitter synthesis and release, axonal transport). Calcium ions are ubiquitous messengers linking membrane excitation to subsequent intracellular molecular responses. Changes in calcium homoeostasis are an aspect aging that may have implications for higher cerebral functions.</P>
<P>Nimodipine [(2-methoxyethyl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5- pyrinedicarboxylate, an anti-hypertensive agent, is an isopropyl calcium channel blocker; it has lipophilic properties and can easily cross the blood-brain barrier. Its primary action is to bind to L-type receptors and reduce the number of open channels conveying calcium ions through the cell membrane, thereby restricting influx of calcium ions into cells. It also has anti-vaso constrictive and vasodilatatory action on arterioles.</P>
<P>In experimental situations inhibition of calcium entry can protect neurons against a range of damaging influences, and this suggests that nimodipine may have neuroprotective potential, particularly against transient ischaemia and hypoxia. The density of nimodipine binding sites is especially high in specific regions of the hippocampus, caudate nucleus, and cerebral cortex, and may have a role in learning and memory processes. Binding sites are found on neurons and cerebrovascular cells, and its action may influence both neural conduction and cerebral blood flow.</P>
<P>Unlike other calcium channel blockers, nimodipine produces its anti-vasoconstrictive and anti-ischaemic effects primarily in the brain at low dosage, most evidently on smaller arterioles determining regional blood flow. It can also modulate other calcium-dependent processes such as acetylcholine release, potentially of benefit in improving memory functions in Alzheimer's disease.</P>
<P>In spite of the uncertainties about its efficacy in dementia, nimodipine is currently frequently prescribed for cognitive impairment and dementia in several continental European countries.</P>
<P>This review will be conducted, if possible, in two phases; the current review is based on evidence from published data only. The second phase will be based on individual-patient data. This will only be possible if the company who sponsored most of the nimodipine clinical trials allows us access to their data.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the clinical efficacy and safety of nimodipine for the manifestations of dementia, whether unclassified or categorised to the major forms of Alzheimer's disease, cerebrovascular disease, and mixed Alzheimer's and cerebrovascular dementia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-06-10 15:17:21 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All relevant unconfounded, double-blind, randomized, placebo-controlled trials of nimodipine administered for longer than one day were selected. Trials in which the allocation to treatment or placebo was not random, or in which treatment allocation was not concealed, were excluded. Prior knowledge of treatment allocation may lead to biased patient allocation (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with unclassified dementia, Alzheimer's disease, cerebrovascular dementia or mixed Alzheimer's and cerebrovascular dementia as diagnosed by accepted criteria such as DSM III-R, NINCDS-ADRDA (National Institute of Neurological, Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders) criteria, and NINCDS-AIREN (National Institute of Neurological Disorders and Stroke or ICD (International Classification of Diseases).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Nimodipine at any dose <BR/>2. Placebo </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcomes of interest were: </P>
<P>1. Cognitive function (as measured by psychometric tests)<BR/>2. Global scales (multidimensional)<BR/>3. Global impression<BR/>4. Functional performance<BR/>4. Behavioural disturbance<BR/>5. Dependency (e.g. institutionalization)<BR/>6. Quality of life<BR/>7. Effect on carer<BR/>8. Death<BR/>9. Acceptability of treatment (as measured by withdrawal rate from trial)<BR/>10. Safety (as measured by the incidence of adverse effects, including adverse effects leading to withdrawal</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-06-10 15:17:21 +0100" MODIFIED_BY="[Empty name]">
<P>We searched ALOIS (<A HREF="http://www.medicine.ox.ac.uk/alois">www.medicine.ox.ac.uk/alois</A>) - the Cochrane Dementia and Cognitive Improvement Group&#8217;s Specialized Register on 26 March 2010. The search term used was: nimodipine.</P>
<P>ALOIS is maintained by the Trials Search Co-ordinator and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in healthy. The studies are identified from:  </P>
<OL>
<LI>Monthly searches of a number of major healthcare databases: Medline, Embase, Cinahl, Psycinfo and Lilacs</LI>
<LI>Monthly searches of a number of trial registers: ISRCTN; UMIN (Japan's Trial Register); the WHO portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others)</LI>
<LI>Quarterly search of <I>The Cochrane Library</I>&#8217;s Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Six-monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses</LI>
</OL>
<P>To view a list of all sources searched for ALOIS see <A HREF="http://www.medicine.ox.ac.uk/alois/content/about-alois">About ALOIS</A> on the ALOIS website.</P>
<P>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the &#8216;methods used in reviews&#8217; section within the editorial information about the <A HREF="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html">Dementia and Cognitive Improvement Group</A>.</P>
<P>Additional searches were performed in many of the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up-to-date and as comprehensive as possible. The search strategies used can be seen in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>Searches carried out in the previous version(s) of the review can be viewed in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>The latest search (March 2010) retrieved a total of 105 results. After a first-assess and a de-duplication of these results the authors were left with two references to further assess. After being assessed they were excluded.</P>
<P>Further sources of citations were pharmaceutical companies. Pharmacological companies were also contacted for information on trials and individual patient data. We are still in the process of obtaining this.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-10 16:54:18 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="3">Selection of trials</HEADING>
<P>A single reviewer (JLA) discarded citations judged as irrelevant on the basis of the title of the publication and its abstract. In the presence of any indication that an article could possibly be relevant, it was retrieved for further assessment.</P>
<P>Two reviewers (JB and JLA) independently selected the trials for inclusion in the review from the culled citation list. Disagreements were resolved by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>The same two reviewers (JB and JLA) assessed the methodological quality of each trial. The quality of the methodology of each selected trial was rated using the Cochrane Collaboration Handbook (<LINK REF="REF-Mulrow-1996" TYPE="REFERENCE">Mulrow 1996</LINK>) in Category A, Category B and Category C (from low to high risk of bias).</P>
<P>Empirical research has shown that lack of adequate allocation concealment is associated with bias. Trials with unclear concealment measures have been shown to yield more pronounced estimates of treatment effects than trials that have taken adequate measures to conceal allocation schedules, but less pronounced than inadequately concealed trials (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Trials were included if they conformed to categories A or B, and those falling into category C were excluded.</P>
<P>Other aspects of trial quality were not assessed by a scoring system although details were noted of blinding, whether intention-to-treat analyses were extractable from the published data, and the number of patients lost to follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Data were extracted independently by the same two reviewers (JB and JLA) and cross-checked. Any discrepancies were solved by discussion.</P>
<P>If possible, data were sought on every patient for each outcome measure. To allow an intention-to-treat analysis, the data were sought irrespective of compliance, whether or not the patient was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. Where dichotomous data were missing, the patients were assumed to have suffered the least favourable outcome. If continuous data were not available in the publications, data for an "on-treatment" analysis were abstracted and indicated as such.</P>
<P>The score stated as baseline assessment was the latest available score prior to the randomization.</P>
<P>In studies where a cross-over design was used, only data from the first treatment period were included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>For continuous or ordinal variables (such as psychometric test scores, clinical global impression scales, functional and quality of life scales) the main outcomes of interest were the final assessment score (corrected for baseline) and the change in score from baseline (i.e. pre-randomization or at randomization) to the final assessment . The mean treatment effect and the standard errors for each trial were calculated from reported information if not stated explicitly in the text. When the only statistic available was an F- or t-value, the standard deviation calculated from these values was applied across all treatment groups.</P>
<P>If ordinal scale data appeared to be approximately normally distributed, or if the analysis performed by the investigators suggested that parametric tests were appropriate, the outcome measures were treated as continuous data.</P>
<P>For binary outcomes such as institutionalization, global impression and death, the end-point itself is of interest and the Peto method of the 'typical odds ratio' was used.</P>
<P>A test for heterogeneity of the treatment effect between the trials was made using a standard chi-square statistic. If a test of heterogeneity was negative then a weighted estimate of the typical treatment effect across trials, the 'typical odds ratio' (i.e. the odds of an unfavourable outcome amongst treatment-allocated patients to the corresponding odds amongst controls) was calculated using Peto's log-rank test adapted for ordinal data (EBCTCG, 1990). If, however, there was evidence of heterogeneity of the treatment effect between trials then either only homogeneous results were pooled, or a random-effects model was used (in which case the confidence intervals would be broader than those of a fixed-effects model).</P>
<P>Additional hypotheses to be tested were that nimodipine had no differential effect, when compared with placebo, for certain subgroups of patients:</P>
<P>1. Unclassified dementia<BR/>2. Alzheimer's disease<BR/>3. Vascular dementia<BR/>4. Mixed Alzheimer's and vascular dementia<BR/>5. Dose (90 and 180 mg/day)<BR/>6. Duration of treatment ( = &lt;12 weeks or &gt;12 weeks)<BR/>7. Severity of dementia at baseline (as defined by each cognitive scale, for example mild, MMSE greater than 17, and moderate MMSE 17-10)</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-13 14:50:38 +0100" MODIFIED_BY="Helen Collins">
<STUDY_DESCRIPTION MODIFIED="2008-10-13 14:50:38 +0100" MODIFIED_BY="Helen Collins">
<P>Fifteen trials were identified that met the criteria for inclusion in this updated review. The oldest were reported in 1985, and the latest in 2005. Most were supported by pharmaceutical companies, particularly Bayer. One author (<LINK REF="STD-Morich-1996" TYPE="STUDY">Morich 1996</LINK>) reported two trials, carried out using an identical protocol and with very similar baseline characteristics. In his report Morich pools the results from the trials and therefore we report <LINK REF="STD-Morich-1996" TYPE="STUDY">Morich 1996</LINK> as one trial. The one identified in the last bibliographic search is a 52-week randomized clinical trial for patients with subcortical vascular dementia but data has not been included because it is not clear who is included in any of the analyses, in spite of the fact non-published data has been provided by the authors (<LINK REF="STD-Pantoni-2005" TYPE="STUDY">Pantoni 2005</LINK>).<BR/>
<BR/>The non-specificity of the effects of nimodipine in terms of the aetiology of dementia was reflected in the range of diagnoses included. Ten trials were restricted to cerebrovascular dementia (CVD), two were restricted to primary degenerative dementia (PDD), the other three trials included the range of dementias, AD, CVD and mixed diagnosis (MIXED), described as "organic brain syndrome" in one older trial. The Hachinski Ischaemic Score (HIS) was frequently used in the inclusion criteria, together with DSM-III criteria.</P>
<P>The diversity of the outcome measures, and the unclear and incomplete reporting of several of the trials, greatly constrained the pooling of results. See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Methods</HEADING>
<P>All trials were randomized, placebo-controlled and double-blind; 12 trials were of parallel group design, and two were of cross-over design. The length of treatment was 12 weeks in 7 of the parallel group trials, 24 weeks in three trials, and 26 weeks in two trials. One cross-over trial was 2 x 6 months and one was 2 x 8 weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>A total of 3166 patients were included; they had mild to moderate dementia, except in two studies, one of which described its patients as severely demented (<LINK REF="STD-Besson-1988" TYPE="STUDY">Besson 1988</LINK>), and the other included patients with MMSE scores as low as 4 (<LINK REF="STD-Branconnier-1988" TYPE="STUDY">Branconnier 1988</LINK>). In all trials, extensive exclusion criteria were employed to ensure the omission of people with other serious illnesses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>Each trial was designed to compare nimodipine with placebo. The dose was fixed at either 90 mg/day or 180 mg/day, taken in three equal parts. All the trials used 90 mg/day in one arm, placebo in a second, and two trials had a third arm of 180 mg/day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome measures</HEADING>
<P>The outcome measures fell within the general groupings of clinical global impression, functional performance, behavioural disturbance and psychometric scores. Within these groups there was a wide variety of scales. Some of the better known were used in a few of the trials, but there were many scales that are less well known and display varying degrees of comparability despite being used to measure the same outcome.</P>
<P>The following outcomes were recorded:<BR/>(*References indicate the outcomes with reported data usable for this review.)</P>
<P>1) Scores of global function:<BR/>*CGIC - Clinical global impression of change (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>CGRS - Clinician's global rating score<BR/>CIBI - Clinician interview based impression<BR/>FCCA - Final comprehensive consensus assessment<BR/>GBS - Gottfries, Brane and Steen scale<BR/>GDS - Global deterioration scale<BR/>RGRS - relatives' global rating score<BR/>*SCAG - Sandoz Clinical assessment-Geriatric (<LINK REF="REF-Shader-1974" TYPE="REFERENCE">Shader 1974</LINK>)</P>
<P>There are two types of global assessment. An example of the first type is the Clinical Global Impression of Change (CGIC) , which provides an overall categorical assessment of the patient relative to baseline. It consists of two global scales. Severity of illness is rated from 1 (normal) to 7 (extremely ill). Global improvement is rated from 1 (very much improved) to 7 (very much worse), with baseline at 4 for everybody. Zero denotes "not assessed" in both scales. The second type of Global Scale, such as the Sandoz Clinical Assessment - Geriatric (SCAG), provides an assessment on an approximately continuous scale, which is divided into sections to cover 18 symptom areas rated on a 7-point scale (1 = not present to 7 = severe) and an overall global assessment. The areas are mood depression, confusion, mental alertness, motivation initiative, irritability, hostility, bothersomeness, indifference to surroundings, unsociability, uncooperativeness, emotional lability, fatigue, self-care, appetite, dizziness, anxiety, impairment of recent memory, disorientation, and overall impression of patient. Each time point provides a separate assessment. Geriatric Evaluation by Relative's Rating Instrument (GERRI) (<LINK REF="REF-Schwartz-1983" TYPE="REFERENCE">Schwartz 1983</LINK>) consists of 49 questions, each rated on a 5-point frequency scale, designed to assess the frequency of typical behavioural disturbances and complaints in cognitive functioning, social functioning and mood. The higher score indicates greater impairment. This is derived from a semi structured interview with the carer and can be considered a global scale. Although it is an outcome measure in one included trial, it has not been included in the efficacy analysis of this review</P>
<P>2) Scores of physical function:<BR/>FLS - Functional life score<BR/>*IADL - Instrumental activities of daily living<BR/>London psychogeriatric scale<BR/>PDS - Progressive deterioration scale<BR/>*PSMS - Physical self maintenance scale<BR/>RDRS-II - Rapid disability rating scale<BR/>Assessment of functional status is needed for evaluation of the efficacy of therapeutic interventions in dementia patients. The performance of instrumental activities of daily living functions is usually assessed by an informant close to the patient. Only two rating scales were dedicated to the assessment of the ability to perform the routine functions of daily living, the Physical and Instrumental Activities of Daily Living (P IADL) (<LINK REF="REF-Lawton-1969" TYPE="REFERENCE">Lawton 1969</LINK>) and the Performances Test of Activities of Daily Living (PTADL) (<LINK REF="REF-Kurianski-1976" TYPE="REFERENCE">Kurianski 1976</LINK>). PIADL scores 1(yes)/0(no) in 8 items that assesses telephoning, shopping, cooking, housekeeping, laundry, transportation, self-medication and money. PTADL assesses whether the patient performs each of the requested tasks without (score = 0) or with help (score = 1).</P>
<P>3) Scores of cognition:<BR/>ADAS-cog Alzheimer's disease assessment score, cognitive component (<LINK REF="REF-Rosen-1984" TYPE="REFERENCE">Rosen 1984</LINK>)<BR/>AMTS - Abbreviated mental test score<BR/>CAMCOG - CAMDEX cognitive examination<BR/>Everyday memory questionnaire<BR/>Kendrick battery object learning test<BR/>Kendrick digit copying task<BR/>Letter cancellation task<BR/>Mattis dementia scale<BR/>*MMSE - Mini mental state rating scale (<LINK REF="REF-Folstein-1975" TYPE="REFERENCE">Folstein 1975</LINK>)<BR/>NART - National adult reading test<BR/>PRM - Rey profile of memory output<BR/>Randt memory test<BR/>Selective reminding test<BR/>WAIS - digit span test<BR/>*Wechsler memory scale (<LINK REF="REF-Wechsler-1945" TYPE="REFERENCE">Wechsler 1945</LINK>)<BR/>These comprise subtests that assess specific domains of cognition such as memory, language, attention, orientation, perception and praxis. Cognitive tests, developed to test adults with a range of abilities and conditions, such as the Wechsler Adult Intelligence Test- Revised (WAIS-R) (<LINK REF="REF-Wechsler-1981" TYPE="REFERENCE">Wechsler 1981</LINK>) have been used in these trials.</P>
<P>Memory tests form a subdivision of cognitive tests and were originally developed for the appraisal of major dimensions of memory function in adults. They were required for diagnostic and screening purposes and provided insight into various areas of memory functioning. Such tests are the Wechsler Memory Scale (WMS) (<LINK REF="REF-Wechsler-1987" TYPE="REFERENCE">Wechsler 1987</LINK>), and the Randt Memory Test (RMT) (<LINK REF="REF-Randt-1980" TYPE="REFERENCE">Randt 1980</LINK>).<BR/>Patients with cognitive impairment can complete only a small section of these standard tests and therefore specific cognitive tests have been developed for them:</P>
<P>- MMSE is in widespread use for evaluating cognitive function. It covers orientation, immediate recall, attention and calculation, delayed recall and language. The maximum score of 30 indicates no impairment.</P>
<P>- ADAS-Cog (<LINK REF="REF-Rosen-1984" TYPE="REFERENCE">Rosen 1984</LINK>) covers the relevant domains and ability ranges, and is sensitive to the changes of interest in clinical trials of anti-dementia drugs.</P>
<P>- Randt Memory Test (<LINK REF="REF-Randt-1980" TYPE="REFERENCE">Randt 1980</LINK>): is specifically designed for longitudinal trials, including trials of possible memory enhancement with drugs, of subjects with mild to moderate memory loss that can result from organic brain disease, and this includes AD. The test is focused on transfer to, and retrieval from long-term memory. It consists of seven subtests: general information, five item learning, digit span, paired words, short story, picture recognition, and incidental learning, and from these three total scores are derived (acquisition, recall and memory index). The five items and paired words resemble items found in the BSRT, and the digit span resembles the same item of the WMS. A zero score indicates the most severe cognitive impairment.</P>
<P>- Short Cognitive performance Test (SKT) assesses disturbances of attention and memory (<LINK REF="REF-Erzigkeit-1986" TYPE="REFERENCE">Erzigkeit 1986</LINK>; <LINK REF="REF-Kim-1993" TYPE="REFERENCE">Kim 1993</LINK>).</P>
<P>- Wechsler Memory Scale (WMS) has been used widely for memory testing, but criticized because it measures learning rather than memory. It consists of seven subtests, information, orientation, mental control, logical memory, digit span, visual reproduction, and associate learning. The total score is the sum of the subtest scores</P>
<P>- Revised Wechsler Adult Intelligence Scale (WAIS-R) (<LINK REF="REF-Wechsler-1987" TYPE="REFERENCE">Wechsler 1987</LINK>), comprises a series of brief subtests, some taken from the WMS, each measuring a different facet of memory, which are summarised into 5 composite scores and finally 2 major scores using weights prescribed by Wechsler. Some subtests of the Revised Wechsler Adult Intelligence Scale (WAIS-R) are identical to those of the WMS-R although the primary purposes of the tests are different.</P>
<P>The numbers of patients withdrawing before the end of treatment, the numbers suffering adverse events by category of event, and withdrawals due to adverse event were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statistical analysis</HEADING>
<P>The trial reports showed that nearly all outcomes were treated as continuous variables. The CGI was usually analysed as a continuous variable, treating the ratings of 1 to 7 as scores.</P>
<P>The mean treatment effects and the standard errors for each trial were calculated from reported information if not stated explicitly in the text. When the only statistic available was an F- or t- value, the standard deviation calculated from these values was applied across all treatment groups.</P>
<P>The meta-analyses compare nimodipine with placebo in three populations, patients with any type of dementia, primary degenerative dementia and vascular dementia.</P>
<P>When the same rating scale or test is used in all trial in a meta-analysis the weighted mean difference is calculated.</P>
<P>The trials pooled for the meta-analyses of cognitive function, and that of activities of daily living, used various scales and a standardized mean difference is calculated. It is sometimes necessary to change the sign on the treatment means in these meta-analyses so that improvement is indicated in the same direction for all scales. The details are shown below.</P>
<P>Cognitive function:<BR/>
<LINK REF="STD-Ban-1990" TYPE="STUDY">Ban 1990</LINK> - MMSE<BR/>
<LINK REF="STD-Dorn-1985" TYPE="STUDY">Dorn 1985</LINK> - Digit symbol<BR/>
<LINK REF="STD-Ferrario-1993" TYPE="STUDY">Ferrario 1993</LINK> - Randt memory Index<BR/>
<LINK REF="STD-Fischhof-1989" TYPE="STUDY">Fischhof 1989</LINK> - SKT (change sign)<BR/>
<LINK REF="STD-Morich-1996" TYPE="STUDY">Morich 1996</LINK> 1996 - MMSE<BR/>
<LINK REF="STD-Pantoni-2000" TYPE="STUDY">Pantoni 2000</LINK> - MMSE<BR/>
<LINK REF="STD-Tobares-1989" TYPE="STUDY">Tobares 1989</LINK> - SCAG- cognitive dysfunction (change sign)</P>
<P>Activities of Daily Living<BR/>
<LINK REF="STD-Morich-1996" TYPE="STUDY">Morich 1996</LINK> - GERRI<BR/>
<LINK REF="STD-Pantoni-2000" TYPE="STUDY">Pantoni 2000</LINK> - IADL<BR/>
<LINK REF="STD-Tobares-1989" TYPE="STUDY">Tobares 1989</LINK> - PADL</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Most trials reported the analyses of participants who completed the trial, (completers) or the "valid for efficacy" population. This second population excludes those with poor compliance, protocol violations or use or health problems. These exclusions may seriously bias results.</P>
<P>
<LINK REF="STD-Pantoni-2000" TYPE="STUDY">Pantoni 2000</LINK> reported analyses based on the intention-to treat (ITT) and the valid-for-efficacy population. <LINK REF="STD-Morich-1996" TYPE="STUDY">Morich 1996</LINK> used the last observation carried forward (LOCF). <LINK REF="STD-Branconnier-1988" TYPE="STUDY">Branconnier 1988</LINK> also used the LOCF population but only if patients completed 10 of 12 weeks. The meta-analyses were carried out on the basis of the results from the analyses of data of those who completed treatment (completers' analyses).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-13 13:56:18 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="3">Update 2008</HEADING>
<P>This last search yield six new articles (<LINK REF="STD-Zirm-1994" TYPE="STUDY">Zirm 1994</LINK>, <LINK REF="STD-Liu-SN-2002" TYPE="STUDY">Liu SN 2002</LINK>, <LINK REF="STD-Sui-2003" TYPE="STUDY">Sui 2003</LINK>, <LINK REF="STD-Liu-XD-2005" TYPE="STUDY">Liu XD 2005</LINK>, <LINK REF="STD-Pantoni-2005" TYPE="STUDY">Pantoni 2005</LINK>, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>), none of them fulfil the inclusion criteria except one that is a randomized controlled trial whose data has not been included in this meta-analysis for the reasons given above (<LINK REF="STD-Pantoni-2005" TYPE="STUDY">Pantoni 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Update 2005</HEADING>
<P>The new search identified two more papers (<LINK REF="STD-Fric-1995" TYPE="STUDY">Fric 1995</LINK>; <LINK REF="STD-Tsolaki-1993" TYPE="STUDY">Tsolaki 1993</LINK>) which were excluded because they were not randomized trials and numeric results were not published. <LINK REF="STD-Zeng-1996" TYPE="STUDY">Zeng 1996</LINK> which was previously awaiting assessment has been excluded because participants were not randomised to treatment. Thus the results and conclusions remain unchanged.</P>
<P>There are 14 included studies which examined cognitive, function and global effects, safety and tolerability of nimodipine compared with placebo. Only two treatment regimes were tested, 90 and 180 mg/day of nimodipine, divided into three equal doses. For the evaluation of efficacy it was not possible to extract results from five trials, resulting in loss of 674 patients for analysis, in particular <LINK REF="STD-Branconnier-1988" TYPE="STUDY">Branconnier 1988</LINK> (227 patients) and <LINK REF="STD-Kanowski-1989" TYPE="STUDY">Kanowski 1989</LINK> (197 patients), and in the loss of the trials with severely demented patients. It was not possible to extract results from the first phase of either cross-over trial.</P>
<P>So the pooled data analysed in this review come from 2492 patients. The data of the two trials with randomized treatment period of 26 weeks were pooled with data from the 24 week-trials.</P>
<P>This review shows benefit of nimodipine compared with placebo for:<BR/>1. all-type dementia at:<BR/>- 90 mg/day dose at 12 weeks for measures on:<BR/>overall clinical improvement, such as:<BR/>SCAG: [WMD -7.59, 95% CI -9.87, -5.31, P &lt; 0.00001]<BR/>CGI-global impression: [WMD -0.87, 95% CI -1.07, -0.67, P &lt; 0.00001]<BR/>CGI-numbers improved: [OR 19.81, 95% CI 8.07, 48.59, P &lt; 0.00001]<BR/>
<BR/>cognitive function: [SMD 0.61, 95% CI 0.42, 0.81, P &lt; 0.00001]</P>
<P>- 90 mg/day dose at 24 weeks for measures on:<BR/>activities of daily living: [SMD -0.12, 95% CIs -0.23, 0.0, P = 0.04]</P>
<P>- 180 mg/day dose at 24 weeks for measures on:<BR/>cognitive function: [SMD 0.19, 95% CIs 0.06, 0.31, P &lt; 0.01]</P>
<P>2. primary degenerative dementia at:<BR/>- 90 mg/day dose at 12 weeks for measures on:<BR/>overall clinical improvement, such as:<BR/>SCAG: [WMD -5.90, 95% CI -10.47, -1.33, P = 0.01]<BR/>CGI-global impression: [WMD -1.34, 95% CI -1.84, -0.84, P &lt; 0.00001]<BR/>CGI-numbers improved: [OR 24.00, 95% CI 6.46, 89.10, P &lt; 0.00001]</P>
<P>cognitive function: [SMD 0.61, 95% CI 0.12, 1.10, P = 0.01]</P>
<P>- 180 mg/day dose at 24 weeks for measures on:<BR/>cognitive function: [SMD 0.19, 95% CI 0.06, 0.31, P = 0.004]</P>
<P>3. cerebrovascular dementia at:<BR/>- 90 mg/day dose at 12 weeks for measures on:<BR/>overall clinical improvement, such as:<BR/>SCAG: [WMD -11.75, 95% CI -15.64, -7.85, P &lt; 0.00001]<BR/>CGI-global impression: [WMD -1.31, 95% CI -1.73, -0.89, P &lt; 0.00001]<BR/>CGI-numbers improved: [OR 17.25, 95% CI 4.89, 60.87, P &lt; 0.00001]</P>
<P>cognitive function: [SMD 0.37, 95% CI 0.08, 0.65, P = 0.01]</P>
<P>However, these analyses were based only on participants who completed the study and are not intention-to-treat analyses.</P>
<P>This meta-analysis was unable to detect efficacy of nimodipine for:</P>
<P>1. demented patients of any type at:<BR/>- 90 mg/day dose at 12 weeks for measures on:<BR/>overall clinical improvement, such as:<BR/>CGI-severity of disease: [WMD -0.40, 95% CI -0.82, 0.02, P = 0.06]<BR/>activities on daily living, ADL: [SMD -0.16, 95% CI -0.65, 0.32, P = 0.5]<BR/>- 90 mg/day dose at 24 weeks for measures on:<BR/>overall clinical improvement, such as:<BR/>SCAG: [WMD -2.28, 95% CI -8.85, 4.29, P = 0.5]<BR/>CGI-global impression: [WMD 0.05, 95% CI -0.05, 0.15, P = 0.5]<BR/>CGI-severity of disease: [WMD -0.01, 95% CI -0.06, 0.05, P = 0.08]</P>
<P>cognitive function: [SMD 0.08, 95% CI -0.02, 0.19, P = 0.12]</P>
<P>- 180 mg/day at 24 weeks for measures on:<BR/>CGI-severity of disease: [WMD -0.01, 95% CI -0.07, 0.05, P = 0.7]<BR/>ADL: [SMD -0.08, 95% CI -0.21, 0.04, P = 0.19]</P>
<P>2. primary degenerative dementia at:<BR/>- 90 mg/day dose at 24 weeks for measures on:<BR/>overall assessment such as:<BR/>CGI-global impression: [WMD 0.06, 95% CI -0.05, 0.17, P = 0.3]<BR/>CGI-severity of disease: [WMD 0.00, 95% CI -0.06, 0.06, P =1]<BR/>ADL: [SMD -0.08, 95% CI -0.21, 0.04, P = 0.2]<BR/>cognitive function: [SMD 0.09, 95% CI -0.04, 0.22, P = 0.16</P>
<P>- 180 mg/day dose at 24 weeks for measures on:<BR/>overall assessment, such as:<BR/>CGI-global impression: [WMD -0.07, 95% CI -0.18, 0.04, P = 0.2]<BR/>CGI-severity of disease: [WMD -0.01, 95% CI -0.07, 0.05, P = 0.7]<BR/>ADL: [SMD -0.08, 95% CIs -0.21, 0.04, P = 0.19]</P>
<P>3. cerebrovascular dementia at:<BR/>-90 mg/day at 12 weeks for measures on:<BR/>ADL: [SMD -0.16, 95% CI -0.65, 0.32, P = 0.5]<BR/>- 90 mg/day at 24 weeks for measures on:<BR/>overall assessment, such as:<BR/>CGI- global impression: [WMD -0.02, 95% CI -0.29, 0.25, P = 0.9]<BR/>CGI- severity of disease: [WMD -0.07, 95% CIs -0.22, 0.08, P = 0.4]<BR/>ADL: [SMD -0.23, 95% CI -0.47, 0.01, P = 0.06]<BR/>cognitive function: [SMD 0.07, 95% CI -0.16, 0.31, P = 0.5]</P>
<P>The meta-analyses of the number of patients suffering at least one adverse event by the end of treatment shows benefit for the 90 mg/day dose of nimodipine at 24 weeks compared with placebo (200/727 nimodipine, 243/743 placebo) [OR 0.78, 95% CI 0.62, 0.98 P = 0.03].</P>
<P>The meta-analyses of the number of patients suffering at least one serious adverse event by the end of treatment shows benefit for placebo compared with the 90 mg/day dose (38/536 nimodipine, 17/551 placebo) [OR 2.3, 95% CI 1.34, 3.96, P &lt; 0.01] and compared with the 180 mg/day dose (33/550 nimodipine, 17/551 placebo) [OR 1.96, 95% CI 1.11, 3.45 P = 0.02] at 24 weeks.</P>
<P>Adverse events were not reported in a systematic manner in most of the trials thereby making formal pooling of data difficult; where attempted this has been carried out for all dementias pooled. Typical adverse effects were dizziness, hypotension, headache, muscle weakness, dyspepsia and constipation; withdrawal rates were typically less than 10%.</P>
<P>The meta-analyses of the number of patients suffering at least one adverse cerebrovascular event by the end of treatment shows benefit for the 90 mg/day dose of nimodipine at 24 weeks compared with placebo (6/128 nimodipine, 17/131 placebo) [OR 0.36, 95% CI 0.15, 0.85 P = 0.02].</P>
<P>The meta-analyses of the number of patients suffering at least one adverse event due to a blood problem by the end of treatment shows benefit for the 90 mg/day dose of nimodipine at 24 weeks compared with placebo (13/664 nimodipine, 26/682 placebo) [OR 0.52, 95% CI 0.27, 0.98 P = 0.04].</P>
<P>The meta-analyses of the number of patients suffering at least one adverse autonomic event by the end of treatment shows benefit for placebo compared with the 90 mg/day dose of nimodipine at 24 weeks (7/128 nimodipine, 1/131 placebo) [OR 4.79, 95% CI 1.17, 19.51 P = 0.03].</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-13 13:57:33 +0100" MODIFIED_BY="Helen Collins">
<P>This is an updated review containing more extensive data than were included in the first version. There are still shortcomings in the meta-analyses that make it difficult to draw reliable conclusions regarding the use of nimodipine for demented patients.</P>
<P>The meta-analyses are based on data from participants who completed the studies. Any bias this may have introduced may be small as the numbers who did not complete treatment were low and there did not appear to be large differences in drop-out rates for treatment and placebo groups, except for one trial where losses were more frequent in the placebo (41 out of 118) than in the nimodipine group (17 out of 124), mainly related to adverse events of any kind (<LINK REF="STD-Pantoni-2005" TYPE="STUDY">Pantoni 2005</LINK>). The studies were all described as randomized, but no further details were given about the methods used. There are other aspects that call for caution. Most of the trials were sponsored by the manufacturer of nimodipine and reports of several of the trials were only available as publications that had not been peer-reviewed, as chapters of books or conference abstracts.</P>
<P>In evaluating the evidence from patients with dementia key issues include the aetiological type of dementia, severity of the disease and co-morbidity. Many of the studies did not use standard criteria for vascular dementia (<LINK REF="STD-Besson-1988" TYPE="STUDY">Besson 1988</LINK>; <LINK REF="STD-Walshe-1985" TYPE="STUDY">Walshe 1985</LINK>) or they have included patients with an obsolete diagnosis, such as chronic cerebrovascular disease (<LINK REF="STD-Bono-1985" TYPE="STUDY">Bono 1985</LINK>; <LINK REF="STD-Mikus-1985" TYPE="STUDY">Mikus 1985</LINK>); a clinical entity that nowadays we would not define as vascular dementia using the NINCS-AIREN criteria.</P>
<P>Most of the patients included in the meta-analysis were at the mild or moderate stages of dementia, according to SCAG criteria, although individual studies have a wide range of severity as assessed by cognitive tests (MMSE: 4-23; <LINK REF="STD-Branconnier-1988" TYPE="STUDY">Branconnier 1988</LINK>). In this context it is noteworthy the study groups included both in- and outpatients. They are likely therefore to represent patients typically seen in routine clinical practice.</P>
<P>This review finds overall positive effects for nimodipine from seven trials, but seven other trials could not be not included in the efficacy analysis at three to six months follow-up (<LINK REF="STD-Besson-1988" TYPE="STUDY">Besson 1988</LINK>, <LINK REF="STD-Bono-1985" TYPE="STUDY">Bono 1985</LINK>, <LINK REF="STD-Branconnier-1988" TYPE="STUDY">Branconnier 1988</LINK>, <LINK REF="STD-Kanowski-1989" TYPE="STUDY">Kanowski 1989</LINK>, <LINK REF="STD-Menazzi-1985" TYPE="STUDY">Menazzi 1985</LINK>, <LINK REF="STD-Walshe-1985" TYPE="STUDY">Walshe 1985</LINK>). Response to nimodipine may depend on dose (although there was little evidence from the one trial that used 90 mg/day and 180 mg/day - indeed, the 90 mg/day performed better) and on the duration of treatment. There was little variation in the duration of the trials, with all but one of the parallel trials being of 12 weeks duration. The main domains where benefit for patients treated with nimodipine was seen, were in overall status and in cognitive function, when all types of dementia were pooled. The improvement may not last beyond 26 weeks of treatment. There is no evidence for an effect of nimodipine on activities of daily living or on behaviour of demented patients. An additional report of <LINK REF="STD-Fischhof-1989" TYPE="STUDY">Fischhof 1989</LINK> looked at the difference in response to nimodipine of two subgroups, patients diagnosed as suffering from "primary degenerative dementia" (PDD) and those diagnosed as having multi-infarct dementia (MID). Fischhof concluded that 'nimodipine improves clinical symptomatology and cognitive functions in dementia significantly better than placebo but is more effective in PDD than MID'. Fischhof based this conclusion on the observation that the PDD patients showed improvement on more items of the SCAG than did the MID patients, and that 19% of PDD patients showed improvement on the CGI, compared with only 3% of the MID patients. These indirect comparisons are not valid criteria for identifying differences between the subgroups; what is required is a direct comparison between the PDD group and the MID group within an analysis of variance. Fishhof does not appear to have carried out a direct comparison, and none has been reported. The reporting within the paper of the individual patient data for the CGI allows us to carry out such an analysis. Fitting a general linear model to the CGI score, and with the treatment group and diagnostic group in the model, there is no effect attributable to diagnostic group (F 1,127 = 0.10, P = 0.75), when corrected for treatment group. We conclude that although there may be differences in the treatment effects for the two diagnostic groups they are not significant for the CGI, and we cannot draw any conclusions about the other outcome measures.</P>
<P>An additional report of <LINK REF="STD-Pantoni-2000" TYPE="STUDY">Pantoni 2000</LINK> examined the response to nimodipine of two subgroups of cerebrovascular dementia, those diagnosed as subcortical vascular dementia due to small vessel disease and the remainder which were regarded as multi-infarct dementia. A patient was defined as affected by subcortical disease when the CT scan showed moderate or severe degree of ischaemic white matter changes, and one or more lacunar infarcts, in the absence of non-lacunar territorial infarcts and radiological signs of hydrocephalus. All remaining cases were included in the multi-infarct dementia group. The paper reports the comparison of nimodipine with placebo, for all outcomes assessed, separately for the two groups. Pantoni concludes that although there are few significant effects, the subcortical group experienced more trends in favour of nimodipine and that the evidence supported a more specific effect in the subcortical group. The only conclusion that can be drawn from the analyses presented by Pantoni is that there seems to be little effect of nimodipine in either group. No direct comparisons were made of the two groups and therefore there is no credible evidence of any difference in action between them. Indirect comparisons as reported do not provide adequate evidence.</P>
<P>Nimodipine appears to have a low incidence of serious side-effects with equal proportions of participants dropping out on account of adverse events in the experimental and the control groups. In addition to gastrointestinal symptoms, many of the adverse effects were attributable to vasodilatation and hypotension, for example dizziness and headache.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-10-13 13:59:25 +0100" MODIFIED_BY="Helen Collins">
<IMPLICATIONS_PRACTICE>
<P>From the data reviewed here, nimodipine can be an option for the treatment of patients with manifestations of dementia, due to unclassified disease or to the major subtypes of Alzheimer's disease, vascular disease, or mixed Alzheimer's and vascular dementia. It is well tolerated with few adverse effects.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-10-13 13:59:25 +0100" MODIFIED_BY="Helen Collins">
<P>Given the high levels of prescription of nimodipine in many continental European countries, its safe adverse effect profile and comparative cheapness, further research is needed.</P>
<SUBSECTION>
<HEADING LEVEL="3">Completeness of reporting</HEADING>
<P>The power of this review would have been greatly strengthened by more complete reporting of data. In particular, the reporting of intention-to-treat analyses is essential for unbiased assessment. Also, where outcome variables are continuous, authors should state the appropriateness of the assumptions used (i.e. approximation to a normal distribution) and provide standard deviations and standard errors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Withdrawal from study</HEADING>
<P>An intention-to treat analysis is desirable, such analyses are usually more conservative than on-treatment analyses. The type of intention-to treat analysis (e.g. last observation carried forward, extrapolation of results, retrieval of drop-outs, etc.) should also be described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cross-over designs</HEADING>
<P>Cross-over studies are inappropriate for a progressive diseases such as dementia. Also, the wash-out of the drug effect needs to be carefully considered. Such studies should report results from the first treatment period separately. Any benefit from reduced sample sizes achieved by cross-over designs in comparison with parallel group designs is greatly outweighed by the associated methodological problems.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Multiple testing</HEADING>
<P>The use of so many scales in the trials, some of which are reported, represents what might be termed "scale publication bias". The scales associated with positive results are published but those with negative or neutral results are not. This is especially so for outcome measures that are described in the protocol as "secondary", or where the protocol does not pre-specify primary and secondary outcome measures.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome scales</HEADING>
<P>It is preferable that some outcomes are assessed using a scale that is common to all included trials so that the pooling of results is straightforward. The trials considered in this review contained many different scales, some of which are not validated and some of which did not use any of the common scales.</P>
<P>The clinical usefulness of the outcome scales can be questioned. No trials had data on what might be called "clinically important endpoints", such as institutionalization, or dependency. The outcome measures used have limited "common sense" relevance to patients and their carers. Therefore, more clinically useful measures should be incorporated in future trials in dementia. However, this is unlikely to occur unless the regulatory authorities require this type of information. At present, the United States Food and Drug Administration only requires an anti-dementia drug to have a demonstrable effect on a cognitive measure plus an effect on global "clinical impression of change". The European regulatory agency requests, in addition to these two types of measures, a benefit on a measure of physical functioning or quality of life. The practical clinical usefulness of these measures, in terms of the impact on the everyday life of a patient and or carer, is questionable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Length of study</HEADING>
<P>Although dementia due to Alzheimer's disease and vascular causes is a chronic disease with a median life expectancy of several years from the time of diagnosis, the trials have all been of short duration (typically lasting 12 weeks) with the longest study being 52 weeks but whose data has not been included for the reasons given above (<LINK REF="STD-Pantoni-2005" TYPE="STUDY">Pantoni 2005</LINK>). In common with other anti-dementia drugs currently available, nimodipine does not swiftly improve manifestations of the disease but rather seems to slow progression. As it is unknown what happens in the longer term, with regard to adverse effects as well as benefits, future trials should be of much longer duration.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of patients</HEADING>
<P>There is little information about which types of patients are likely to benefit from nimodipine. In particular, it is unclear what type and severity of dementia are appropriate for treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study size</HEADING>
<P>Given the modest beneficial effect that can be hoped for, the size of studies has generally been inadequate to provide reliable results on the efficacy of nimodipine. In total the eligible studies contain over 1000 patients. This remains of insufficient size to address the secondary but important issue of which subgroups of patients stand to gain and those for whom nimodipine offers no benefit or even harm.</P>
<P>WORK IN PROGRESS<BR/>An individual-patient data meta-analysis is being planned to overcome many of the problems encountered in this review of published data.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Thanks are expressed to the editors and the external reviewer. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-10-13 14:00:07 +0100" MODIFIED_BY="Helen Collins">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-10-10 17:01:12 +0100" MODIFIED_BY="Helen Collins">
<P>-All correspondence: JAR<BR/>-Drafting review versions and updates: JAL and JB<BR/>-In-and exclusion of studies: JAL and JB<BR/>-Analysis: JB</P>
<P>-Contact editor for this review is J Grimley Evans<BR/>-This review has been peer reviewed by two external experts</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-06-10 15:15:15 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-06-10 15:09:08 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-06-10 15:09:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ban-1990" MODIFIED="2008-10-13 14:11:18 +0100" MODIFIED_BY="Helen Collins" NAME="Ban 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-10-13 14:11:18 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V</AU>
<TI>Nimodipine in the treatment of old age dementias</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1990</YR>
<VL>14</VL>
<PG>525-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991046773"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Besson-1988" MODIFIED="2008-10-13 14:11:34 +0100" MODIFIED_BY="Helen Collins" NAME="Besson 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-10-13 14:11:34 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;RCT&lt;/p&gt;" NOTES_MODIFIED="2008-10-13 14:11:34 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Besson JA, Palin AN, Ebmeier KP, Eagles JM, Smith FW</AU>
<TI>Calcium antagonists and multi-infarct dementia: A trial involving sequential NMR and psychometric assessment</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>2</NO>
<PG>99-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bono-1985" NAME="Bono 1985" YEAR="?">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bono G, Sinforiani E, Trucco M, Cavallini A, Acuto GC, Nappi G</AU>
<TI>Nimodipine in cCVD patients:clinical and neuropsychological results of a double-blind cross-over study</TI>
<SO>Nimodipine. Pharmacological and clinical properties. Proceedings of the 1st International Nimotop Symposium, Munich 1984</SO>
<YR>1984</YR>
<PG>275-87</PG>
<ED>Betz E, Deck K , Hoffmeister F</ED>
<PB>Schattauer Verlag</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branconnier-1988" MODIFIED="2008-10-13 14:12:44 +0100" MODIFIED_BY="Helen Collins" NAME="Branconnier 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Baumel B, Eisner LS, Karukin M, MacNamara R, Raphan H</AU>
<TI>Nimodipine in the treatment of Alzheimer's disease</TI>
<SO>Diagnosis and treatment of senile dementia</SO>
<YR>1989</YR>
<PG>366-73</PG>
<ED>Bergener, Reisberg</ED>
<PB>Springer-Verlag</PB>
<CY>Berlin Heidelberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Branconnier RJ, Harto NE, Dessain EC, Cole JO</AU>
<TI>Palliation of the progressive memory impairment of Alzheimer's disease by nimodipine</TI>
<SO>Psychopharmacology</SO>
<YR>1988</YR>
<VL>Suppl 96</VL>
<PG>242</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 14:12:32 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Jarvik LF</AU>
<TI>Calcium channel blocker nimodipine for primary degenerative dementia</TI>
<SO>Biological Psychiatry</SO>
<YR>1991</YR>
<VL>30</VL>
<PG>1171-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 14:12:44 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD</AU>
<TI>Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia</TI>
<SO>Biological Psychiatry</SO>
<YR>1990</YR>
<VL>27</VL>
<PG>1133-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dorn-1985" NAME="Dorn 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dorn M</AU>
<TI>Effect of nimodipine on the well-being, symptoms and efficiency of ambulatory patients with cerebrovascular disorders</TI>
<SO>Nimodipine. Pharmacological and clinical properties. Proceedings of the 1st International Nimotop Symposium, Munich, 1984</SO>
<YR>1985</YR>
<PG>295-305</PG>
<ED>Betz E, Deck K, Hoffmeister F</ED>
<PB>Schattauer Verlag</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrario-1993" NAME="Ferrario 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrario E, Fioravanti M, Fabris F</AU>
<TI>Nimodipine in the treatment of senile brain deterioration: Polycentric controlled study of the Italian group for the study of geriatric therapy</TI>
<SO>Geriatria</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>4</NO>
<PG>267-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischhof-1989" MODIFIED="2008-10-13 14:14:31 +0100" MODIFIED_BY="Helen Collins" NAME="Fischhof 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Fischhof PK, Wagner G, Littschauer L, Ruther E, Apecechea M, Hiersemenzel R</AU>
<TI>Therapeutic results with nimodipine in primary degenerative dementia and multi-infarct dementia</TI>
<SO>Diagnosis and treatment of senile dementia</SO>
<YR>1989</YR>
<PG>350-9</PG>
<ED>Bergener, Reisberg</ED>
<PB>Springer-Verlag</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 14:14:31 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischhof PK</AU>
<TI>Divergent neuroprotectrive effects of nimodipine in PPD and MID provide indirect evidence of disturbances in Ca2+ homeostasis in dementia</TI>
<SO>Methods and Findings in Experimental and Clinical Pharmacology</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>8</NO>
<PG>549-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanowski-1989" MODIFIED="2010-06-10 15:09:08 +0100" MODIFIED_BY="[Empty name]" NAME="Kanowski 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-10 15:09:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>Superiority of nimodipine in mild to moderate dementia</TI>
<TO>Uberlegenheit von nimodipin bei leichter bis mittleschwerer demenz</TO>
<SO>Fortschritte der Medizin</SO>
<YR>1990</YR>
<VL>108</VL>
<NO>Suppl 103</NO>
<PG>5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Kanowski S, Fischhof P, HiersemenzeI R, Rohmel J, Kern U</AU>
<TI>Therapeutic efficacy of nootropic drugs. A discussion of clinical phase III studies with nimodipine as a model</TI>
<SO>Diagnosis and treatment of senile dementia</SO>
<YR>1989</YR>
<PG>339-49</PG>
<ED>Bergener, Reisberg</ED>
<PB>Springer-Verlag</PB>
<CY>Berlin Heidelberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menazzi-1985" NAME="Menazzi 1985" YEAR="?">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Menazzi D, Montenegro R, Castro JM</AU>
<TI>Nimodipine in the treatment of chronic cerebrovascular insufficiency</TI>
<SO>Nimodipine. Pharmacological and clinical properties - Proceedings of the 1st International Nimotop Symposium</SO>
<YR>1985</YR>
<PG>333-44</PG>
<ED>Betz E, Deck K , Hoffmeister F</ED>
<PB>Schattauer Verlag</PB>
<CY>Munich</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mikus-1985" NAME="Mikus 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mikus P, Aufdembrinke B</AU>
<TI>Nimodipine, a centrally active calcium antagonist. Results of a clinico-psychometric study</TI>
<SO>Nimodipine. Pharmacological and clinical properties. Proceedings of the 1st International Nimotop Symposium, Munich, 1984</SO>
<YR>1985</YR>
<PG>329-331</PG>
<ED>Betz E, Deck K , Hoffmeister F</ED>
<PB>FK Schattauer Verlag</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morich-1996" NAME="Morich 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morich FJ, Bieber F, Lewis JM, Kaiser L, Cutler NR, Escobar JI, Willmer J, Petersen RC, Reisberg B, the North American Nimodipine Study Group</AU>
<TI>Nimodipine in the treatment of probable Alzheimer's disease. Results of two multicentre trials</TI>
<SO>Clin Drug Inves</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>4</NO>
<PG>185-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pantoni-2000" MODIFIED="2008-10-13 14:31:07 +0100" MODIFIED_BY="Helen Collins" NAME="Pantoni 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-10-13 14:30:48 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inzitari D, Pantoni L</AU>
<TI>Subcortical vascular Dementia: Therapeutical Aspects</TI>
<SO>Archives of Gerontology and Geriatrics</SO>
<YR>1998</YR>
<VL>Suppl 6</VL>
<PG>263-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;RCT&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T</AU>
<TI>The Scandinavian Multi-Infarct Dementia Trial: A double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2000</YR>
<VL>175</VL>
<NO>2</NO>
<PG>116-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkkinjuntti T, Wallin A</AU>
<TI>Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the scandinavian Multi-Infarct Dementia Trial</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2000</YR>
<VL>175</VL>
<PG>124-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 14:31:07 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossi R, Inzitari D, Pantoni D, del Ser T, Erkinjuntii T, Wallin A, Bianchi C, Badenas JM, Beneke M</AU>
<TI>Nimodipine in subcortical dementia trial</TI>
<SO>Alzheimer's Disease and Associated Disorders</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>Suppl 3</NO>
<PG>159-165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pantoni-2005" MODIFIED="2008-10-13 14:31:51 +0100" MODIFIED_BY="Helen Collins" NAME="Pantoni 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-10-13 14:31:51 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, et al</AU>
<TI>Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial</TI>
<SO>Stroke</SO>
<YR>2005</YR>
<VL>36</VL>
<NO>3</NO>
<PG>619-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tobares-1989" NAME="Tobares 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Tobares N, Pedromingo A, Bigorra J</AU>
<TI>Nimodipine treatment improves cognitive functions in vascular dementia</TI>
<SO>Diagnosis and treatment of senile dementia</SO>
<YR>1989</YR>
<PG>360-5</PG>
<ED>Bergener &amp; Reisberg</ED>
<PB>Springer-Verlag</PB>
<CY>Berlin Heidelberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walshe-1985" NAME="Walshe 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walshe TM</AU>
<TI>The use of nimodipine in vascular dementia</TI>
<SO>Journal of Neurology</SO>
<YR>1985</YR>
<VL>232</VL>
<PG>74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-06-10 14:56:25 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adan-1995" NAME="Adan 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adan GO, Marin GA, Belio CJ, Alonso AG, Vera AE, Enriquez VC, et al</AU>
<TI>Treatment of cerebro-vascular insufficiency (multiinfarct dementia) with nimodipine in elderly patients</TI>
<SO>Inves Med Int</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>24-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-1997" NAME="Alvarez 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez XA, Laredo M, Corzo D, Fernandez-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R</AU>
<TI>Citicoline improves memory performance in elderly subjects</TI>
<SO>Methods and Findings in Experimental &amp; Clinical Pharmacology</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>3</NO>
<PG>201-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baumel-1987" NAME="Baumel 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Baumel B, Eisner LS, McNamara R, Karukin M. Nimodipine in the treatment of primary degenerative dementia. International Symposium on Calcium Antagonists. Pharmacology and Clinical Research. New York, 1987. Abstract book, pg: 96.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Baumel B, Eisner LS, McNamara R, Karukin M</AU>
<TI>Nimodipine in the treatment of primary degenerative dementia</TI>
<SO>International Symposium on Calcium Antagonists - Pharmacology and Clinical Research</SO>
<YR>1987</YR>
<PG>96</PG>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Centozone-1992" MODIFIED="2008-10-13 14:33:21 +0100" MODIFIED_BY="Helen Collins" NAME="Centozone 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-10-13 14:33:21 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Centozone V</AU>
<TI>Brain, aging and calcium antagonists drugs. A preliminary open study with nimodipine</TI>
<SO>Clinical Therapeutics</SO>
<YR>1992</YR>
<VL>140</VL>
<PG>11-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Maio-1987" NAME="Di Maio 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Maio L, Campanella G, Di Somma S, De Divitis O, Gagliardi R, Caresia L</AU>
<TI>Nimodipine: a new drug for the treatment of organic brain syndromes</TI>
<SO>Acta Therap</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>61-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eicher-1992" MODIFIED="2008-10-13 14:34:05 +0100" MODIFIED_BY="Helen Collins" NAME="Eicher 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-10-13 14:34:05 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eicher H, Hilgert D, Zeeh J, Platt D, Becker C, Mutschler E</AU>
<TI>Pharmacokinetics of nimodipine in multimorbid elderly patients with chronic brain failure</TI>
<SO>Archives of Gerontology and Geriatrics</SO>
<YR>1992</YR>
<VL>14</VL>
<PG>309-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fornazzari-1997" NAME="Fornazzari 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;CCT&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fornazzari L, Alvarez F, Gabrielli H, Sastre A, Fustinoni O, Gold L, Pangre N, Roselli D, Roselli A, Chaskel R, Hernandez RE, Villavicencio de Ojeda A, Vidal MG, Flaskamp R, Castaneda JR, Arocha I, Rentschler P, Lemme L, Lara C, Merino E</AU>
<TI>Efficacy and tolerability of nimodipine in the treatment of Primary Degenerative Dementia and Multiinfarct Dementia. A multicentre latinamerican study</TI>
<TO>EFICACI Y TOLERABILIDAD DE NIMODIPINO EN EL TRATAMIENTO DE DEMENCIA DEGENERATIVA PRIMARIA Y DEMENCIA VASCULAR TIPO INFARTOS MULTIPLES. ESTUDIO MULTICENTRICO LATINOAMERICANO</TO>
<SO>Revista-Neurologica-Argentina</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>2</NO>
<PG>54-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fric-1995" NAME="Fric 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fric M, Horn R, Hasse-Sander I, Schroder MR, Xie Y, Muller H, Matthias K</AU>
<TI>Effects of nimodipine-treatment in primary degenerative dementia Results of a clinical and psychometric study</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1995</YR>
<VL>28</VL>
<PG>177</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Held-1985" NAME="Held 1985" YEAR="?">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Held K, Boehme K, Rode CP</AU>
<TI>Efficacy and tolerability of nimodipine in patients with old-age cerebrovascular dysfunction</TI>
<SO>Nimodipine. Pharmacological and clinical properties - Proceedings of the 1st International Nimotop Symposium</SO>
<YR>1985</YR>
<PG>289-93</PG>
<ED>Betz E, Deck K, Hoffmeister F</ED>
<PB>FK Schattauer</PB>
<CY>Munich</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janssen_x002d_Cilag-NCT00814568" MODIFIED="2010-06-10 14:56:25 +0100" MODIFIED_BY="[Empty name]" NAME="Janssen-Cilag NCT00814568" YEAR="4568">
<REFERENCE MODIFIED="2010-06-10 14:56:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janssen-Cilag Farmaceutica Ltda [sponsor]</AU>
<TI>The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life</TI>
<SO>Clinicaltrials.gov</SO>
<YR>24 December 2008</YR>
<VL>N/A</VL>
<PG>http://clinicaltrials.gov/ct2/show/NCT00814658</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kapoula-1990" MODIFIED="2008-10-13 14:34:30 +0100" MODIFIED_BY="Helen Collins" NAME="Kapoula 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-10-13 14:34:30 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;RCT&lt;/p&gt;" NOTES_MODIFIED="2008-10-13 14:34:30 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapoula O, Lehrl S, Fischer B, Burkard G, Schuback G, Ban TA, et al</AU>
<TI>Efficacy of nimodipine in patients suffering from senile dementia: A placebo double-blind study: Nimodipine in the treatment of old age dementias</TI>
<TO>Nimodipin bei Hirnleistungsstoerungen im Alter - eine placebokontrollierte Doppelblindstudie in aerztlichen Praxen</TO>
<SO>Geriatrie-&amp;-Rehabilitation: Prog-Neuropsychopharmacol-Biol-Psychiatry</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>135-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-SN-2002" NAME="Liu SN 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu SN; Li YZ; Han DC; Chi ZF, and Zhang R et al</AU>
<TI>Buflomedil vs nimodipine in treating vascular dementia: a double-blind comparative study</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>2</NO>
<PG>74-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-XD-2005" MODIFIED="2008-10-13 14:34:59 +0100" MODIFIED_BY="Helen Collins" NAME="Liu XD 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-10-13 14:34:59 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu XD, Wan Q, Wei D, Wang XM</AU>
<TI>Cognitive and non-cognitive functions in patients with vascular dementia and the interventional efficacy of dihydroergotamine mesilate plus nimodipine</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>20</NO>
<PG>48-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendoza-2006" MODIFIED="2010-06-10 14:52:04 +0100" MODIFIED_BY="[Empty name]" NAME="Mendoza 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-10 14:52:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendoza et al</AU>
<TI>Comparison of two nimodipine formulations in elderly patients with cognitive impairment in a randomized national multicentre double-blind study</TI>
<TO>Comporación de dos formulaciones de nimodipina en pacientes de edad avanzada con deterioro cognitivo estudio multicéntrico nacional aleatorizado doble ciego</TO>
<SO>Arch. venez. farmacol. ter</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>1</NO>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-06-10 14:48:08 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navia-1998" MODIFIED="2008-10-13 14:35:09 +0100" MODIFIED_BY="Helen Collins" NAME="Navia 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-13 14:35:09 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, et al</AU>
<TI>A phase I/II trial of nimodipine for HIV-related neurologic complications</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>1</NO>
<PG>221-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nimodipine-1996" NAME="Nimodipine 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;RCT&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nimodipine Clinical Study Group</AU>
<TI>Effects of Nimodipine on vascular dementia</TI>
<SO>Cerebrovasc-Dis</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-author-1990b" NAME="No author 1990b" YEAR="1990b">
<REFERENCE NOTES="&lt;p&gt;RCT?&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>No Author</AU>
<TI>Nimodipine therapy in patients with mental disturbances</TI>
<SO>MUNCH-MED-WOCHENSCHR</SO>
<YR>1990b</YR>
<VL>132</VL>
<NO>48 SUPPL.</NO>
<PG>8-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-Author-1995a" MODIFIED="2008-10-13 14:35:38 +0100" MODIFIED_BY="Helen Collins" NAME="No Author 1995a" YEAR="1995a">
<REFERENCE MODIFIED="2008-10-13 14:35:38 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;RCT?&lt;/p&gt;" NOTES_MODIFIED="2008-10-13 14:35:38 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>No Author</AU>
<TI>Nimodipine in brain dysfunction is effective and well tolerated also in general practice</TI>
<SO>Therapiewoche</SO>
<YR>1995a</YR>
<VL>45</VL>
<NO>18</NO>
<PG>1067</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parnetti-1993" MODIFIED="2008-10-13 14:36:00 +0100" MODIFIED_BY="Helen Collins" NAME="Parnetti 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-10-13 14:36:00 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Parnetti L, Senin U, Carosi M, Baasch H. Mental deterioration in old age:results of two multicentre, clinical trials wihth nimodipine. Clin Therap 1993; 15(2):394-406.&lt;/p&gt;" NOTES_MODIFIED="2008-10-13 14:36:00 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parnetti L, Senin U, Carosi M, Baasch H</AU>
<TI>Mental deterioration in old age:results of two multicentre, clinical trials with nimodipine</TI>
<SO>Clinical Therapeutics</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>2</NO>
<PG>394-406</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Politi-1990" NAME="Politi 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Politi GC, et al</AU>
<TI>The use of nimodipine (Nimotop-Bayer) in patients with chronic ischaemic cerebral vasculopathies. Twenty-eight case reports</TI>
<SO>Panminerva Med</SO>
<YR>1990</YR>
<VL>32</VL>
<PG>85-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schinco-1991" NAME="Schinco 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Schinco P. Mid-term treatment of dementia with nimodipine. Arch Gerontol Geriatr 1991 (Suppl 2):169-72.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schinco P</AU>
<TI>Mid-term treatment of dementia with nimodipine</TI>
<SO>Arch Gerontol Geriatr</SO>
<YR>1991</YR>
<VL>Suppl 2</VL>
<PG>169-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simkins-1987" NAME="Simkins 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;RCT?&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simkins R, Vera M, Kobelt R, Sahakian B, Joyce E, Lishman WA</AU>
<TI>Alzheimer model cognitive dementia and senile dementia treated with nimopidine: Cholinergic effects on constructional abilities and on mnemonic processes: a case report.[</TI>
<TO>Aspectos cognitivos en demencias tipo Alzheimer y multiinfarto tratado con nimodipina</TO>
<SO>PCM-Ser.-Symp: Psychol-Med</SO>
<YR>1987</YR>
<VL>1. 17</VL>
<NO>1. 2</NO>
<PG>329-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Struckmann-1990" NAME="Struckmann 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Struckmann J</AU>
<TI>Nimodipine: New prospect for senile dementia</TI>
<TO>Nimodipin: neue chance bei altersdemenz</TO>
<SO>Pharmazeutische Zeitung</SO>
<YR>1990</YR>
<VL>135</VL>
<NO>25</NO>
<PG>34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sui-2003" NAME="Sui 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sui CF; Shen SH, and Wang J</AU>
<TI>Comparison of efficacy between nimodipine and hydergine in the treatment of vascular dementia</TI>
<SO>Chinese Journal of Clinical Neurosciences</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>2</NO>
<PG>175-177</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sze-1998" MODIFIED="2008-10-13 14:36:37 +0100" MODIFIED_BY="Helen Collins" NAME="Sze 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-13 14:36:37 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;RCT&lt;/p&gt;" NOTES_MODIFIED="2008-10-13 14:36:37 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sze KH, Sim TC, Wong E, Cheng S, Woo J</AU>
<TI>Effect of nimodipine on memory after cerebral infarction</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>6</NO>
<PG>386-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tedeschi-1991" NAME="Tedeschi 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tedeschi D</AU>
<TI>Calcium regulation in brain aging by nimodipine: a multicenter trial in Italy</TI>
<SO>Cur Therap Res</SO>
<YR>1991</YR>
<VL>50</VL>
<PG>553-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomassini-1989" NAME="Tomassini 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomassini PF, Tedeschi D, Lipponi G, Paciaroni E</AU>
<TI>Evaluation of the efficacy of nimodipine in patients with vasuclar and degenrative deterioration</TI>
<TO>Valutazione dell'efficacia della nimodipina in pazienti affeti da deterioramento mentale di grtado lieve-medio su base sia vascolare che degenerativa</TO>
<SO>G Ital Gerontol</SO>
<YR>1989</YR>
<VL>37</VL>
<PG>923-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsolaki-1993" NAME="Tsolaki 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tsolaki M, Fountoulakis C, Kazis A</AU>
<TI>Nimodipine in the treatment of patients with cognitive disorders</TI>
<SO>Proceedings of the 13th Greek Congress of Neurology, Thessaloniki</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsolaki-1996" NAME="Tsolaki 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsolaki M, Kapinas K, Kazis A</AU>
<TI>Nimodipine vs dihydroergocristine in the treatment of old age dementias: a blind, randomized, placebo-controlled study</TI>
<SO>Rev Clin Pharmacol Pharmacokinetics</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>16-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ulrich-1988" NAME="Ulrich 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Ulrich G, Stieglitz RD. Effect of nimodipine upon electroencephalographic vigilance in elderly persons with minor impairment of braion functions. Arzneim Forsch/Drug Res 1988;38:392-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ulrich G, Stieglitz RD</AU>
<TI>Effect of nimodipine upon electroencephalographic vigilance in elderly persons with minor impairment of brain functions</TI>
<SO>Arzneim Forsch/Drug Res</SO>
<YR>1988</YR>
<VL>38</VL>
<PG>392-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988251534"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2008-10-13 14:37:58 +0100" MODIFIED_BY="Helen Collins" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-10-13 14:37:58 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang W, Wang LN, Zhang XH, Ma L, Li DJ</AU>
<TI>A nimodipine interventional study of patients with mild cognitive impairment</TI>
<SO>Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine]</SO>
<YR>2006</YR>
<VL>45</VL>
<NO>4</NO>
<PG>274-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weyer-1992" NAME="Weyer 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Ganzer B. Nimodipin bei Hirnleistungsstorungen. PZ 1990, 135(25):34.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzer B</AU>
<TI>Nimodipine for memory problems</TI>
<TO>Nimodipin bei Hirnleistungsstorungen</TO>
<SO>Pharmazeutische Zeitung</SO>
<YR>1990</YR>
<VL>135</VL>
<NO>25</NO>
<PG>34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zamperini-1984" MODIFIED="2008-10-13 14:38:32 +0100" MODIFIED_BY="Helen Collins" NAME="Zamperini 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-10-13 14:38:32 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Zamperini D, Ursaia G, Biagiarelli CA, Schipani A, Cicalini A, Acuto G, et al. Eur Rev Med Pharmacol Sci 1984; 6:137-46.&lt;/p&gt;" NOTES_MODIFIED="2008-10-13 14:38:32 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zamperini D, Ursaia G, Biagiarelli CA, Schipani A, Cicalini A, Acuto G, et al</AU>
<TI>No title</TI>
<SO>European Review for Medical and Pharmacological Sciences</SO>
<YR>1984</YR>
<VL>6</VL>
<PG>137-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeng-1996" MODIFIED="2008-10-13 14:39:28 +0100" MODIFIED_BY="Helen Collins" NAME="Zeng 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-13 14:39:28 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng ZX, Liu L, Zhang YD</AU>
<TI>Treatment of multi-infarct dementia with nimodipine (NM): a double blind trial</TI>
<SO>Chin Journal of Pharmacoepidemiology</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>71-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zirm-1994" MODIFIED="2008-10-13 14:39:43 +0100" MODIFIED_BY="Helen Collins" NAME="Zirm 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-10-13 14:39:43 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zirm B, Steinwachs KC, Pracher G, Zirm A, Zimmermann-Meinzingen S</AU>
<TI>Effects of Nimodipine and Piracetam on speed of information processing (ZVT-G) and clinical dementia symptoms-results of a unicentre randomized clinical trial</TI>
<SO>Zeitschrift Fur Gerontopsychologie Und Psychiatrie</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>3</NO>
<PG>157-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-06-10 15:15:15 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-06-10 15:15:15 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Chalmers-1983" MODIFIED="2008-10-13 14:40:08 +0100" MODIFIED_BY="Helen Collins" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H Jr</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<NO>1</NO>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erzigkeit-1986" MODIFIED="2010-06-10 15:15:15 +0100" MODIFIED_BY="[Empty name]" NAME="Erzigkeit 1986" TYPE="BOOK">
<AU>Erzigkeit H</AU>
<TI>The Syndrome Short-test for the Assessment of Disturbed Concentration and Memory</TI>
<SO>Der Syndrom-Kurztest zur Erfassung von Aufmerksamkeits- und Gedächtnisstörungen</SO>
<YR>1986</YR>
<ED>Vaterstetten (F.R.G.)</ED>
<PB>VLESS - Verlagsgesellschaft für Medizinpsychologie und Psychopathometrie mbH</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Folstein-1975" MODIFIED="2010-06-10 15:15:10 +0100" MODIFIED_BY="[Empty name]" NAME="Folstein 1975" TYPE="JOURNAL_ARTICLE">
<AU>Folstein MF, Folstein SE, McHugh PR</AU>
<TI>Mini-Mental State - A practical method for grading the cognitive state of patients for the clinician</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1975</YR>
<VL>12</VL>
<PG>189-198</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2010-06-10 15:14:50 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK_SECTION">
<AU>Guy W</AU>
<TI>Clinical global impressions</TI>
<SO>ECDEU assessment manual for psychopharmacology - DHW publication no (ADM) 76 - 338)</SO>
<YR>1976</YR>
<PG>218-2</PG>
<ED>Guy, W</ED>
<PB>MD: Dept of Health, Education &amp; Welfare</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-1993" MODIFIED="2008-10-13 14:40:49 +0100" MODIFIED_BY="Helen Collins" NAME="Kim 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kim YS, Nibbelink DW, Overall JE</AU>
<TI>Factor structure and scoring of the SKT</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>1993</YR>
<VL>49</VL>
<PG>61-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurianski-1976" NAME="Kurianski 1976" TYPE="JOURNAL_ARTICLE">
<AU>Kuriansky J, Gurland BJ, Fleiss JL, Cowan PW</AU>
<TI>The assessment of self care capacity in geriatric psychiatric patients by objective and subjective measures</TI>
<TO>The assessment of self care capacity in geriatric psychiatric patients by objective and subjective measures</TO>
<SO>J Clin Psychol</SO>
<YR>1976</YR>
<VL>32</VL>
<PG>95-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawton-1969" MODIFIED="2008-10-13 14:41:16 +0100" MODIFIED_BY="Helen Collins" NAME="Lawton 1969" TYPE="JOURNAL_ARTICLE">
<AU>Lawton MP, Brody EM</AU>
<TI>Assessment of the older people: Self-maintaining and instrumental activities of daily living</TI>
<SO>Gerontologist</SO>
<YR>1969</YR>
<VL>9</VL>
<PG>179-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1996" MODIFIED="2010-06-10 15:14:33 +0100" MODIFIED_BY="[Empty name]" NAME="Mulrow 1996" TYPE="BOOK_SECTION">
<AU>Mulrow CD, Oxman AD</AU>
<TI>Cochrane Collaboration Handbook</TI>
<SO>The Cochrane Library [database on disk and CD-ROM]</SO>
<YR>1996</YR>
<EN>1st</EN>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Randt-1980" MODIFIED="2008-10-13 14:41:47 +0100" MODIFIED_BY="Helen Collins" NAME="Randt 1980" TYPE="JOURNAL_ARTICLE">
<AU>Randt CT, Brown ER, Osbourne DP</AU>
<TI>A memory test for longitudinal measurement of mild to moderate deficits</TI>
<SO>Clinical Neuropsychology</SO>
<YR>1980</YR>
<VL>2</VL>
<PG>194-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosen-1984" MODIFIED="2008-10-13 14:41:57 +0100" MODIFIED_BY="Helen Collins" NAME="Rosen 1984" TYPE="JOURNAL_ARTICLE">
<AU>Rosen WG, Mohs RC, Davis KL</AU>
<TI>A new rating scale for Alzheimer's disease</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<PG>1356-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2010-06-10 15:14:41 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-1983" MODIFIED="2008-10-13 14:42:36 +0100" MODIFIED_BY="Helen Collins" NAME="Schwartz 1983" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz GE</AU>
<TI>Development and validation of the Geriatric Evaluation by the Relative's Rating Instrument (GERRI)</TI>
<SO>Psychological Reports</SO>
<YR>1983</YR>
<VL>53</VL>
<PG>479-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shader-1974" MODIFIED="2010-06-10 15:14:58 +0100" MODIFIED_BY="[Empty name]" NAME="Shader 1974" TYPE="JOURNAL_ARTICLE">
<AU>Shader RI, Harmatz JS, Salzman C</AU>
<TI>A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment-Geriatric (SCAG)</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1974</YR>
<VL>22</VL>
<PG>107-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wechsler-1945" MODIFIED="2010-06-10 15:15:03 +0100" MODIFIED_BY="[Empty name]" NAME="Wechsler 1945" TYPE="JOURNAL_ARTICLE">
<AU>Wechsler D</AU>
<TI>A standardized memory scale for clinical use</TI>
<SO>Journal of Psychology</SO>
<YR>1945</YR>
<VL>19</VL>
<PG>87-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wechsler-1981" NAME="Wechsler 1981" TYPE="BOOK">
<AU>Wechsler D</AU>
<SO>Wechsler adult intelligence scale revised (WAIS-R)</SO>
<YR>1981</YR>
<PB>The Psychological Corporation Harcourt Brace Jovanovich Inc.</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wechsler-1987" NAME="Wechsler 1987" TYPE="BOOK">
<AU>Wechsler D</AU>
<SO>Wechsler Memory Scale Revised (WMS-R)</SO>
<YR>1987</YR>
<PB>The Psychological Corporation Harcourt Jovanovich Inc.</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-10-13 14:48:44 +0100" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-L_x00f3_pez_x002d_Arrieta-2002" MODIFIED="2008-10-13 14:48:44 +0100" MODIFIED_BY="Helen Collins" NAME="López-Arrieta 2002" TYPE="COCHRANE_REVIEW">
<AU>López-Arrieta , Birks J</AU>
<TI>Nimodipine for primary degenerative, mixed and vascular dementia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-10-13 14:48:44 +0100" MODIFIED_BY="Helen Collins">
<IDENTIFIER MODIFIED="2008-10-13 14:48:44 +0100" MODIFIED_BY="Helen Collins" TYPE="DOI" VALUE="10.1002/14651858.CD000147"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-06-10 14:47:14 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-13 14:08:07 +0100" MODIFIED_BY="Helen Collins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-10-13 14:01:14 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Ban-1990">
<CHAR_METHODS MODIFIED="2008-10-13 14:00:14 +0100" MODIFIED_BY="Helen Collins">
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled<BR/>Duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-13 14:00:42 +0100" MODIFIED_BY="Helen Collins">
<P>Country: Italy<BR/>Multi-centre: 6 sites<BR/>176 participants, mean age 75.4 (SD = 9.6) range 55-70 years<BR/>105 (59%) female, 73 (41%) male<BR/>34 (19%) outpatients, 141 (79%) inpatients<BR/>Diagnosis:defined by DSM-III and re-classed by the Hachinski Ischaemic Score (HIS).<BR/>HIS =&lt;4: primary degenerative dementia, 86 patients (48%)<BR/>HIS = 5-6: mixed dementia 40 patients (23%)<BR/>HIS =&gt; 7: vascular dementia 52 patients (29%)<BR/>exclusion criteria: severe cardiac condition defect<BR/>recent myocardial infarction<BR/>severe renal, hepatic, respiratory or cardiac insufficiency<BR/>endocrine or metabolic disorder such as thyroid disease or insulin treated diabetes<BR/>peptic ulcer<BR/>epilepsy<BR/>hypertension<BR/>hypotension<BR/>other psychiatric disorders<BR/>treatment with other calcium antagonists, antihypertensives, beta-blockers, neuroleptics,antidepressants<BR/>Drugs excluded:other calcium antagonists, antihypertensives, beta-blockers, antidepressants, neuroleptics, anxiolytics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>GDS (Global Deterioration Scale)<BR/>SCAG (Sandoz Clinical Assessment Geriatric Scale)<BR/>PGRS (Plutchik Geriatric Rating Scale)<BR/>CGI (Clinical Global Impression), CGI-SI (Clinical Global Impression-Severity of Illness), CGI-GI (Clinical Global Impression-Global Improvement) <BR/>HPRSD (Hamilton Psychiatric Rating Scale for Depression)<BR/>WMS (Weschler Memory Scale)<BR/>MMSE (Minimental State Examination)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-13 14:01:14 +0100" MODIFIED_BY="Helen Collins">
<P>No. excluded after randomization: Total = 0, Treated = 0, Control = 0.<BR/>No. not included in analysis:<BR/>Total = 3, Treated = 2, Control = 1.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:01:23 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Besson-1988">
<CHAR_METHODS>
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled <BR/>Duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>participants: 20 patients, 11 males, 9 female, mean age 71.2 years<BR/>Diagnosis: VD, no criteria given<BR/>inclusion and exclusion criteria: none given</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:01:23 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>RCP test (Royal College of Physicians Test)<BR/>SCAG<BR/>MSQ (Mental Status Questionnaire)<BR/>Katzman memory-orientation-concentration and dementia check list</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:01:46 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Bono-1985">
<CHAR_METHODS>
<P>Randomized: method not described.<BR/>Double-blind<BR/>crossover<BR/>Placebo-controlled<BR/>Duration: <BR/>6 months + 6 months <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-10 17:01:58 +0100" MODIFIED_BY="Helen Collins">
<P>Country: Italy<BR/>participants: 40 men, mean age 56.43 (8.0) range 45-70<BR/>Inclusion criteria:<BR/>non-disabling focal neurological deficits due to minor strokes<BR/>cerebrovascular risk factors<BR/>cerebral + systemic atherosclerotic lesions by angiography<BR/>slight to mild cognitive impairment<BR/>exclusion criteria:<BR/>possible cardiogenic brain embolism in the apthogenesis of the neurological deficits<BR/>CT findings of diffuse white matter low attenuation and or lacunar infarcts<BR/>epilepsy, toxic or metabolic brain disorders<BR/>diabetes, heart disorders<BR/>hypotensive drug use<BR/>CNS stimulants or depressants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:01:46 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment : Nimodipine 90 mg/day t.i.d. (fixed dose).</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>token test<BR/>10 word learning<BR/>digit symbol<BR/>digit span<BR/>Corsi's test<BR/>10 word learning retrieval<BR/>word fluency<BR/>Raven's progressive matrices</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:02:24 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Branconnier-1988">
<CHAR_METHODS>
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-cz<BR/>Duration: 12 weeks after a 2 week single-blind placebo run-in</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>10 centres<BR/>participants: 227 patients mean age 69.5 years<BR/>Diagnosis: PDD according to DSM-III<BR/>Inclusion criteria:<BR/>Hachinski &lt; 4<BR/>normal CAT scan or no pathology other than atrophy<BR/>MMSE 4-23<BR/>Hamilton Depression score &lt; 16<BR/>exclusion criteria:<BR/>cardiac conduction deficit or major cardiovascular disease<BR/>major medical problems, history of head trauma, CNS disease, primary psychiatric diagnosis of anxiety or depressive disorder</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:02:24 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment 1: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Treatment 2: Nimodipine 180 mg/day t.i.d. (fixed dose)<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BSRT (Buschke Selective Reminding Test)<BR/>word fluency subtest<BR/>standardized roadmap test<BR/>first and last names test<BR/>symbol digit modality test<BR/>CGI<BR/>RAGS (Relatives Assessment of Global Symptomatology)<BR/>ADL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:03:22 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Dorn-1985">
<CHAR_METHODS>
<P>Randomized: method not described.<BR/>Double-blind<BR/>cross-over<BR/>Placebo-controlled <BR/>Duration :12 week<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-13 14:02:38 +0100" MODIFIED_BY="Helen Collins">
<P>Country: FRG<BR/>participants: 76 out-patients (26 male 42 female) mean age 72(8)<BR/>diagnosis: cerebrovascular disease<BR/>inclusion criteria:<BR/>Heinemann scale aCVD score &gt; 100 and cCVD score &gt; 75<BR/>Hachinski &gt; 7<BR/>SCAG scale shows mild to moderate severity<BR/>sufficient premedication of additional disease<BR/>exclusion criteria:<BR/>primary degenerative cerebral disease<BR/>tumours of the brain<BR/>cerebral haemorrhage<BR/>schizophrenic psychosis<BR/>epilepsy<BR/>acute unrest and confusion<BR/>insulin dependent diabetes<BR/>severe liver or kidney insufficiency</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:03:22 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG<BR/>Bf-S scale<BR/>Labyrinth test<BR/>digit symbol test<BR/>trail making test<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:03:42 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Ferrario-1993">
<CHAR_METHODS>
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled <BR/>Duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-13 14:03:34 +0100" MODIFIED_BY="Helen Collins">
<P>Country: Italy<BR/>multi-centre<BR/>participants 124 in and outpatients (70 female, 54 male) , mean age 78.2 (4.3) years<BR/>diagnosis: dementia PDD, VD or mixed as diagnosed using the Hachinski score<BR/>inclusion criteria:<BR/>GDS 3, 4 or 5<BR/>MMSE 10-26<BR/>exclusion criteria:<BR/>other serious illness, such as liver disease, renal disease, neoplasms, psychiatric, heart disease Parkinson's disease, epilepsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:03:42 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG<BR/>GRSS (Relatives stress scale)<BR/>Randt memory test<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:04:41 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Fischhof-1989">
<CHAR_METHODS>
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled <BR/>4 week single blind placebo wash-out phase preceding<BR/> 12 weeks of treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-13 14:04:13 +0100" MODIFIED_BY="Helen Collins">
<P>Country: Austria<BR/>No. of centres: 2<BR/>participants: 144 inpatients<BR/>Sex: 103 (88%) female, 27 (12%) male<BR/>Age: range 50-85<BR/>Diagnosis:<BR/>vascular dementia: DSM-III, Hachinski =&gt;7, CT, EEG<BR/>primary degenerative dementia: DSM-III, Hachinski = &lt;4.<BR/>SKT =&gt; 9.<BR/>41&lt;SCAG&lt;90</P>
<P>Exclusion criteria: HIS 5-6. Other neurological or psychiatric disease. Unstable metabolic conditions. Diseases preventing or interfering with psychometric tests, severe gastrointestinal disorders and hepatic failure and hypotension.<BR/>Drugs excluded: all psychotropic drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:04:21 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Evaluations at: 6 and 12 weeks.<BR/>Outcome measures:<BR/>CGI (Clinical Global Improvement)<BR/>SKT (Syndrom-Kurztest)<BR/>SCAG (Sandoz Clinical Assessmet Geriatric)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-13 14:04:41 +0100" MODIFIED_BY="Helen Collins">
<P>Stratification by diagnosis<BR/>Total = 14, Treated = 10, Control = 4.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:05:00 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Kanowski-1989">
<CHAR_METHODS MODIFIED="2008-10-13 14:04:47 +0100" MODIFIED_BY="Helen Collins">
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled<BR/>Duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-10 17:02:17 +0100" MODIFIED_BY="Helen Collins">
<P>Country: Austria<BR/>Participants: 197 inpatients (156 female, 40 male) age range 61-86 years<BR/>Diagnosis: mild or moderate chronic organic brain syndrome of diffuse type according to the Lausanne grading and DSM-III<BR/>inclusion criteria:<BR/>age 60-85<BR/>SCAG 41-90<BR/>exclusion criteria:<BR/>transient organic psychoses, recent stroke, unstable hypertension, hypotension, diabetes, gout<BR/>renal or myocardial insufficiency<BR/>severe gastrointestinal disorders<BR/>alcohol or drug abuse<BR/>long term use of psychotropic drugs, nootropic drugs, hynoptics, calcium antagonists, alpha-methyldopa, beta-blockers or anti-arrhythmic drugs of the local anaesthetic type</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:05:00 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment 1: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Treatment 2: hydergine<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG<BR/>BGP (assessment scale for the behaviour of geriatric patients)<BR/>SKT<BR/>ZVT-G<BR/>CGI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:05:32 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Menazzi-1985">
<CHAR_METHODS MODIFIED="2008-10-13 14:05:08 +0100" MODIFIED_BY="Helen Collins">
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled<BR/>Duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-13 14:05:21 +0100" MODIFIED_BY="Helen Collins">
<P>Country: Argentina<BR/>participants: 86 patients (54 females, 32 males) mean age 64.5 (7.6) range 52-80 years<BR/>diagnosis: cerebral insufficiency<BR/>inclusion criteria:<BR/>age &gt; 50 years<BR/>3 &lt; SPMSQ &lt; 6<BR/>Hachinski&gt;= 7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:05:26 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG<BR/>Wechsler-Bellevue</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-13 14:05:32 +0100" MODIFIED_BY="Helen Collins">
<P>Matched pairs of patients were formed with similar values of the SPMSQ and Hachinski before randomization</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:05:52 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Mikus-1985">
<CHAR_METHODS>
<P>Randomised: method not described.<BR/>Double-blind<BR/>crossover<BR/>Placebo-controlled <BR/>Duration: 8 weeks + 8 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-13 14:05:47 +0100" MODIFIED_BY="Helen Collins">
<P>Country: FRG<BR/>participants: 59 (31 male, 28 female) mean age 64.7 (11.5)<BR/>diagnosis:<BR/>cerebrovascular disease as diagnosed using Heinemann Scale score for acute cerebrovascular disease and Heinemann Scale score for chronic cerebrovascular disease<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:05:52 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG<BR/>Index of effectiveness</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:06:26 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Morich-1996">
<CHAR_METHODS>
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled <BR/>Duration: 26 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA and Canada<BR/>20 centres<BR/>participants : 1648 outpatients <BR/>Diagnostic criteria: DSM-III-R for PDD<BR/>inclusion criteria: Hachinski &lt;= 4<BR/>MMSE 12-23<BR/>GDS 4 or 5<BR/>Hamilton Depression Scale &lt;= 16<BR/>scan to exclude other types of dementia<BR/>exclusion criteria:<BR/>evidence of VD, brain lesions, intracranial haemorrhage<BR/>other medical conditions known to cause dementia or cognitive impairment<BR/>recent myocardial infarction or substantial arrhythmias<BR/>recent diagnosis of depression, anxiety, schizophrenia,or manic depressive illness<BR/>calcium antagonists, beta-blockers,captopril or ergoloid mesylates</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:06:19 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment 1: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Treatment 2: Nimodipine 180 mg/day t.i.d. (fixed dose)<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS-total<BR/>CGI-GI<BR/>MMSE<BR/>GDS<BR/>GERRI<BR/>BSRT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-13 14:06:26 +0100" MODIFIED_BY="Helen Collins">
<P>Stratification of patients before randomization to take account of severity of disease using MMSE scores, 12-18 and 19-23</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:06:43 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Pantoni-2000">
<CHAR_METHODS>
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled <BR/>Duration: 26 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country : Finland, Sweden, Denmark<BR/>participants: 259 (123 male, 136 female) mean age 74.3 (6.8) years<BR/>Diagnosis: dementia of mild to moderate severity according to DSM-III-R<BR/>duration &gt; 6 months<BR/>MMSE =&gt; 12<BR/>40 &lt; ZVT-G &lt; 180<BR/>DSM-III-R criteria for multi infarct dementia<BR/>CT evidence<BR/>Hachinski &gt;= 4</P>
<P>exclusion criteria:<BR/>major depression, schizophrenia, major anxiety syndrome, manic depressive illness<BR/>AD according to NINCDS-ADRDA<BR/>neurodegenerative disease<BR/>clinically relevant cardiac or pulmonary insufficiency, ECG abnormality, tachycardia<BR/>recent MI, stroke, cancer, anaemia<BR/>insulin dependent diabetes<BR/>clinically relevant impairment of liver function</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:06:43 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>GBS<BR/>CDR<BR/>MMSE<BR/>CGI<BR/>RDS<BR/>ADL<BR/>ZVT-G<BR/>FOM<BR/>word fluency test<BR/>digit span<BR/>MMSE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:07:30 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Pantoni-2005">
<CHAR_METHODS>
<P>Randomized: method not described.<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled <BR/>Duration: 52 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-13 14:07:20 +0100" MODIFIED_BY="Helen Collins">
<P>Multicentre, Italian and Spanish authors<BR/>participants: 230 (137 male, 93 female) mean age 75.3 (6.0) years<BR/>Diagnosis: subcortical vascular dementia (ICD-10)<BR/>MMSE 12-24<BR/>Global Deterioration Scale 3-5<BR/>CT evidence scan performed not &gt; 3 months before baseline showing white matter changes of severe degree, corresponding to grade 2 of van Swieten et al.'s scale</P>
<P>Exclusion criteria:</P>
<P>major depression, schizophrenia, major anxiety syndrome, or manic-depressive illness; Alzheimer disease, Parkinson disease, Huntington disease, and fronto-temporal dementia; other diseases known to cause dementia, contraindications to dihydropyridine derivatives; cardiac or pulmonary insufficiency; myocardial infarction within the past 6 months; stroke still requiring neurological rehabilitation; severe/untreated blood pressure (systolic &gt;180 mm Hg, diastolic &gt;95 mm Hg); clinically relevant liver function impairment; insulin-dependent diabetes mellitus; idiopathic epilepsy and anti-epileptic treatment; severe anaemia; severe gastrointestinal disease; and cancer<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:07:30 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG, GDS, Set test, Digit Span, MMSE, ZVT-G, NOSGER,ADL index, CGI, HAM-D, gait performance scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-10 17:03:10 +0100" MODIFIED_BY="Helen Collins">
<P>Data were not included because it is not clear who is included in any of the analyses. The study authors were contacted to clarify</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:07:51 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Tobares-1989">
<CHAR_METHODS MODIFIED="2008-10-13 14:07:42 +0100" MODIFIED_BY="Helen Collins">
<P>Randomized: method not described<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo-controlled<BR/>24 week<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-13 14:07:45 +0100" MODIFIED_BY="Helen Collins">
<P>country: Spain<BR/>participants: 65 patients (27 male, 38 female) mean age 80.4 (5.0) range 67-91<BR/>Diagnosis: DMS-III + physical and neurological examination<BR/>Hachinski &gt;7<BR/>exclusion:<BR/>depression,<BR/>serious systemic or neurological disease</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:07:51 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Short portable mental state questionnaire<BR/>digit span test<BR/>number span test<BR/>SCAG<BR/>Crichton Behaviour Rating Scale<BR/>PADL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-13 14:08:07 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Walshe-1985">
<CHAR_METHODS MODIFIED="2008-10-13 14:07:57 +0100" MODIFIED_BY="Helen Collins">
<P>Randomized: method not described<BR/>Double-blind<BR/>Parallel-group<BR/>Duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>participants : 45 <BR/>Diagnosis: all with VD, diagnosed by neurological and medical examination and CAT scan<BR/>Hachinski &gt; 5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 14:08:03 +0100" MODIFIED_BY="Helen Collins">
<P>Route: oral<BR/>Treatment: Nimodipine 90 mg/day t.i.d. (fixed dose).<BR/>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-13 14:08:07 +0100" MODIFIED_BY="Helen Collins">
<P>General status, by relative's assessment and symptomatology questionnaire<BR/>WAIS (Wechsler memory scale)<BR/>IPESC-E test<BR/>number span test<BR/>selective reminding test<BR/>non-verbal learning and memory test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>no results reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-06-10 14:47:14 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adan-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alvarez-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>A confounded comparison of nimodipine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-13 14:08:21 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Baumel-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-13 14:08:21 +0100" MODIFIED_BY="Helen Collins">
<P>No placebo group. Open label follow up study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-13 14:08:18 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Centozone-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-13 14:08:18 +0100" MODIFIED_BY="Helen Collins">
<P>An open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-10 16:48:56 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Di-Maio-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-10 16:48:56 +0100" MODIFIED_BY="Helen Collins">
<P>Uncontrolled and open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eicher-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fornazzari-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fric-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open study with no numeric data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-13 14:08:26 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Held-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-13 14:08:26 +0100" MODIFIED_BY="Helen Collins">
<P>Low dose of nimodipine used as the control. No mention of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Janssen_x002d_Cilag-NCT00814568">
<CHAR_REASON_FOR_EXCLUSION/>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kapoula-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liu-SN-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>head to head trial with no placebo group. No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liu-XD-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded trial. Experimental group was treated with nimodipine plus dihydroergotamine mesilate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mendoza-2006">
<CHAR_REASON_FOR_EXCLUSION/>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-10 16:48:59 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Navia-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-10 16:48:59 +0100" MODIFIED_BY="Helen Collins">
<P>Patients did not have primary degenerative, mixed or vascular dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-13 14:08:34 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Nimodipine-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-13 14:08:34 +0100" MODIFIED_BY="Helen Collins">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-No-author-1990b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-No-Author-1995a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Parnetti-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Politi-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case study reports</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schinco-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomization and no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simkins-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Struckmann-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report of a trial by Kanowski that we have not been able to identify so far</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sui-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded trial. Experimental group was treated with nimodipine plus Hydergine (dihydroergotamine mesilate)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sze-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tedeschi-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomization and no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-10 16:49:03 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Tomassini-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-10 16:49:03 +0100" MODIFIED_BY="Helen Collins">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsolaki-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cross-sectional study with no randomization. No numeric results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-13 14:08:45 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Tsolaki-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-13 14:08:45 +0100" MODIFIED_BY="Helen Collins">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-13 14:08:48 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Ulrich-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-13 14:08:48 +0100" MODIFIED_BY="Helen Collins">
<P>Not randomized. No efficacy measures used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Sample of MCI patients, not demented</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-13 14:08:55 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Weyer-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-13 14:08:55 +0100" MODIFIED_BY="Helen Collins">
<P>Unusable results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-13 14:08:58 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Zamperini-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-13 14:08:58 +0100" MODIFIED_BY="Helen Collins">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-10 16:49:09 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Zeng-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-10 16:49:09 +0100" MODIFIED_BY="Helen Collins">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zirm-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head to head trial with no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-10-10 17:01:48 +0100" MODIFIED_BY="Helen Collins">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-10-10 17:01:48 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-13 14:10:11 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-13 14:09:23 +0100" MODIFIED_BY="Helen Collins" NO="1">
<TITLE>Included trials - baseline characteristics</TITLE>
<TABLE COLS="8" ROWS="16">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Diagnosis</P>
</TH>
<TH>
<P>Diagnostic criteria</P>
</TH>
<TH>
<P>Mean age</P>
</TH>
<TH>
<P>Nean MMSE</P>
</TH>
<TH>
<P>Mean SCAG</P>
</TH>
<TH>
<P>Number randomized</P>
</TH>
<TH>
<P>% female</P>
</TH>
</TR>
<TR>
<TD>
<P>Ban 1990</P>
</TD>
<TD>
<P>48.3% PDD 29.2% VD 22.5% MIXED</P>
</TD>
<TD>
<P>DSM-III-R, further classified using Hachinski score &lt;= 4, 5 and 6, &gt;= 7</P>
</TD>
<TD>
<P>75.4</P>
</TD>
<TD>
<P>18.0</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>176</P>
</TD>
<TD>
<P>59</P>
</TD>
</TR>
<TR>
<TD>
<P>Besson 1988</P>
</TD>
<TD>
<P>VD</P>
</TD>
<TD>
<P>Hachinski score &gt;9</P>
</TD>
<TD>
<P>71.2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>52.8</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45</P>
</TD>
</TR>
<TR>
<TD>
<P>Bono 1985</P>
</TD>
<TD>
<P>cCVD</P>
</TD>
<TD>
<P>no recognised diagnostic criteria</P>
</TD>
<TD>
<P>56.4</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Branconnier 1988</P>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>DSM-III-R for PDD, further classified using Hachinski score &lt;= 4</P>
</TD>
<TD>
<P>69.5</P>
</TD>
<TD>
<P>4 - 23</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>227</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Dorn 1985</P>
</TD>
<TD>
<P>cerebrovascular insufficiency</P>
</TD>
<TD>
<P>Heinemann scales</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>55</P>
</TD>
</TR>
<TR>
<TD>
<P>Ferrario 1993</P>
</TD>
<TD>
<P>PDD (74%) , MIXED+VD (26%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>78.2</P>
</TD>
<TD>
<P>20.3 (10-26)</P>
</TD>
<TD>
<P>42.1</P>
</TD>
<TD>
<P>124</P>
</TD>
<TD>
<P>56</P>
</TD>
</TR>
<TR>
<TD>
<P>Fischhof 1989</P>
</TD>
<TD>
<P>52.3% PDD 47.7% VD</P>
</TD>
<TD>
<P>DSM-III-R, further classified using Hachinski score, (&lt;= 4 or &gt;= 7) SKT and scan</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>71.2</P>
</TD>
<TD>
<P>144</P>
</TD>
<TD>
<P>88</P>
</TD>
</TR>
<TR>
<TD>
<P>Kanowski 1989</P>
</TD>
<TD>
<P>chronic organic brain syndrome of diffuse type</P>
</TD>
<TD>
<P>Lausanne grading (AGP mental finding II)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>61.0</P>
</TD>
<TD>
<P>197</P>
</TD>
<TD>
<P>79</P>
</TD>
</TR>
<TR>
<TD>
<P>Menazzi 1985</P>
</TD>
<TD>
<P>chronic cerebrovascular disease</P>
</TD>
<TD>
<P>Hachinski score &gt;= 7</P>
</TD>
<TD>
<P>64.5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>63</P>
</TD>
</TR>
<TR>
<TD>
<P>Mikus 1985</P>
</TD>
<TD>
<P>cerebrovascular disease</P>
</TD>
<TD>
<P>Heinemann scales</P>
</TD>
<TD>
<P>64.7</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>47</P>
</TD>
</TR>
<TR>
<TD>
<P>Morich 1996</P>
</TD>
<TD>
<P>primary degenerative dementia with probable AD</P>
</TD>
<TD>
<P>DSM-III-R</P>
</TD>
<TD>
<P>72.1</P>
</TD>
<TD>
<P>18.0 (12-23)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1648</P>
</TD>
<TD>
<P>59</P>
</TD>
</TR>
<TR>
<TD>
<P>ANON 1997a</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pantoni 2000</P>
</TD>
<TD>
<P>VD</P>
</TD>
<TD>
<P>DSM-III-R , further classified by the Hachinski score &gt;= 4 and CT evidence</P>
</TD>
<TD>
<P>74.3</P>
</TD>
<TD>
<P>21.3 (12-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>259</P>
</TD>
<TD>
<P>53</P>
</TD>
</TR>
<TR>
<TD>
<P>Tobares 1989</P>
</TD>
<TD>
<P>VD</P>
</TD>
<TD>
<P>DSM-III and Hachinski &gt; 7</P>
</TD>
<TD>
<P>80.4</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>58</P>
</TD>
</TR>
<TR>
<TD>
<P>Walshe 1985</P>
</TD>
<TD>
<P>VD</P>
</TD>
<TD>
<P>examination +CAT scan, Hachinski &gt; 5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-10-13 14:10:11 +0100" MODIFIED_BY="Helen Collins" NO="2">
<TITLE>INCLUDED TRIALS - MAIN HYPOTHESES</TITLE>
<TABLE COLS="2" ROWS="16">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Hypothesis</P>
</TH>
</TR>
<TR>
<TD>
<P>Ban 1990</P>
</TD>
<TD>
<P>Nimodipine has therapeutic effects in elderly patients with cognitive decline</P>
</TD>
</TR>
<TR>
<TD>
<P>Beeson 1988</P>
</TD>
<TD>
<P>to determine whether the long-term administration of Nimodipine alters the clinical course in patients with multi-infarct dementia as assessed by cognitive testing and NMR</P>
</TD>
</TR>
<TR>
<TD>
<P>Bono 1985</P>
</TD>
<TD>
<P>not given</P>
</TD>
</TR>
<TR>
<TD>
<P>Branconnier 1988</P>
</TD>
<TD>
<P>To assess the relative safety and efficacy of nimodipine to that of placebo for the treatment and/or prevention of cognitive, behavioural, or affective impairments in PDD of the AD type</P>
</TD>
</TR>
<TR>
<TD>
<P>Dorn 1985</P>
</TD>
<TD>
<P>the influence of nimodipine on the well-being, the symptoms and the general efficiency of ambulatory patients with cerebrovascular disease</P>
</TD>
</TR>
<TR>
<TD>
<P>Ferrario 1993</P>
</TD>
<TD>
<P>To assess the efficacy and tolerability of nimodipine in patients with cognitive impairment (GDS = 3,4 or 5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Fischhof 1989</P>
</TD>
<TD>
<P>To confirm the efficacy of nimodipine compared with placebo in a patient sample composed of two different diagnostic dementia group, PDD and VD.</P>
</TD>
</TR>
<TR>
<TD>
<P>Kanowski 1989</P>
</TD>
<TD>
<P>to investigate whether nimodipine effects a clinically relevant improvement in elderly patients with diffuse organic brain syndrome and a defined pattern of symptoms</P>
</TD>
</TR>
<TR>
<TD>
<P>Menazzi 1985</P>
</TD>
<TD>
<P>to determine the therapeutic effect of nimodipine on the symptoms of chronic cerebrovascular insufficiency and on psychic performance</P>
</TD>
</TR>
<TR>
<TD>
<P>Mikus 1985</P>
</TD>
<TD>
<P>not given</P>
</TD>
</TR>
<TR>
<TD>
<P>Morich 1996</P>
</TD>
<TD>
<P>To evaluate the efficacy and tolerability of nimodipine 90 and 180 mg/day in PDD patients</P>
</TD>
</TR>
<TR>
<TD>
<P>Pantoni 2000</P>
</TD>
<TD>
<P>to evaluate the efficacy of nimodipine in improving cognition or slowing cognitive deterioration in patients with VD</P>
</TD>
</TR>
<TR>
<TD>
<P>Tobares 1989</P>
</TD>
<TD>
<P>to evaluate the effect of nimodipine on mental performance in senile vascular dementia</P>
</TD>
</TR>
<TR>
<TD>
<P>Walske 1985</P>
</TD>
<TD>
<P>not given</P>
</TD>
</TR>
<TR>
<TD>
<P>ANON 1997a</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-10-13 14:46:22 +0100" MODIFIED_BY="Helen Collins">
<COMPARISON ID="CMP-001" MODIFIED="2008-10-13 14:44:10 +0100" MODIFIED_BY="Helen Collins" NO="1">
<NAME>Nimodipine vs placebo (all types of dementia)</NAME>
<CONT_OUTCOME CHI2="30.576833541258804" CI_END="-4.866869012059237" CI_START="-9.176188285525825" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.021528648792531" ESTIMABLE="YES" I2="86.91820068744984" I2_Q="55.39873036319476" ID="CMP-001.01" MODIFIED="2008-10-13 14:43:29 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="3.734272709832176E-6" P_Q="0.1342995660188674" P_Z="1.6910381973006367E-10" Q="2.2420886403977924" RANDOM="NO" SCALE="31.067855869525317" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="304" TOTAL_2="303" UNITS="" WEIGHT="200.0" Z="6.387061340655269">
<NAME>SCAG - change from baseline</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="28.33474490086101" CI_END="-5.3121896403512725" CI_START="-9.873813270661117" DF="3" EFFECT_SIZE="-7.593001455506195" ESTIMABLE="YES" I2="89.4122921858074" ID="CMP-001.01.01" NO="1" P_CHI2="3.0894412147430828E-6" P_Z="6.805878733769063E-11" STUDIES="4" TAU2="0.0" TOTAL_1="243" TOTAL_2="247" WEIGHT="100.00000000000001" Z="6.524873857837985">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="-2.46628661995271" CI_START="-10.73371338004729" EFFECT_SIZE="-6.6" ESTIMABLE="YES" MEAN_1="-12.7" MEAN_2="-6.1" ORDER="4805" SD_1="13.95" SD_2="13.95" SE="2.1090761935696234" STUDY_ID="STD-Ban-1990" TOTAL_1="87" TOTAL_2="88" WEIGHT="30.443752805500083"/>
<CONT_DATA CI_END="-17.298841609610715" CI_START="-30.701158390389285" EFFECT_SIZE="-24.0" ESTIMABLE="YES" MEAN_1="-29.3" MEAN_2="-5.3" ORDER="4806" SD_1="12.9" SD_2="15.2" SE="3.419021187760167" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="34" WEIGHT="11.584549291613664"/>
<CONT_DATA CI_END="6.6893282195973836" CI_START="-7.489328219597384" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="-1.86" MEAN_2="-1.46" ORDER="4807" SD_1="18.19" SD_2="20.71" SE="3.617070658194283" STUDY_ID="STD-Ferrario-1993" TOTAL_1="61" TOTAL_2="56" WEIGHT="10.350676629842473"/>
<CONT_DATA CI_END="-2.4948581629004334" CI_START="-9.105141837099566" EFFECT_SIZE="-5.8" ESTIMABLE="YES" MEAN_1="-5.7" MEAN_2="0.1" ORDER="4808" SD_1="8.5" SD_2="10.7" SE="1.6863278423328711" STUDY_ID="STD-Fischhof-1989" TOTAL_1="61" TOTAL_2="69" WEIGHT="47.621021273043795"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.289780484828392" CI_START="-8.849780484828393" DF="0" EFFECT_SIZE="-2.2800000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="0.4963823469104033" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="56" WEIGHT="99.99999999999999" Z="0.680192876317701">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="4.289780484828392" CI_START="-8.849780484828393" EFFECT_SIZE="-2.2800000000000002" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-4.22" ORDER="4809" SD_1="16.81" SD_2="19.23" SE="3.3519904124004225" STUDY_ID="STD-Ferrario-1993" TOTAL_1="61" TOTAL_2="56" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="30.983496245200744" CI_END="0.2769341025512571" CI_START="0.12672420409911805" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.20182915332518758" ESTIMABLE="YES" I2="74.17980225120922" I2_Q="91.06450680764952" ID="CMP-001.02" MODIFIED="2008-10-13 14:43:53 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.4145706278678727E-4" P_Q="1.3793424045727143E-5" P_Z="1.38670161615421E-7" Q="22.382648130851543" RANDOM="NO" SCALE="1.2418919409997504" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1367" TOTAL_2="1389" UNITS="" WEIGHT="300.0" Z="5.267001384381096">
<NAME>Cognitive function - change from baseline</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.17621819214148" CI_END="0.8051742936094193" CI_START="0.4218279582747" DF="3" EFFECT_SIZE="0.6135011259420596" ESTIMABLE="YES" I2="58.19525104064931" ID="CMP-001.02.01" NO="1" P_CHI2="0.0664883449675554" P_Z="3.532755352357458E-10" STUDIES="4" TAU2="0.0" TOTAL_1="215" TOTAL_2="228" WEIGHT="100.0" Z="6.273387798379744">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="1.2198831192494768" CI_START="0.596756888875031" EFFECT_SIZE="0.9083200040622539" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="0.8" ORDER="4810" SD_1="2.85" SD_2="2.85" SE="0.15896369404988714" STUDY_ID="STD-Ban-1990" TOTAL_1="87" TOTAL_2="88" WEIGHT="37.84692202643906"/>
<CONT_DATA CI_END="0.9841391291254156" CI_START="0.048412287335832416" EFFECT_SIZE="0.516275708230624" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="5.7" ORDER="4811" SD_1="7.9" SD_2="6.7" SE="0.23871021334332596" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="39" WEIGHT="16.783574341511518"/>
<CONT_DATA CI_END="0.8812727458260845" CI_START="0.18002108041832304" EFFECT_SIZE="0.5306469131222038" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="0.9" ORDER="4812" SD_1="5.5" SD_2="6.4" SE="0.17889401819093237" STUDY_ID="STD-Fischhof-1989" TOTAL_1="61" TOTAL_2="69" WEIGHT="29.883731138962332"/>
<CONT_DATA CI_END="0.6453052857061329" CI_START="-0.3288425693345166" EFFECT_SIZE="0.1582313581858081" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.3" ORDER="4813" SD_1="5.7" SD_2="2.3" SE="0.24851167233801322" STUDY_ID="STD-Tobares-1989" TOTAL_1="33" TOTAL_2="32" WEIGHT="15.48577249308709"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4246299222077194" CI_END="0.19169336688349853" CI_START="-0.02247150727383465" DF="3" EFFECT_SIZE="0.08461092980483194" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.6997716508203006" P_Z="0.12146327636075702" STUDIES="4" TAU2="0.0" TOTAL_1="665" TOTAL_2="678" WEIGHT="100.0" Z="1.5486608228209204">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.4325367838093872" CI_START="-0.3000987240725683" EFFECT_SIZE="0.06621902986840945" ESTIMABLE="YES" MEAN_1="3.46" MEAN_2="1.69" ORDER="4814" SD_1="26.97" SD_2="26.07" SE="0.18690024757110102" STUDY_ID="STD-Ferrario-1993" TOTAL_1="61" TOTAL_2="54" WEIGHT="8.54516706673323"/>
<CONT_DATA CI_END="0.2169780177711511" CI_START="-0.03699573603123757" EFFECT_SIZE="0.08999114086995677" ESTIMABLE="YES" MEAN_1="-1.68" MEAN_2="-1.97" ORDER="4815" SD_1="3.22" SD_2="3.22" SE="0.06479041344782385" STUDY_ID="STD-Morich-1996" TOTAL_1="471" TOTAL_2="483" WEIGHT="71.10805648023467"/>
<CONT_DATA CI_END="0.26553372052211854" CI_START="-0.27726514445923345" EFFECT_SIZE="-0.005865711968557435" ESTIMABLE="YES" MEAN_1="-0.68" MEAN_2="-0.66" ORDER="4816" SD_1="3.49" SD_2="3.31" SE="0.13847164265845704" STUDY_ID="STD-Pantoni-2000" TOTAL_1="100" TOTAL_2="109" WEIGHT="15.567490988601772"/>
<CONT_DATA CI_END="0.8219744487890968" CI_START="-0.15766610831190025" EFFECT_SIZE="0.3321541702385983" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="0.3" ORDER="4817" SD_1="5.3" SD_2="2.5" SE="0.24991289759104676" STUDY_ID="STD-Tobares-1989" TOTAL_1="33" TOTAL_2="32" WEIGHT="4.779285464430324"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3123268824522641" CI_START="0.06005510753218779" DF="0" EFFECT_SIZE="0.18619099499222594" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="1.0" P_Z="0.0038142219381838965" STUDIES="1" TAU2="0.0" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0" Z="2.8931309857874927">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.3123268824522641" CI_START="0.06005510753218779" EFFECT_SIZE="0.18619099499222594" ESTIMABLE="YES" MEAN_1="-1.37" MEAN_2="-1.97" ORDER="4818" SD_1="3.22" SD_2="3.22" SE="0.06435622718324517" STUDY_ID="STD-Morich-1996" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="48.59260770400357" CI_START="8.073715873678903" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="19.807142857142857" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.6865702059383045" LOG_CI_START="0.9070734618609428" LOG_EFFECT_SIZE="1.2968218338996236" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="6.963144861728661E-11" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="61" TOTAL_2="69" WEIGHT="100.0" Z="6.521448891532999">
<NAME>CGI - Numbers improved compared with baseline</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="48.59260770400357" CI_START="8.073715873678903" DF="0" EFFECT_SIZE="19.807142857142857" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="10" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.6865702059383045" LOG_CI_START="0.9070734618609428" LOG_EFFECT_SIZE="1.2968218338996236" NO="1" P_CHI2="1.0" P_Z="6.963144861728661E-11" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="69" WEIGHT="100.0" Z="6.521448891532999">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="48.59260770400357" CI_START="8.073715873678903" EFFECT_SIZE="19.807142857142857" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="10" LOG_CI_END="1.6865702059383045" LOG_CI_START="0.9070734618609428" LOG_EFFECT_SIZE="1.2968218338996236" ORDER="4819" O_E="0.0" SE="0.4578802460421558" STUDY_ID="STD-Fischhof-1989" TOTAL_1="61" TOTAL_2="69" VAR="0.20965431971562518" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="77.3335420218855" CI_END="-0.04211200525672969" CI_START="-0.18204775607461243" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.11207988066567107" ESTIMABLE="YES" I2="94.82760016492198" I2_Q="96.94127200994217" ID="CMP-001.04" MODIFIED="2008-10-13 14:44:10 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="8.881784197001252E-16" P_Q="6.5503158452884236E-15" P_Z="0.0016916720895671302" Q="65.38665767275987" RANDOM="NO" SCALE="1.7348365124764749" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1206" TOTAL_2="1232" UNITS="" WEIGHT="300.0" Z="3.1396198357080585">
<NAME>Clinical Global Impression - global</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.652538294908467" CI_END="-0.6729440050875493" CI_START="-1.0742622643271436" DF="1" EFFECT_SIZE="-0.8736031347073464" ESTIMABLE="YES" I2="91.41817881485147" ID="CMP-001.04.01" NO="1" P_CHI2="6.41156888191996E-4" P_Z="1.4256180752219987E-17" STUDIES="2" TAU2="0.0" TOTAL_1="148" TOTAL_2="157" WEIGHT="100.0" Z="8.533031534881944">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="-0.34516175578203057" CI_START="-0.8548382442179687" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="3.3" ORDER="4820" SD_1="0.86" SD_2="0.86" SE="0.1300219015390592" STUDY_ID="STD-Ban-1990" TOTAL_1="87" TOTAL_2="88" WEIGHT="61.999564623979616"/>
<CONT_DATA CI_END="-0.9944897730250578" CI_START="-1.6455102269749418" EFFECT_SIZE="-1.3199999999999998" ESTIMABLE="YES" MEAN_1="2.72" MEAN_2="4.04" ORDER="4821" SD_1="1.05" SD_2="0.81" SE="0.1660796981692139" STUDY_ID="STD-Fischhof-1989" TOTAL_1="61" TOTAL_2="69" WEIGHT="38.000435376020384"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2943460542171761" CI_END="0.1503663785767915" CI_START="-0.05372337902613363" DF="1" EFFECT_SIZE="0.04832149977532894" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="0.5874489240967516" P_Z="0.35335292911894933" STUDIES="2" TAU2="0.0" TOTAL_1="571" TOTAL_2="592" WEIGHT="100.00000000000001" Z="0.9281053625715867">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.17042248387297954" CI_START="-0.05042248387298032" EFFECT_SIZE="0.05999999999999961" ESTIMABLE="YES" MEAN_1="4.51" MEAN_2="4.45" ORDER="4822" SD_1="0.87" SD_2="0.87" SE="0.056339037219039934" STUDY_ID="STD-Morich-1996" TOTAL_1="471" TOTAL_2="483" WEIGHT="85.4018747191616"/>
<CONT_DATA CI_END="0.24708080157453033" CI_START="-0.28708080157453036" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="3.97" MEAN_2="3.99" ORDER="4823" SD_1="0.94" SD_2="1.03" SE="0.13626821904954867" STUDY_ID="STD-Pantoni-2000" TOTAL_1="100" TOTAL_2="109" WEIGHT="14.598125280838415"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.039500263633846386" CI_START="-0.17950026363384697" DF="0" EFFECT_SIZE="-0.07000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="0.21022684110917256" STUDIES="1" TAU2="0.0" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0" Z="1.2529419963459927">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.039500263633846386" CI_START="-0.17950026363384697" EFFECT_SIZE="-0.07000000000000028" ESTIMABLE="YES" MEAN_1="4.38" MEAN_2="4.45" ORDER="4824" SD_1="0.87" SD_2="0.87" SE="0.055868508042785876" STUDY_ID="STD-Morich-1996" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.9813219857721527" CI_END="0.026683432062817262" CI_START="-0.05237981687933113" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.012848192408256933" ESTIMABLE="YES" I2="24.648144241512064" I2_Q="39.05654081199083" ID="CMP-001.05" NO="5" P_CHI2="0.2634881687162993" P_Q="0.19381246378726025" P_Z="0.5241190869650467" Q="3.2817303557220896" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1145" TOTAL_2="1163" UNITS="" WEIGHT="300.0" Z="0.6370088435159179">
<NAME>Clinical Global Impression - Severity of disease</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.685711861809134E-32" CI_END="0.02077942649943737" CI_START="-0.8207794264994375" DF="0" EFFECT_SIZE="-0.4" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.05.01" NO="1" P_CHI2="0.0" P_Z="0.062437687144625255" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="88" WEIGHT="100.0" Z="1.8631747287128118">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="0.020779426499437426" CI_START="-0.8207794264994374" EFFECT_SIZE="-0.39999999999999997" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.2" ORDER="4825" SD_1="1.42" SD_2="1.42" SE="0.21468732579705127" STUDY_ID="STD-Ban-1990" TOTAL_1="87" TOTAL_2="88" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6995916300500629" CI_END="0.04569238235601909" CI_START="-0.06342907175221879" DF="1" EFFECT_SIZE="-0.008868344698099849" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="0.40292137441719167" P_Z="0.750049473028686" STUDIES="2" TAU2="0.0" TOTAL_1="571" TOTAL_2="592" WEIGHT="100.0" Z="0.31857413105073823">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.05838430181789743" CI_START="-0.05838430181789743" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.19" ORDER="4826" SD_1="0.46" SD_2="0.46" SE="0.029788456460641804" STUDY_ID="STD-Morich-1996" TOTAL_1="471" TOTAL_2="483" WEIGHT="87.33093614557164"/>
<CONT_DATA CI_END="0.08328790417604127" CI_START="-0.22328790417604127" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="-0.11" ORDER="4827" SD_1="0.56" SD_2="0.57" SE="0.07820955149439311" STUDY_ID="STD-Pantoni-2000" TOTAL_1="100" TOTAL_2="109" WEIGHT="12.669063854428357"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.04789669111674651" CI_START="-0.06789669111674654" DF="0" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.03" NO="3" P_CHI2="1.0" P_Z="0.7349654767858589" STUDIES="1" TAU2="0.0" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0" Z="0.3385278064661522">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.04789669111674651" CI_START="-0.06789669111674654" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="0.19" ORDER="4828" SD_1="0.46" SD_2="0.46" SE="0.029539670919174144" STUDY_ID="STD-Morich-1996" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3288750254037403" CI_END="-0.020603596713665198" CI_START="-0.18556436147731642" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.10308397909549082" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.8564578007745651" P_Q="0.9047710030924812" P_Z="0.014302971731016006" Q="0.20014697522631653" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1124" TOTAL_2="1139" UNITS="" WEIGHT="300.0" Z="2.449562921216053">
<NAME>Activities of Daily Living</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3247947789875315" CI_START="-0.6494377465100641" DF="0" EFFECT_SIZE="-0.16232148376126632" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.5136803944144557" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.6531177183325736">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="0.32479477898753145" CI_START="-0.649437746510064" EFFECT_SIZE="-0.16232148376126632" ESTIMABLE="YES" MEAN_1="-0.43" MEAN_2="-0.19" ORDER="4829" SD_1="1.17" SD_2="1.71" SE="0.2485332723412821" STUDY_ID="STD-Tobares-1989" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1287280501774237" CI_END="-0.003623359773162707" CI_START="-0.2276390905178241" DF="2" EFFECT_SIZE="-0.1156312251454934" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="0.5687218793228559" P_Z="0.04303530708600507" STUDIES="3" TAU2="0.0" TOTAL_1="604" TOTAL_2="624" WEIGHT="100.0" Z="2.0233671628331424">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.04370993883643716" CI_START="-0.21024526849233427" EFFECT_SIZE="-0.08326766482794855" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.14" ORDER="4830" SD_1="0.36" SD_2="0.36" SE="0.06478568211761483" STUDY_ID="STD-Morich-1996" TOTAL_1="471" TOTAL_2="483" WEIGHT="77.81132087326088"/>
<CONT_DATA CI_END="0.038895805398314776" CI_START="-0.5057793896950962" EFFECT_SIZE="-0.23344179214839073" ESTIMABLE="YES" MEAN_1="0.07" MEAN_2="0.15" ORDER="4831" SD_1="0.32" SD_2="0.36" SE="0.13895030709485975" STUDY_ID="STD-Pantoni-2000" TOTAL_1="100" TOTAL_2="109" WEIGHT="16.915383065154128"/>
<CONT_DATA CI_END="0.27248843015231416" CI_START="-0.7030344026867573" EFFECT_SIZE="-0.2152729862672216" ESTIMABLE="YES" MEAN_1="-0.63" MEAN_2="-0.24" ORDER="4832" SD_1="1.62" SD_2="1.95" SE="0.24886243842587696" STUDY_ID="STD-Tobares-1989" TOTAL_1="33" TOTAL_2="32" WEIGHT="5.273296061584984"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.04264837419012896" CI_START="-0.20918587526650895" DF="0" EFFECT_SIZE="-0.08326875053819" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" NO="3" P_CHI2="1.0" P_Z="0.19493401317038017" STUDIES="1" TAU2="0.0" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0" Z="1.2961203842974813">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.04264837419012896" CI_START="-0.20918587526650895" EFFECT_SIZE="-0.08326875053819" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.14" ORDER="4833" SD_1="0.36" SD_2="0.36" SE="0.06424461149364843" STUDY_ID="STD-Morich-1996" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.107320686448487" CI_END="1.9650138926264902" CI_START="0.7802302244287728" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.238209687593189" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="37" I2="25.992812766995964" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.2933656251794839" LOG_CI_START="-0.10777723007089605" LOG_EFFECT_SIZE="0.09279419755429387" METHOD="PETO" NO="7" P_CHI2="0.2303457804207587" P_Q="0.5353813768034308" P_Z="0.36452546317016266" Q="1.2495531012681553" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="511" TOTAL_2="518" WEIGHT="300.0" Z="0.9067756426432755">
<NAME>Withdrawals before end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8200189098244306" CI_END="3.0058553336919767" CI_START="0.7799926701511467" DF="2" EFFECT_SIZE="1.5311907548749342" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.4779680749564248" LOG_CI_START="-0.10790947849909324" LOG_EFFECT_SIZE="0.18502929822866573" NO="1" P_CHI2="0.40252046528560437" P_Z="0.2157255082512195" STUDIES="3" TAU2="0.0" TOTAL_1="230" TOTAL_2="239" WEIGHT="100.0" Z="1.2379745852148936">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="19.112696467556674" CI_START="0.2015371752284838" EFFECT_SIZE="1.962630596182275" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2813219627414851" LOG_CI_START="-0.6956448328605285" LOG_EFFECT_SIZE="0.2928385649404784" ORDER="4834" O_E="0.5" SE="1.16128008188009" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="0.7415254237288136" WEIGHT="8.782435489730364"/>
<DICH_DATA CI_END="2.513895738576797" CI_START="0.39778897137799935" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.40034726177486524" LOG_CI_START="-0.4003472617748653" LOG_EFFECT_SIZE="0.0" ORDER="4835" O_E="0.0" SE="0.47033192663492585" STUDY_ID="STD-Branconnier-1988" TOTAL_1="70" TOTAL_2="77" VAR="4.520547945205479" WEIGHT="53.54020163915465"/>
<DICH_DATA CI_END="7.944545991737507" CI_START="0.882245744277088" EFFECT_SIZE="2.6474595164844374" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.9000690835551065" LOG_CI_START="-0.054410427886026486" LOG_EFFECT_SIZE="0.42282932783453997" ORDER="4836" O_E="3.0972222222222223" SE="0.5606659897703029" STUDY_ID="STD-Fischhof-1989" TOTAL_1="71" TOTAL_2="73" VAR="3.1812044051627386" WEIGHT="37.67736287111499"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.0377486753559015" CI_END="2.036707675063064" CI_START="0.30627474752315675" DF="2" EFFECT_SIZE="0.7898051208737606" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="60.299726546824886" ID="CMP-001.07.02" LOG_CI_END="0.3089286999783597" LOG_CI_START="-0.5138888094730625" LOG_EFFECT_SIZE="-0.10248005474735133" NO="2" P_CHI2="0.08055030416079412" P_Z="0.6253953397230871" STUDIES="3" TAU2="0.0" TOTAL_1="201" TOTAL_2="202" WEIGHT="100.0" Z="0.4882181386062494">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="102.29824003226075" CI_START="0.8544440687358337" EFFECT_SIZE="9.349231221746512" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0098681620518235" LOG_CI_START="-0.06831636060199149" LOG_EFFECT_SIZE="0.9707759007249159" ORDER="4837" O_E="1.5" SE="1.2207358757861475" STUDY_ID="STD-Besson-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.6710526315789473" WEIGHT="15.676129320908263"/>
<DICH_DATA CI_END="1.7932887915995468" CI_START="0.08590095750446594" EFFECT_SIZE="0.39248595424604404" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2536502340678613" LOG_CI_START="-1.066001995230593" LOG_EFFECT_SIZE="-0.4061758805813658" ORDER="4838" O_E="-1.556451612903226" SE="0.7751702518737998" STUDY_ID="STD-Ferrario-1993" TOTAL_1="63" TOTAL_2="61" VAR="1.6642010989568794" WEIGHT="38.87658048797397"/>
<DICH_DATA CI_END="2.4967568977372" CI_START="0.15025995434777928" EFFECT_SIZE="0.6125051652610733" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3973762583661568" LOG_CI_START="-0.8231567474442884" LOG_EFFECT_SIZE="-0.21289024453906571" ORDER="4839" O_E="-0.9536679536679538" SE="0.7169471293488741" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="1.9454753821279818" WEIGHT="45.44729019111777"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.97723874391574" CI_START="0.5412470814914621" DF="0" EFFECT_SIZE="1.269417890628496" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.47381366199232133" LOG_CI_START="-0.26660443243178034" LOG_EFFECT_SIZE="0.10360461478027047" NO="3" P_CHI2="1.0" P_Z="0.5833455699927683" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="77" WEIGHT="100.0" Z="0.5485044601980393">
<NAME>nimodipine 180 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="2.97723874391574" CI_START="0.5412470814914622" EFFECT_SIZE="1.269417890628496" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.47381366199232133" LOG_CI_START="-0.2666044324317802" LOG_EFFECT_SIZE="0.10360461478027047" ORDER="4840" O_E="1.261146496815286" SE="0.4349252537933951" STUDY_ID="STD-Branconnier-1988" TOTAL_1="80" TOTAL_2="77" VAR="5.2865305816744" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.709107474531557" CI_END="1.8182630442655159" CI_START="0.9410283126354304" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.308066131536376" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.2596567118943523" LOG_CI_START="-0.026397309796591065" LOG_EFFECT_SIZE="0.11662970104888067" METHOD="PETO" NO="8" P_CHI2="0.45240194861279326" P_Q="0.6335564148337154" P_Z="0.10999187096400924" Q="0.9128125594915417" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1396" TOTAL_2="1418" WEIGHT="300.0" Z="1.5982296786615442">
<NAME>Withdrawals before end of treatment due to an adverse event</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1471752806840656" CI_END="6.53274735431086" CI_START="0.6567228367710864" DF="2" EFFECT_SIZE="2.0712808535859732" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="6.854367317286609" ID="CMP-001.08.01" LOG_CI_END="0.8150958627282583" LOG_CI_START="-0.18261788136548351" LOG_EFFECT_SIZE="0.3162389906813874" NO="1" P_CHI2="0.34178034315036643" P_Z="0.21406150090086395" STUDIES="3" TAU2="0.0" TOTAL_1="230" TOTAL_2="239" WEIGHT="99.99999999999999" Z="1.242474679560155">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="120.42589505670153" CI_START="0.463797468547941" EFFECT_SIZE="7.473501540437265" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0807198828606" LOG_CI_START="-0.3336716261134276" LOG_EFFECT_SIZE="0.8735241283735862" ORDER="4841" O_E="1.0" SE="1.4182255238020633" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="0.4971751412429378" WEIGHT="17.07640788111185"/>
<DICH_DATA CI_END="5.477999815978266" CI_START="0.05714841211671996" EFFECT_SIZE="0.5595167477912006" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7386220133287449" LOG_CI_START="-1.2429958320845669" LOG_EFFECT_SIZE="-0.25218690937791094" ORDER="4842" O_E="-0.4285714285714286" SE="1.1640121315623142" STUDY_ID="STD-Branconnier-1988" TOTAL_1="70" TOTAL_2="77" VAR="0.7380486441151803" WEIGHT="25.34965777151354"/>
<DICH_DATA CI_END="11.446568895547225" CI_START="0.5543377984053459" EFFECT_SIZE="2.518981103710935" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.058675326585229" LOG_CI_START="-0.25622550733719685" LOG_EFFECT_SIZE="0.4012249096240161" ORDER="4843" O_E="1.5486111111111112" SE="0.7723792587101345" STUDY_ID="STD-Fischhof-1989" TOTAL_1="71" TOTAL_2="73" VAR="1.6762500134895968" WEIGHT="57.5739343473746"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6491196343559495" CI_END="2.17565316702406" CI_START="0.8506335734245383" DF="1" EFFECT_SIZE="1.3603983343117154" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="32" I2="39.36158546856778" ID="CMP-001.08.02" LOG_CI_END="0.33758966324436357" LOG_CI_START="-0.0702574802332465" LOG_EFFECT_SIZE="0.1336660915055585" NO="2" P_CHI2="0.19907886305139544" P_Z="0.19889694509662947" STUDIES="2" TAU2="0.0" TOTAL_1="616" TOTAL_2="628" WEIGHT="100.0" Z="1.2847005526202104">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="11.858435473756433" CI_START="0.81023120720316" EFFECT_SIZE="3.099689418222808" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.074027394767321" LOG_CI_START="-0.09139103336285277" LOG_EFFECT_SIZE="0.491318180702234" ORDER="4844" O_E="2.4140127388535033" SE="0.684572553597923" STUDY_ID="STD-Branconnier-1988" TOTAL_1="80" TOTAL_2="77" VAR="2.1338359802394855" WEIGHT="12.247038628299919"/>
<DICH_DATA CI_END="2.0018901096286625" CI_START="0.7346190388551244" EFFECT_SIZE="1.2126939383987154" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" LOG_CI_END="0.3014402339366326" LOG_CI_START="-0.13393782039233695" LOG_EFFECT_SIZE="0.08375120677214778" ORDER="4845" O_E="2.9484820607175735" SE="0.2557432242689636" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="15.28944523085028" WEIGHT="87.75296137170008"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8949203213381969" CI_START="0.690641260937287" DF="0" EFFECT_SIZE="1.1439887062837208" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.2775909532325025" LOG_CI_START="-0.16074747918365043" LOG_EFFECT_SIZE="0.058421737024426046" NO="3" P_CHI2="1.0" P_Z="0.6013585028506248" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="0.5224479170169417">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.8949203213381969" CI_START="0.690641260937287" EFFECT_SIZE="1.1439887062837208" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" LOG_CI_END="0.2775909532325025" LOG_CI_START="-0.16074747918365043" LOG_EFFECT_SIZE="0.058421737024426046" ORDER="4846" O_E="2.029064486830155" SE="0.2574821650114829" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="15.083623920455436" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0260622621034692" CI_END="0.9417935607299164" CI_START="0.6759516311925198" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7978764902050934" ESTIMABLE="YES" EVENTS_1="368" EVENTS_2="437" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.026044283259430413" LOG_CI_START="-0.1700843795875608" LOG_EFFECT_SIZE="-0.09806433142349556" METHOD="PETO" NO="9" P_CHI2="0.9604364169833618" P_Q="0.61338664229169" P_Z="0.0076137072025594735" Q="0.977519778847567" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1400" TOTAL_2="1417" WEIGHT="300.0" Z="2.6687368678260817">
<NAME>number of patients with at least one adverse event by end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.024723169804293996" CI_END="2.570592553218595" CI_START="0.5357707114268955" DF="1" EFFECT_SIZE="1.1735621845588782" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.41003324509412453" LOG_CI_START="-0.2710210313275663" LOG_EFFECT_SIZE="0.06950610688327917" NO="1" P_CHI2="0.8750588498142937" P_Z="0.6891162638756412" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="123" WEIGHT="100.0" Z="0.40005465324314066">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="2.9037755855647305" CI_START="0.43532938276664085" EFFECT_SIZE="1.1243214991081223" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4629630494533631" LOG_CI_START="-0.36118201893780455" LOG_EFFECT_SIZE="0.0508905152577793" ORDER="4847" O_E="0.5" SE="0.48410689275685503" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="4.266949152542373" WEIGHT="68.28984392396607"/>
<DICH_DATA CI_END="5.179805752398698" CI_START="0.31980000654930724" EFFECT_SIZE="1.2870516359265634" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7143134735979066" LOG_CI_START="-0.4951215316957004" LOG_EFFECT_SIZE="0.1095959709511031" ORDER="4848" O_E="0.5" SE="0.7104281089092949" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="34" VAR="1.9813432835820894" WEIGHT="31.71015607603393"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.023819313451608207" CI_END="0.9777170260218655" CI_START="0.6221864252981382" DF="2" EFFECT_SIZE="0.7799501659552815" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="243" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-0.009786821919660875" LOG_CI_START="-0.2060794684481832" LOG_EFFECT_SIZE="-0.10793314518392204" NO="2" P_CHI2="0.9881609833583332" P_Z="0.031130154328422956" STUDIES="3" TAU2="0.0" TOTAL_1="727" TOTAL_2="743" WEIGHT="100.0" Z="2.1554050142971755">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="2.942468213913715" CI_START="0.19715660130516624" EFFECT_SIZE="0.7616607069448385" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4687117800638372" LOG_CI_START="-0.7051886770619181" LOG_EFFECT_SIZE="-0.11823844849904043" ORDER="4849" O_E="-0.57258064516129" SE="0.6895549394166484" STUDY_ID="STD-Ferrario-1993" TOTAL_1="63" TOTAL_2="61" VAR="2.103111278901551" WEIGHT="2.7960537604533924"/>
<DICH_DATA CI_END="1.0199996095828634" CI_START="0.6082552111779392" EFFECT_SIZE="0.7876674919839208" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="181" LOG_CI_END="0.00860000553050529" LOG_CI_START="-0.21591416159791932" LOG_EFFECT_SIZE="-0.10365707803370706" ORDER="4850" O_E="-13.723091076356951" SE="0.13188073313428772" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="57.49595533823134" WEIGHT="76.43997906676982"/>
<DICH_DATA CI_END="1.2390802540384847" CI_START="0.4595428891987057" EFFECT_SIZE="0.7545929498013557" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="57" LOG_CI_END="0.09309943612369348" LOG_CI_START="-0.33767394962477904" LOG_EFFECT_SIZE="-0.12228725675054282" ORDER="4851" O_E="-4.3976833976833944" SE="0.25303841915130254" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="15.618059342581208" WEIGHT="20.763967172776795"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0191933263106379" CI_START="0.6097433936322632" DF="0" EFFECT_SIZE="0.7883187157184605" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="181" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.008256571235434261" LOG_CI_START="-0.214852896425624" LOG_EFFECT_SIZE="-0.10329816259509488" NO="3" P_CHI2="1.0" P_Z="0.06953928968220807" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="1.8148999276276456">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.0191933263106379" CI_START="0.6097433936322632" EFFECT_SIZE="0.7883187157184605" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="181" LOG_CI_END="0.008256571235434261" LOG_CI_START="-0.214852896425624" LOG_EFFECT_SIZE="-0.10329816259509488" ORDER="4852" O_E="-13.848319709355138" SE="0.1310556057137822" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="58.22222469705932" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.50711794245267" CI_END="2.1483353604935544" CI_START="1.1158039419962837" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.5482638870582481" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="62" I2="57.92626088986891" I2_Q="22.093874703083905" ID="CMP-001.10" LOG_CI_END="0.3321020767684014" LOG_CI_START="0.0475878913853466" LOG_EFFECT_SIZE="0.18984498407687403" METHOD="PETO" NO="10" P_CHI2="0.04960123021997942" P_Q="0.2770393621508259" P_Z="0.008906775499761712" Q="2.5671922360117296" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1364" TOTAL_2="1387" WEIGHT="300.0" Z="2.6156118081444117">
<NAME>number of patients with at least one serious adverse event before end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.877216094799277" CI_START="0.0545570753123135" DF="0" EFFECT_SIZE="0.3961975456432873" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.4589724810264141" LOG_CI_START="-1.2631489193224101" LOG_EFFECT_SIZE="-0.40208821914799797" NO="1" P_CHI2="1.0" P_Z="0.36006490885013276" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="77" WEIGHT="100.0" Z="0.915241431850618">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="2.8772160947992784" CI_START="0.05455707531231348" EFFECT_SIZE="0.3961975456432873" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4589724810264143" LOG_CI_START="-1.2631489193224104" LOG_EFFECT_SIZE="-0.40208821914799797" ORDER="4853" O_E="-0.9047619047619047" SE="1.0115826352033148" STUDY_ID="STD-Branconnier-1988" TOTAL_1="70" TOTAL_2="77" VAR="0.9772310750784331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.93992570644094" CI_END="2.1872008492805906" CI_START="0.9638335361196825" DF="2" EFFECT_SIZE="1.4519288993494426" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="42" I2="71.18124768765462" ID="CMP-001.10.02" LOG_CI_END="0.33988866585844096" LOG_CI_START="-0.015997966706384988" LOG_EFFECT_SIZE="0.1619453495760279" NO="2" P_CHI2="0.031118218134841613" P_Z="0.07446369252671986" STUDIES="3" TAU2="0.0" TOTAL_1="744" TOTAL_2="759" WEIGHT="100.0" Z="1.7837537214885253">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="5.863240344859335" CI_START="0.2854412334933232" EFFECT_SIZE="1.2936810102588916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7681376970684339" LOG_CI_START="-0.5444832905586436" LOG_EFFECT_SIZE="0.11182720325489523" ORDER="4854" O_E="0.43312101910828016" SE="0.7710400657108257" STUDY_ID="STD-Branconnier-1988" TOTAL_1="80" TOTAL_2="77" VAR="1.6820779123509455" WEIGHT="7.350970225814467"/>
<DICH_DATA CI_END="3.9553245942607265" CI_START="1.337134256688934" EFFECT_SIZE="2.2997391180980236" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="17" LOG_CI_END="0.5971821297330107" LOG_CI_START="0.12617501534865075" LOG_EFFECT_SIZE="0.3616785725408307" ORDER="4855" O_E="10.879484820607175" SE="0.27667191051219153" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="13.063810195740807" WEIGHT="57.09110088150677"/>
<DICH_DATA CI_END="1.412631103317777" CI_START="0.35744453037235835" EFFECT_SIZE="0.7105893760216297" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.1500287643182129" LOG_CI_START="-0.44679134413507676" LOG_EFFECT_SIZE="-0.14838128990843197" ORDER="4856" O_E="-2.7799227799227815" SE="0.35057508601264564" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="8.13650510911892" WEIGHT="35.55792889267877"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4517362759383925" CI_START="1.110269386493788" DF="0" EFFECT_SIZE="1.9576407018205542" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.5380376067766672" LOG_CI_START="0.04542836515917347" LOG_EFFECT_SIZE="0.29173298596792036" NO="3" P_CHI2="1.0" P_Z="0.0202620697985021" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="2.3214592715393643">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="3.4517362759383925" CI_START="1.110269386493788" EFFECT_SIZE="1.9576407018205542" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5380376067766672" LOG_CI_START="0.04542836515917347" LOG_EFFECT_SIZE="0.29173298596792036" ORDER="4857" O_E="8.022706630336057" SE="0.2893611069811888" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="11.943171965705357" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1773494414094734" CI_END="0.9527725212151078" CI_START="0.1793388032751279" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.41336313786807827" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" I2="54.072599419197246" I2_Q="54.072599419197246" ID="CMP-001.11" LOG_CI_END="-0.021010776773744713" LOG_CI_START="-0.7463257326073108" LOG_EFFECT_SIZE="-0.3836682546905278" METHOD="PETO" NO="11" P_CHI2="0.14005556081225368" P_Q="0.14005556081225368" P_Z="0.038124314859747536" Q="2.1773494414094734" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="217" TOTAL_2="220" WEIGHT="200.0" Z="2.0735156642139523">
<NAME>number of patients with at least one adverse event of a cerebrovascular problem during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="372.3848896839504" CI_START="0.1466175227450357" DF="0" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" NO="1" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="89" WEIGHT="100.0" Z="1.0">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="4858" O_E="0.5" SE="2.0" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="0.25" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8471877577728719" CI_START="0.15332923564130913" DF="0" EFFECT_SIZE="0.360414554844819" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="-0.07202032859710385" LOG_CI_START="-0.8143750293129638" LOG_EFFECT_SIZE="-0.4431976789550337" NO="2" P_CHI2="1.0" P_Z="0.019270321740501244" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="2.3402599537551594">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="0.8471877577728719" CI_START="0.15332923564130913" EFFECT_SIZE="0.360414554844819" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.07202032859710385" LOG_CI_START="-0.8143750293129638" LOG_EFFECT_SIZE="-0.4431976789550337" ORDER="4859" O_E="-5.366795366795367" SE="0.4360628259155297" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="5.258984250094963" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9417023398862936" CI_END="5.868300685319509" CI_START="1.023042761401203" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.4502086723056555" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.7685123585164144" LOG_CI_START="0.00989378684261662" LOG_EFFECT_SIZE="0.38920307267951554" METHOD="PETO" NO="12" P_CHI2="0.5845946056177301" P_Q="0.41083927414158383" P_Z="0.044316259329347366" Q="0.6763716884230342" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="314" TOTAL_2="315" WEIGHT="200.0" Z="2.0110870827775784">
<NAME>number of patients with at least one adverse event of a psychiatricproblem during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="118.13259129726035" CI_START="0.4621768593542267" DF="1" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="2.072369730533861" LOG_CI_START="-0.3351918029208536" LOG_EFFECT_SIZE="0.8685889638065036" NO="1" P_CHI2="1.0" P_Z="0.15729920705263303" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="123" WEIGHT="100.0" Z="1.4142135623730951">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="4860" O_E="0.5" SE="2.0" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="0.25" WEIGHT="50.0"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="4861" O_E="0.5" SE="2.0" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="34" VAR="0.25" WEIGHT="50.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2653306514632594" CI_END="5.445383229437723" CI_START="0.8643524161403504" DF="1" EFFECT_SIZE="2.1694999772239316" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" I2="20.969274012008206" ID="CMP-001.12.02" LOG_CI_END="0.7360284494863567" LOG_CI_START="-0.06330914967460542" LOG_EFFECT_SIZE="0.33635964990587564" NO="2" P_CHI2="0.2606445749971078" P_Z="0.09904569657541147" STUDIES="2" TAU2="0.0" TOTAL_1="191" TOTAL_2="192" WEIGHT="100.0" Z="1.649497785066068">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="19.83815146441578" CI_START="0.9502742747819949" EFFECT_SIZE="4.341852714667216" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.2975012017795577" LOG_CI_START="-0.022151027518896346" LOG_EFFECT_SIZE="0.6376750871303307" ORDER="4862" O_E="2.443548387096774" SE="0.7751702518737998" STUDY_ID="STD-Ferrario-1993" TOTAL_1="63" TOTAL_2="61" VAR="1.6642010989568794" WEIGHT="36.68947454660858"/>
<DICH_DATA CI_END="4.613616003760943" CI_START="0.45650286354757025" EFFECT_SIZE="1.4512508112058948" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6640414448908356" LOG_CI_START="-0.3405564938821293" LOG_EFFECT_SIZE="0.16174247550435314" ORDER="4863" O_E="1.0694980694980698" SE="0.5901058020752374" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="2.8717076855713835" WEIGHT="63.31052545339143"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8544637039447514" CI_END="1.4531049492072237" CI_START="1.030606980189457" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.223756554058368" ESTIMABLE="YES" EVENTS_1="391" EVENTS_2="344" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.1622969819618835" LOG_CI_START="0.013093079564506704" LOG_EFFECT_SIZE="0.0876950307631951" METHOD="PETO" NO="13" P_CHI2="0.7224112637413114" P_Q="0.44759371894912636" P_Z="0.021225498309088688" Q="1.6077395102873229" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1408" TOTAL_2="1429" WEIGHT="300.0" Z="2.3039491482096284">
<NAME>number of patients with at least one adverse event of a CNS problem during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.21362358474246526" CI_END="3.8898953709671993" CI_START="0.9146127698124562" DF="2" EFFECT_SIZE="1.8861993477681416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.5899379199831116" LOG_CI_START="-0.0387627392986904" LOG_EFFECT_SIZE="0.27558759034221064" NO="1" P_CHI2="0.8986948001736169" P_Z="0.08574563256061836" STUDIES="3" TAU2="0.0" TOTAL_1="194" TOTAL_2="196" WEIGHT="100.0" Z="1.7182795776735584">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="7.655592165295859" CI_START="0.5278270115258664" EFFECT_SIZE="2.0101811694643223" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8839787893091084" LOG_CI_START="-0.2775083885448042" LOG_EFFECT_SIZE="0.3032352003821521" ORDER="4864" O_E="1.5" SE="0.6822633177256446" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="2.148305084745763" WEIGHT="29.299417882972264"/>
<DICH_DATA CI_END="16.32548279165502" CI_START="0.06125393121673332" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2128660334785861" LOG_CI_START="-1.2128660334785861" LOG_EFFECT_SIZE="0.0" ORDER="4865" O_E="0.0" SE="1.42488702369803" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="34" VAR="0.4925373134328358" WEIGHT="6.717414892183696"/>
<DICH_DATA CI_END="4.840050149852555" CI_START="0.7922653633820093" EFFECT_SIZE="1.9582145160222062" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6848498615806516" LOG_CI_START="-0.10112933034234907" LOG_EFFECT_SIZE="0.2918602656191513" ORDER="4866" O_E="3.1527777777777786" SE="0.4616880679953184" STUDY_ID="STD-Fischhof-1989" TOTAL_1="71" TOTAL_2="73" VAR="4.691402540360874" WEIGHT="63.983167224844046"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0331006089149632" CI_END="1.5752152691096137" CI_START="0.9659174524459554" DF="1" EFFECT_SIZE="1.2335022982517414" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="171" I2="3.204006330973698" ID="CMP-001.13.02" LOG_CI_END="0.19733991291796746" LOG_CI_START="-0.015059986916851795" LOG_EFFECT_SIZE="0.09113996300055782" NO="2" P_CHI2="0.309431853812537" P_Z="0.09256385661542778" STUDIES="2" TAU2="0.0" TOTAL_1="664" TOTAL_2="682" WEIGHT="100.0" Z="1.6820256993748643">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.530923573788775" CI_START="0.9156909935321036" EFFECT_SIZE="1.1839987028305234" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="161" LOG_CI_END="0.18495351054784914" LOG_CI_START="-0.038251057385287716" LOG_EFFECT_SIZE="0.07335122658128074" ORDER="4867" O_E="9.825206991720336" SE="0.13111146808435517" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="58.17262203970206" WEIGHT="90.55291986107959"/>
<DICH_DATA CI_END="4.047360145616397" CI_START="0.8243813486800211" EFFECT_SIZE="1.826627552468486" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.6071718508691566" LOG_CI_START="-0.0838718425320508" LOG_EFFECT_SIZE="0.2616500041685529" ORDER="4868" O_E="3.6563706563706564" SE="0.40592248622532023" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="6.068953084486892" WEIGHT="9.447080138920414"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4845584954390636" CI_START="0.8896749436042228" DF="0" EFFECT_SIZE="1.1492495358741368" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="161" I2="0.0" ID="CMP-001.13.03" LOG_CI_END="0.17159731459349745" LOG_CI_START="-0.050768640529472144" LOG_EFFECT_SIZE="0.06041433703201266" NO="3" P_CHI2="1.0" P_Z="0.28687572736477374" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="1.0650004823546653">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.4845584954390636" CI_START="0.8896749436042228" EFFECT_SIZE="1.1492495358741368" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="161" LOG_CI_END="0.17159731459349745" LOG_CI_START="-0.050768640529472144" LOG_EFFECT_SIZE="0.06041433703201266" ORDER="4869" O_E="8.153496821071741" SE="0.13061886276846255" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="58.61222437533049" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5201493104398947" CI_START="0.3143255073480504" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8900265224120342" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.40142627204312453" LOG_CI_START="-0.502620374785731" LOG_EFFECT_SIZE="-0.05059705137130323" METHOD="PETO" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.8263479798993254" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="0.21938779101616593">
<NAME>number of patients with at least one adverse event of problems due to circulation</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5201493104398947" CI_START="0.3143255073480504" DF="0" EFFECT_SIZE="0.8900265224120342" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.40142627204312453" LOG_CI_START="-0.502620374785731" LOG_EFFECT_SIZE="-0.05059705137130323" NO="1" P_CHI2="1.0" P_Z="0.8263479798993254" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="0.21938779101616593">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="2.5201493104398947" CI_START="0.3143255073480504" EFFECT_SIZE="0.8900265224120342" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.40142627204312453" LOG_CI_START="-0.502620374785731" LOG_EFFECT_SIZE="-0.05059705137130323" ORDER="4870" O_E="-0.4131274131274134" SE="0.5310414754503451" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="3.546035806069927" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.505319298071849" CI_END="1.3666006173238072" CI_START="0.8813759467543152" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0974921015336747" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="184" I2="27.342997137315237" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.1356416125671619" LOG_CI_START="-0.054838805805238415" LOG_EFFECT_SIZE="0.040401403380961674" METHOD="PETO" NO="15" P_CHI2="0.23926253633335104" P_Q="0.8026023205115116" P_Z="0.40573237563510256" Q="0.43979218401751474" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1337" TOTAL_2="1356" WEIGHT="300.0" Z="0.8314271485560043">
<NAME>number of patients with at least one adverse event due to cardiac problems during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.676770063584809" CI_END="4.944414192670443" CI_START="0.05304403907066153" DF="1" EFFECT_SIZE="0.5121246914741999" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="62.641542745708584" ID="CMP-001.15.01" LOG_CI_END="0.694114844373778" LOG_CI_START="-1.2753634137263345" LOG_EFFECT_SIZE="-0.29062428467627816" NO="1" P_CHI2="0.10182212017318526" P_Z="0.5629666664442405" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="123" WEIGHT="100.00000000000001" Z="0.5784406389413075">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="2.1561135362183066" CI_START="0.00830386188559494" EFFECT_SIZE="0.13380608735935193" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.33367162611342754" LOG_CI_START="-2.0807198828606" LOG_EFFECT_SIZE="-0.8735241283735862" ORDER="4871" O_E="-1.0" SE="1.4182255238020633" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="0.4971751412429378" WEIGHT="66.54064272211721"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="4872" O_E="0.5" SE="2.0" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="34" VAR="0.25" WEIGHT="33.4593572778828"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3887570504695255" CI_END="1.5042611742493808" CI_START="0.8193048590077234" DF="1" EFFECT_SIZE="1.110156966054432" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="96" I2="58.13722455352068" ID="CMP-001.15.02" LOG_CI_END="0.1773232462875563" LOG_CI_START="-0.08655446948579618" LOG_EFFECT_SIZE="0.045384388400880014" NO="2" P_CHI2="0.12221094652186182" P_Z="0.5001909735069237" STUDIES="2" TAU2="0.0" TOTAL_1="664" TOTAL_2="682" WEIGHT="100.0" Z="0.6741893036735543">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.6408973576288723" CI_START="0.869339768718044" EFFECT_SIZE="1.1943606362280756" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="86" LOG_CI_END="0.21508141566030534" LOG_CI_START="-0.0608104527344837" LOG_EFFECT_SIZE="0.07713548146291085" ORDER="4873" O_E="6.762649494020238" SE="0.16206024918187314" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="38.07562100602173" WEIGHT="91.48031078609115"/>
<DICH_DATA CI_END="1.4337710234945804" CI_START="0.178827025253596" EFFECT_SIZE="0.5063566006544592" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.15647979904933906" LOG_CI_START="-0.7475668477795163" LOG_EFFECT_SIZE="-0.2955435243650887" ORDER="4874" O_E="-2.4131274131274134" SE="0.5310414754503451" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="3.546035806069927" WEIGHT="8.51968921390884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.515132979860382" CI_START="0.798879696595282" DF="0" EFFECT_SIZE="1.100185882136454" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="86" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="0.18045075157435891" LOG_CI_START="-0.09751861622865583" LOG_EFFECT_SIZE="0.04146606767285155" NO="3" P_CHI2="1.0" P_Z="0.5587124189334878" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="0.5847550747166046">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.515132979860382" CI_START="0.798879696595282" EFFECT_SIZE="1.100185882136454" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="86" LOG_CI_END="0.18045075157435891" LOG_CI_START="-0.09751861622865583" LOG_EFFECT_SIZE="0.04146606767285155" ORDER="4875" O_E="3.5812897366030825" SE="0.1632805826180529" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="37.50860542104816" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.669862495733474" CI_END="1.3503217071435705" CI_START="0.8990286474691257" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1018066518321101" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="219" I2="0.0" I2_Q="19.966642195210266" ID="CMP-001.16" LOG_CI_END="0.13043724923030733" LOG_CI_START="-0.046226469290645514" LOG_EFFECT_SIZE="0.04210538996983086" METHOD="PETO" NO="16" P_CHI2="0.5978554103262923" P_Q="0.2866541971061888" P_Z="0.35016907328007296" Q="2.498958003084442" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1400" TOTAL_2="1417" WEIGHT="300.0" Z="0.9342614158333237">
<NAME>number of patients with at least one adverse event of a gastrointestinal problem during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9995373116223387" CI_END="6.8829213238556735" CI_START="0.737122682445017" DF="1" EFFECT_SIZE="2.252455866226573" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.8377728053214767" LOG_CI_START="-0.1324602246581565" LOG_EFFECT_SIZE="0.35265629033166007" NO="1" P_CHI2="0.31742274354858535" P_Z="0.15421525037104464" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="123" WEIGHT="100.0" Z="1.424799211352481">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="6.068440379380016" CI_START="0.29771371678157244" EFFECT_SIZE="1.3441197641626288" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7830770894836727" LOG_CI_START="-0.5262011553253584" LOG_EFFECT_SIZE="0.12843796707915722" ORDER="4876" O_E="0.5" SE="0.7690765220326613" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="1.6906779661016949" WEIGHT="54.91464842546373"/>
<DICH_DATA CI_END="22.29676208257426" CI_START="0.8003380806874887" EFFECT_SIZE="4.224328085117568" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.348241799740079" LOG_CI_START="-0.09672651855651458" LOG_EFFECT_SIZE="0.6257576405917823" ORDER="4877" O_E="2.0" SE="0.8487815428759521" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="34" VAR="1.3880597014925373" WEIGHT="45.08535157453627"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1713671810266933" CI_END="1.3040217718528395" CI_START="0.7310663112188971" DF="2" EFFECT_SIZE="0.9763843436360427" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="113" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.11528484240557568" LOG_CI_START="-0.13604322866412255" LOG_EFFECT_SIZE="-0.010379193129273384" NO="2" P_CHI2="0.9178846485138817" P_Z="0.8713981554050723" STUDIES="3" TAU2="0.0" TOTAL_1="727" TOTAL_2="743" WEIGHT="100.0" Z="0.16188279037338407">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="5.9645230041631105" CI_START="0.2857087154702064" EFFECT_SIZE="1.305418019605957" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7755757179237095" LOG_CI_START="-0.5440765113747447" LOG_EFFECT_SIZE="0.11574960327448242" ORDER="4878" O_E="0.443548387096774" SE="0.7751702518737998" STUDY_ID="STD-Ferrario-1993" TOTAL_1="63" TOTAL_2="61" VAR="1.6642010989568794" WEIGHT="3.6271290245539465"/>
<DICH_DATA CI_END="1.3226257099769443" CI_START="0.7153123800717518" EFFECT_SIZE="0.9726718586181562" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="102" LOG_CI_END="0.1214369605217458" LOG_CI_START="-0.1455042584585472" LOG_EFFECT_SIZE="-0.012033648968400729" ORDER="4879" O_E="-1.126954921803133" SE="0.156802593409369" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="40.671811615746115" WEIGHT="88.6442801204312"/>
<DICH_DATA CI_END="2.5201493104398947" CI_START="0.3143255073480504" EFFECT_SIZE="0.8900265224120342" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.40142627204312453" LOG_CI_START="-0.502620374785731" LOG_EFFECT_SIZE="-0.05059705137130323" ORDER="4880" O_E="-0.4131274131274134" SE="0.5310414754503451" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="3.546035806069927" WEIGHT="7.728590855014838"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5982734188230727" CI_START="0.8845259454306922" DF="0" EFFECT_SIZE="1.1889971853798573" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="102" I2="0.0" ID="CMP-001.16.03" LOG_CI_END="0.20365107668551694" LOG_CI_START="-0.05328942358849272" LOG_EFFECT_SIZE="0.07518082654851208" NO="3" P_CHI2="1.0" P_Z="0.25139342947986654" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="1.1469714755431377">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.5982734188230727" CI_START="0.8845259454306922" EFFECT_SIZE="1.1889971853798573" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="102" LOG_CI_END="0.20365107668551694" LOG_CI_START="-0.05328942358849272" LOG_EFFECT_SIZE="0.07518082654851208" ORDER="4881" O_E="7.599455040871931" SE="0.1509281217369422" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="43.899509239804296" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06667147610517513" CI_END="1.2853091732009452" CI_START="0.7446737537186578" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9783332799698539" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="116" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.10900760709505722" LOG_CI_START="-0.12803395274455742" LOG_EFFECT_SIZE="-0.009513172824750078" METHOD="PETO" NO="17" P_CHI2="0.9672137749352866" P_Q="0.7969929042369006" P_Z="0.8749940750158941" Q="0.06617282214008746" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1214" TOTAL_2="1233" WEIGHT="200.0" Z="0.1573182030006139">
<NAME>number of patients with at least one adverse event of urogenital problems during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.986539650876601E-4" CI_END="1.4712560040888278" CI_START="0.6958296414237592" DF="1" EFFECT_SIZE="1.0118021238205037" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="61" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.16768824817932537" LOG_CI_START="-0.15749707482300615" LOG_EFFECT_SIZE="0.005095586678159622" NO="1" P_CHI2="0.9821842709111743" P_Z="0.9510211731819148" STUDIES="2" TAU2="0.0" TOTAL_1="664" TOTAL_2="682" WEIGHT="99.99999999999999" Z="0.06142445961021031">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.5007434750731603" CI_START="0.6801695502189342" EFFECT_SIZE="1.0103266869852106" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="55" LOG_CI_END="0.1763064638081003" LOG_CI_START="-0.1673828144319603" LOG_EFFECT_SIZE="0.004461824688069981" ORDER="4882" O_E="0.25206991720331473" SE="0.20188478332757695" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="24.535382214347454" WEIGHT="89.52202624920098"/>
<DICH_DATA CI_END="3.256936646100024" CI_START="0.32226368733888233" EFFECT_SIZE="1.0244961752009258" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5128093107549965" LOG_CI_START="-0.4917886280179685" LOG_EFFECT_SIZE="0.01051034136851395" ORDER="4883" O_E="0.0694980694980698" SE="0.5901058020752374" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="2.8717076855713835" WEIGHT="10.477973750799013"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.402987045795843" CI_START="0.6321097038392659" DF="0" EFFECT_SIZE="0.941722743703441" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="55" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.14705366107443565" LOG_CI_START="-0.1992075425444124" LOG_EFFECT_SIZE="-0.026076940734988393" NO="2" P_CHI2="1.0" P_Z="0.7678335532698619" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="0.2952098827902336">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.4029870457958429" CI_START="0.6321097038392659" EFFECT_SIZE="0.941722743703441" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="55" LOG_CI_END="0.1470536610744356" LOG_CI_START="-0.1992075425444124" LOG_EFFECT_SIZE="-0.026076940734988393" ORDER="4884" O_E="-1.4514078110808342" SE="0.20339554502631257" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="24.172252786460334" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1549154242772028" CI_END="1.4214313079806469" CI_START="0.9156273255953273" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1408336193520017" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="183" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.1527258768398357" LOG_CI_START="-0.03828125490293218" LOG_EFFECT_SIZE="0.05722231096845178" METHOD="PETO" NO="18" P_CHI2="0.5613237841420562" P_Q="0.3179115935164023" P_Z="0.24025884176438972" Q="0.997519983231273" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1214" TOTAL_2="1233" WEIGHT="200.0" Z="1.1743401158586664">
<NAME>number of patients with at least one adverse event of a pulmonary problem during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.15739544104592987" CI_END="1.7240894895362842" CI_START="0.9365237042119015" DF="1" EFFECT_SIZE="1.270689055250468" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="92" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="0.2365598042979354" LOG_CI_START="-0.028481225786722554" LOG_EFFECT_SIZE="0.10403928925560638" NO="1" P_CHI2="0.6915660724268473" P_Z="0.12387028453546503" STUDIES="2" TAU2="0.0" TOTAL_1="664" TOTAL_2="682" WEIGHT="100.0" Z="1.5387297570719574">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.7144937209678073" CI_START="0.9261300834814558" EFFECT_SIZE="1.2600969061656913" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="91" LOG_CI_END="0.2341358989265964" LOG_CI_START="-0.033328008382419144" LOG_EFFECT_SIZE="0.10040394527208861" ORDER="4885" O_E="9.366145354185832" SE="0.15710962312100957" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="40.5130020837683" WEIGHT="98.1964645765189"/>
<DICH_DATA CI_END="19.442521656064958" CI_START="0.2066286796953607" EFFECT_SIZE="2.0043409340082743" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.288752591366613" LOG_CI_START="-0.6848093993265543" LOG_EFFECT_SIZE="0.3019715960200294" ORDER="4886" O_E="0.5173745173745175" SE="1.1592800826225775" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="0.7440862019294273" WEIGHT="1.803535423481094"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3944058410164886" CI_START="0.7393945329280818" DF="0" EFFECT_SIZE="1.015389607751909" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="91" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.14438919331874445" LOG_CI_START="-0.1311237649178269" LOG_EFFECT_SIZE="0.006632714200458734" NO="2" P_CHI2="1.0" P_Z="0.9248163875812893" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="0.0943685628135436">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.3944058410164886" CI_START="0.7393945329280818" EFFECT_SIZE="1.015389607751909" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="91" LOG_CI_END="0.14438919331874445" LOG_CI_START="-0.1311237649178269" LOG_EFFECT_SIZE="0.006632714200458734" ORDER="4887" O_E="0.5831062670299758" SE="0.16183767547930059" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="38.18042304865283" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2044448501560538" CI_END="1.223797123396759" CI_START="0.6470758629971995" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8898817785276021" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="86" I2="0.0" I2_Q="7.773301475958704" ID="CMP-001.19" LOG_CI_END="0.08770942802848218" LOG_CI_START="-0.18904479978006736" LOG_EFFECT_SIZE="-0.05066768587579257" METHOD="PETO" NO="19" P_CHI2="0.5475935493680903" P_Q="0.2977414568286769" P_Z="0.47297088022548917" Q="1.0842847201554373" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1214" TOTAL_2="1233" WEIGHT="200.0" Z="0.7176536400754807">
<NAME>number of patients with at least one adverse event (skeletal) during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.12016013000061651" CI_END="1.1777833509024869" CI_START="0.4822856007825164" DF="1" EFFECT_SIZE="0.7536762905794843" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="47" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.07106541085792036" LOG_CI_START="-0.31669570426938587" LOG_EFFECT_SIZE="-0.12281514670573278" NO="1" P_CHI2="0.7288609386086523" P_Z="0.21440102944824035" STUDIES="2" TAU2="0.0" TOTAL_1="664" TOTAL_2="682" WEIGHT="100.0" Z="1.2415544256943378">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.1899509832710886" CI_START="0.44287198927850246" EFFECT_SIZE="0.7259448733238475" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" LOG_CI_END="0.07552907220486277" LOG_CI_START="-0.3537217870588281" LOG_EFFECT_SIZE="-0.13909635742698268" ORDER="4888" O_E="-5.03771849126035" SE="0.2521440795575141" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="15.72904842806425" WEIGHT="81.60300747329413"/>
<DICH_DATA CI_END="2.5201493104398947" CI_START="0.3143255073480504" EFFECT_SIZE="0.8900265224120342" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.40142627204312453" LOG_CI_START="-0.502620374785731" LOG_EFFECT_SIZE="-0.05059705137130323" ORDER="4889" O_E="-0.4131274131274134" SE="0.5310414754503451" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="3.546035806069927" WEIGHT="18.396992526705876"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6665018555151527" CI_START="0.6709404068129825" DF="0" EFFECT_SIZE="1.0574135581190203" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="39" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.22180580154863003" LOG_CI_START="-0.1733160523222547" LOG_EFFECT_SIZE="0.024244874613187653" NO="2" P_CHI2="1.0" P_Z="0.8099203851475834" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="0.24052874112635309">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.6665018555151527" CI_START="0.6709404068129825" EFFECT_SIZE="1.0574135581190203" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="39" LOG_CI_END="0.22180580154863003" LOG_CI_START="-0.1733160523222547" LOG_EFFECT_SIZE="0.024244874613187653" ORDER="4890" O_E="1.0363306085376962" SE="0.23209653284847845" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="18.563621049644407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.033951412987057" CI_END="1.1778852425614734" CI_START="0.6583047857534048" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8805722527121371" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="105" I2="43.13295948256559" I2_Q="41.59435014803256" ID="CMP-001.20" LOG_CI_END="0.07110298064630247" LOG_CI_START="-0.18157298765630256" LOG_EFFECT_SIZE="-0.05523500350500007" METHOD="PETO" NO="20" P_CHI2="0.13410508877423066" P_Q="0.18047525500210992" P_Z="0.3915019161254928" Q="3.4243262510889236" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1346" TOTAL_2="1365" WEIGHT="300.0" Z="0.8568968254716892">
<NAME>number of patients with at least one adverse event of a skin problem during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4714033761652807" CI_END="20.499318300696142" CI_START="0.7827973506765766" DF="1" EFFECT_SIZE="4.0058472332904556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="71.1932065611845" ID="CMP-001.20.01" LOG_CI_END="1.3117394189499691" LOG_CI_START="-0.10635065285114756" LOG_EFFECT_SIZE="0.6026943830494107" NO="1" P_CHI2="0.062438433542627125" P_Z="0.09571615199657027" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="132" WEIGHT="100.0" Z="1.665986255670086">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="4891" O_E="-0.5" SE="2.0" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="0.25" WEIGHT="17.346938775510203"/>
<DICH_DATA CI_END="49.135117071863334" CI_START="1.3538560710034488" EFFECT_SIZE="8.156094442023546" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6913919951617005" LOG_CI_START="0.13157249677787514" LOG_EFFECT_SIZE="0.9114822459697878" ORDER="4892" O_E="2.5" SE="0.9162456945817024" STUDY_ID="STD-Menazzi-1985" TOTAL_1="43" TOTAL_2="43" VAR="1.1911764705882353" WEIGHT="82.65306122448979"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1382217857328528" CI_END="1.2742866676360323" CI_START="0.5654324265450661" DF="1" EFFECT_SIZE="0.8488362637137199" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="55" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="0.1052671392769327" LOG_CI_START="-0.24761928911538206" LOG_EFFECT_SIZE="-0.07117607491922472" NO="2" P_CHI2="0.710055344692293" P_Z="0.4291558234840367" STUDIES="2" TAU2="0.0" TOTAL_1="664" TOTAL_2="682" WEIGHT="100.0" Z="0.7906370558831226">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.3383584278493796" CI_START="0.5673343139254862" EFFECT_SIZE="0.8713763024378848" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="49" LOG_CI_END="0.12657243808881352" LOG_CI_START="-0.24616094832704002" LOG_EFFECT_SIZE="-0.05979425511911325" ORDER="4893" O_E="-2.8721251149953986" SE="0.21894543624069185" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="20.86066773962586" WEIGHT="89.63411241506907"/>
<DICH_DATA CI_END="2.390186081650373" CI_START="0.19159242092266304" EFFECT_SIZE="0.6767137783723995" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.37843171311887785" LOG_CI_START="-0.7176216748846594" LOG_EFFECT_SIZE="-0.16959498088289068" ORDER="4894" O_E="-0.942084942084942" SE="0.6438271856650506" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="2.4124669828180654" WEIGHT="10.365887584930935"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2706758665958122" CI_START="0.536626978003914" DF="0" EFFECT_SIZE="0.8257596201763654" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" I2="0.0" ID="CMP-001.20.03" LOG_CI_END="0.10403478163067498" LOG_CI_START="-0.2703274977026248" LOG_EFFECT_SIZE="-0.08314635803597495" NO="3" P_CHI2="1.0" P_Z="0.3839610298254851" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="0.870621193387352">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.2706758665958122" CI_START="0.536626978003914" EFFECT_SIZE="0.8257596201763654" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="0.10403478163067498" LOG_CI_START="-0.2703274977026248" LOG_EFFECT_SIZE="-0.08314635803597495" ORDER="4895" O_E="-3.959128065395099" SE="0.21990225600354982" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="20.6795283950434" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.893889135943174" CI_END="1.3209757847047596" CI_START="0.5447944115559724" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8483278996401795" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" I2="70.98879949240185" I2_Q="77.68350846081955" ID="CMP-001.21" LOG_CI_END="0.12089485647486671" LOG_CI_START="-0.26376735601974205" LOG_EFFECT_SIZE="-0.07143624977243765" METHOD="PETO" NO="21" P_CHI2="0.03184280994921462" P_Q="0.0342738846395404" P_Z="0.466628132774059" Q="4.480991101331173" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1214" TOTAL_2="1233" WEIGHT="200.0" Z="0.7279762461541385">
<NAME>number of patients with at least one adverse event of a blood problem during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4128980346120006" CI_END="0.97841985913155" CI_START="0.2738798572258392" DF="1" EFFECT_SIZE="0.5176576970603979" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="26" I2="58.556060568850256" ID="CMP-001.21.01" LOG_CI_END="-0.009474740943440543" LOG_CI_START="-0.5624399072033108" LOG_EFFECT_SIZE="-0.2859573240733756" NO="1" P_CHI2="0.12033960324531534" P_Z="0.042649150039779746" STUDIES="2" TAU2="0.0" TOTAL_1="664" TOTAL_2="682" WEIGHT="100.0" Z="2.0271297018223735">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.408896529606388" CI_START="0.3301562511564189" EFFECT_SIZE="0.6820234574280664" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.14887909937547789" LOG_CI_START="-0.48128047541039604" LOG_EFFECT_SIZE="-0.16620068801745913" ORDER="4896" O_E="-2.793008279668813" SE="0.3701588535694256" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="7.29833370871989" WEIGHT="77.00066381892493"/>
<DICH_DATA CI_END="0.775563952587854" CI_START="0.05452414946597308" EFFECT_SIZE="0.20563794608807248" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.11038238468357828" LOG_CI_START="-1.2634111003501898" LOG_EFFECT_SIZE="-0.6868967425168842" ORDER="4897" O_E="-3.447876447876448" SE="0.677294775166761" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="2.1799400447151194" WEIGHT="22.999336181075062"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4970721268030633" CI_START="0.7277535505509543" DF="0" EFFECT_SIZE="1.3480553053427562" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="0.3974310869329135" LOG_CI_START="-0.1380156670558632" LOG_EFFECT_SIZE="0.1297077099385251" NO="2" P_CHI2="1.0" P_Z="0.34233012960433773" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="0.9495713181669823">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="2.4970721268030633" CI_START="0.7277535505509543" EFFECT_SIZE="1.3480553053427562" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="0.3974310869329135" LOG_CI_START="-0.1380156670558632" LOG_EFFECT_SIZE="0.1297077099385251" ORDER="4898" O_E="3.0190735694822877" SE="0.31452407379718644" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="10.108628024560284" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.512306985421297" CI_START="1.174290680645138" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.7867651134004126" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="1.2903086200765699" LOG_CI_START="0.06977561426612491" LOG_EFFECT_SIZE="0.6800421171713474" METHOD="PETO" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.02895791177107999" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="2.1840590156612416">
<NAME>number of patients with at least one adverse event of an autonomic problem during treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.512306985421297" CI_START="1.174290680645138" DF="0" EFFECT_SIZE="4.7867651134004126" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="1.2903086200765699" LOG_CI_START="0.06977561426612491" LOG_EFFECT_SIZE="0.6800421171713474" NO="1" P_CHI2="1.0" P_Z="0.02895791177107999" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="2.1840590156612416">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="19.512306985421297" CI_START="1.174290680645138" EFFECT_SIZE="4.7867651134004126" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.2903086200765699" LOG_CI_START="0.06977561426612491" LOG_EFFECT_SIZE="0.6800421171713474" ORDER="4899" O_E="3.0463320463320462" SE="0.7169471293488741" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="1.9454753821279818" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3220971396752397E-4" CI_END="33.074118813321896" CI_START="1.7042343447135826" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.507732627285073" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="1.5194882821986222" LOG_CI_START="0.23152931321135828" LOG_EFFECT_SIZE="0.8755087977049902" METHOD="PETO" MODIFIED="2008-10-10 17:05:08 +0100" MODIFIED_BY="Helen Collins" NO="23" P_CHI2="0.9998339089384279" P_Q="0.9998339089384279" P_Z="0.007707354795475052" Q="3.3220971396752397E-4" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1175" TOTAL_2="1191" WEIGHT="300.0" Z="2.6646279159017423">
<NAME>Number of deaths before end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="372.3848896839504" CI_START="0.1466175227450357" DF="0" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" NO="1" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="89" WEIGHT="100.0" Z="1.0">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="4900" O_E="0.5" SE="2.0" STUDY_ID="STD-Ban-1990" TOTAL_1="89" TOTAL_2="89" VAR="0.25" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.49377865939131" CI_START="0.7915618424115312" DF="0" EFFECT_SIZE="7.6272452983638255" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.23.02" LOG_CI_END="1.8662505770671538" LOG_CI_START="-0.1015151493185086" LOG_EFFECT_SIZE="0.8823677138743227" NO="2" P_CHI2="1.0" P_Z="0.07879198751011376" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="551" WEIGHT="100.00000000000001" Z="1.757738654683397">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="73.49377865939131" CI_START="0.7915618424115312" EFFECT_SIZE="7.6272452983638255" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8662505770671538" LOG_CI_START="-0.1015151493185086" LOG_EFFECT_SIZE="0.8823677138743227" ORDER="4901" O_E="1.5206991720331187" SE="1.155875328276378" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="0.7484762289737334" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.57151229529082" CI_START="0.7712303670691263" DF="0" EFFECT_SIZE="7.429543976529759" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.23.03" LOG_CI_END="1.8547401938879804" LOG_CI_START="-0.11281587849460957" LOG_EFFECT_SIZE="0.8709621576966855" MODIFIED="2008-10-10 17:05:08 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="1.0" P_Z="0.08270488029262818" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="99.99999999999999" Z="1.735202858961636">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="71.57151229529082" CI_START="0.771230367069126" EFFECT_SIZE="7.429543976529759" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8547401938879804" LOG_CI_START="-0.11281587849460976" LOG_EFFECT_SIZE="0.8709621576966855" ORDER="4902" O_E="1.5013623978201636" SE="1.1557521764771694" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="0.7486357460520161" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-10-13 14:45:39 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Nimodipine vs placebo (primary degenerative dementia)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.3294201828104555" CI_START="-10.470579817189545" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2008-10-13 14:44:41 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.011404683916408668" Q="0.0" RANDOM="NO" SCALE="12.762713697726328" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="36" UNITS="" WEIGHT="100.00000000000001" Z="2.530048258931163">
<NAME>SCAG - change from baseline</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.3294201828104555" CI_START="-10.470579817189545" DF="0" EFFECT_SIZE="-5.9" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="0.011404683916408668" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="36" WEIGHT="100.00000000000001" Z="2.530048258931163">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="-1.3294201828104555" CI_START="-10.470579817189545" EFFECT_SIZE="-5.9" ESTIMABLE="YES" MEAN_1="-5.7" MEAN_2="0.2" ORDER="4903" SD_1="8.5" SD_2="10.7" SE="2.33197132867833" STUDY_ID="STD-Fischhof-1989" TOTAL_1="32" TOTAL_2="36" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.58694717567548" CI_END="0.2418008874548151" CI_START="0.06575749765980948" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1537791925573123" ESTIMABLE="YES" I2="56.39801542503098" I2_Q="56.39801542503098" ID="CMP-002.02" MODIFIED="2008-10-13 14:44:50 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="0.10091546607071389" P_Q="0.10091546607071389" P_Z="6.166691708222439E-4" Q="4.58694717567548" RANDOM="NO" SCALE="1.1238613623084368" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="990" TOTAL_2="1002" UNITS="" WEIGHT="300.0" Z="3.4241749075037737">
<NAME>Cognitive function - change from baseline</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0979982260719081" CI_START="0.1224615140868559" DF="0" EFFECT_SIZE="0.610229870079382" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="1.0" P_Z="0.014204802223979407" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="36" WEIGHT="100.0" Z="2.4520421485982404">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="1.0979982260719081" CI_START="0.1224615140868559" EFFECT_SIZE="0.610229870079382" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="0.8" ORDER="4904" SD_1="5.5" SD_2="6.4" SE="0.24886597908940197" STUDY_ID="STD-Fischhof-1989" TOTAL_1="32" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.5879532402822247E-32" CI_END="0.2169780177711511" CI_START="-0.03699573603123758" DF="0" EFFECT_SIZE="0.08999114086995676" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-002.02.02" NO="2" P_CHI2="0.0" P_Z="0.16484562619965779" STUDIES="1" TAU2="0.0" TOTAL_1="471" TOTAL_2="483" WEIGHT="100.0" Z="1.3889576571760454">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.2169780177711511" CI_START="-0.03699573603123757" EFFECT_SIZE="0.08999114086995677" ESTIMABLE="YES" MEAN_1="-1.68" MEAN_2="-1.97" ORDER="4905" SD_1="3.22" SD_2="3.22" SE="0.06479041344782385" STUDY_ID="STD-Morich-1996" TOTAL_1="471" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3123268824522641" CI_START="0.06005510753218779" DF="0" EFFECT_SIZE="0.18619099499222594" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.03" NO="3" P_CHI2="1.0" P_Z="0.0038142219381838965" STUDIES="1" TAU2="0.0" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0" Z="2.8931309857874927">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.3123268824522641" CI_START="0.06005510753218779" EFFECT_SIZE="0.18619099499222594" ESTIMABLE="YES" MEAN_1="-1.37" MEAN_2="-1.97" ORDER="4906" SD_1="3.22" SD_2="3.22" SE="0.06435622718324517" STUDY_ID="STD-Morich-1996" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.402944587280066E-31" CI_END="89.10278842520606" CI_START="6.4644441569132365" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="23.999999999999996" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" I2="100.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.9498912952684262" LOG_CI_START="0.8105311881547856" LOG_EFFECT_SIZE="1.380211241711606" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="2.0486227165914335E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="36" WEIGHT="100.0" Z="4.748567740650657">
<NAME>CGI - Numbers improved compared with baseline</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.402944587280066E-31" CI_END="89.10278842520606" CI_START="6.4644441569132365" DF="0" EFFECT_SIZE="23.999999999999996" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" I2="100.0" ID="CMP-002.03.01" LOG_CI_END="1.9498912952684262" LOG_CI_START="0.8105311881547856" LOG_EFFECT_SIZE="1.380211241711606" NO="1" P_CHI2="0.0" P_Z="2.0486227165914335E-6" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="36" WEIGHT="100.0" Z="4.748567740650657">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="89.10278842520606" CI_START="6.464444156913239" EFFECT_SIZE="24.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" LOG_CI_END="1.9498912952684262" LOG_CI_START="0.8105311881547859" LOG_EFFECT_SIZE="1.380211241711606" ORDER="4907" O_E="0.0" SE="0.6692657668420421" STUDY_ID="STD-Fischhof-1989" TOTAL_1="32" TOTAL_2="36" VAR="0.44791666666666663" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="29.42386081545923" CI_END="0.039749155480581444" CI_START="-0.11390729077491721" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.03707906764716788" ESTIMABLE="YES" I2="93.20279547084724" I2_Q="93.20279547084724" ID="CMP-002.04" MODIFIED="2008-10-13 14:45:04 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="4.080330784361763E-7" P_Q="4.080330784361763E-7" P_Z="0.34418751529106695" Q="29.42386081545923" RANDOM="NO" SCALE="1.9068826006981447" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="990" TOTAL_2="1002" UNITS="" WEIGHT="300.0" Z="0.9459237010848509">
<NAME>Clinical Global Impression - global</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8402145215633391" CI_START="-1.8397854784366614" DF="0" EFFECT_SIZE="-1.3400000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="1.0" P_Z="1.48058189190333E-7" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="36" WEIGHT="100.0" Z="5.254958082213499">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="-0.8402145215633391" CI_START="-1.8397854784366614" EFFECT_SIZE="-1.3400000000000003" ESTIMABLE="YES" MEAN_1="2.69" MEAN_2="4.03" ORDER="4908" SD_1="1.18" SD_2="0.88" SE="0.254997276673911" STUDY_ID="STD-Fischhof-1989" TOTAL_1="32" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5169164193905427E-32" CI_END="0.17042248387297954" CI_START="-0.050422483872980324" DF="0" EFFECT_SIZE="0.0599999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-002.04.02" NO="2" P_CHI2="0.0" P_Z="0.2868845774862233" STUDIES="1" TAU2="0.0" TOTAL_1="471" TOTAL_2="483" WEIGHT="100.0" Z="1.0649809255122031">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.17042248387297954" CI_START="-0.05042248387298032" EFFECT_SIZE="0.05999999999999961" ESTIMABLE="YES" MEAN_1="4.51" MEAN_2="4.45" ORDER="4909" SD_1="0.87" SD_2="0.87" SE="0.056339037219039934" STUDY_ID="STD-Morich-1996" TOTAL_1="471" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.039500263633846386" CI_START="-0.17950026363384697" DF="0" EFFECT_SIZE="-0.07000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.03" NO="3" P_CHI2="1.0" P_Z="0.21022684110917256" STUDIES="1" TAU2="0.0" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0" Z="1.2529419963459927">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.039500263633846386" CI_START="-0.17950026363384697" EFFECT_SIZE="-0.07000000000000028" ESTIMABLE="YES" MEAN_1="4.38" MEAN_2="4.45" ORDER="4910" SD_1="0.87" SD_2="0.87" SE="0.055868508042785876" STUDY_ID="STD-Morich-1996" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.05681998016020194" CI_END="0.03606852184912384" CI_START="-0.04615238802787341" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.005041933089374784" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.8115945856442155" P_Q="0.8115945856442155" P_Z="0.8100380176561266" Q="0.05681998016020194" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="958" TOTAL_2="966" UNITS="" WEIGHT="200.0" Z="0.24037698639966065">
<NAME>Clinical Global Impression - Severity of disease</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.05838430181789743" CI_START="-0.05838430181789743" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="471" TOTAL_2="483" WEIGHT="100.0" Z="0.0">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.05838430181789743" CI_START="-0.05838430181789743" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.19" ORDER="4911" SD_1="0.46" SD_2="0.46" SE="0.029788456460641804" STUDY_ID="STD-Morich-1996" TOTAL_1="471" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.04789669111674651" CI_START="-0.06789669111674654" DF="0" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" NO="2" P_CHI2="1.0" P_Z="0.7349654767858589" STUDIES="1" TAU2="0.0" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0" Z="0.3385278064661522">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.04789669111674651" CI_START="-0.06789669111674654" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="0.19" ORDER="4912" SD_1="0.46" SD_2="0.46" SE="0.029539670919174144" STUDY_ID="STD-Morich-1996" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4160117495331477E-10" CI_END="0.006141218112213423" CI_START="-0.17267764258374219" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08326821223576439" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="0.9999905054695876" P_Q="0.9999905054695876" P_Z="0.06794959000700193" Q="1.4160117495331477E-10" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="958" TOTAL_2="966" UNITS="" WEIGHT="200.0" Z="1.825340978059669">
<NAME>Activities of Daily Living</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.04370993883643716" CI_START="-0.21024526849233427" DF="0" EFFECT_SIZE="-0.08326766482794855" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" NO="1" P_CHI2="1.0" P_Z="0.19869486999092428" STUDIES="1" TAU2="0.0" TOTAL_1="471" TOTAL_2="483" WEIGHT="100.0" Z="1.2852788163406337">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.04370993883643716" CI_START="-0.21024526849233427" EFFECT_SIZE="-0.08326766482794855" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.14" ORDER="4913" SD_1="0.36" SD_2="0.36" SE="0.06478568211761483" STUDY_ID="STD-Morich-1996" TOTAL_1="471" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.04264837419012896" CI_START="-0.20918587526650895" DF="0" EFFECT_SIZE="-0.08326875053819" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" NO="2" P_CHI2="1.0" P_Z="0.19493401317038017" STUDIES="1" TAU2="0.0" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0" Z="1.2961203842974813">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.04264837419012896" CI_START="-0.20918587526650895" EFFECT_SIZE="-0.08326875053819" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.14" ORDER="4914" SD_1="0.36" SD_2="0.36" SE="0.06424461149364843" STUDY_ID="STD-Morich-1996" TOTAL_1="487" TOTAL_2="483" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.13867933607501592" CI_END="2.126456701193111" CI_START="0.6081911793953448" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1372300598523468" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.32765654405716593" LOG_CI_START="-0.21595988272478256" LOG_EFFECT_SIZE="0.05584833066619168" METHOD="PETO" NO="7" P_CHI2="0.7095975865517794" P_Q="0.7095975865517794" P_Z="0.687159327889981" Q="0.13867933607501592" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="150" TOTAL_2="154" WEIGHT="200.0" Z="0.40271305762555876">
<NAME>Withdrawals before end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.513895738576797" CI_START="0.39778897137799935" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.40034726177486524" LOG_CI_START="-0.4003472617748653" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="77" WEIGHT="100.0" Z="0.0">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="2.513895738576797" CI_START="0.39778897137799935" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.40034726177486524" LOG_CI_START="-0.4003472617748653" LOG_EFFECT_SIZE="0.0" ORDER="4915" O_E="0.0" SE="0.47033192663492585" STUDY_ID="STD-Branconnier-1988" TOTAL_1="70" TOTAL_2="77" VAR="4.520547945205479" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.97723874391574" CI_START="0.5412470814914621" DF="0" EFFECT_SIZE="1.269417890628496" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="0.47381366199232133" LOG_CI_START="-0.26660443243178034" LOG_EFFECT_SIZE="0.10360461478027047" NO="2" P_CHI2="1.0" P_Z="0.5833455699927683" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="77" WEIGHT="100.0" Z="0.5485044601980393">
<NAME>nimodipine 180 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="2.97723874391574" CI_START="0.5412470814914622" EFFECT_SIZE="1.269417890628496" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.47381366199232133" LOG_CI_START="-0.2666044324317802" LOG_EFFECT_SIZE="0.10360461478027047" ORDER="4916" O_E="1.261146496815286" SE="0.4349252537933951" STUDY_ID="STD-Branconnier-1988" TOTAL_1="80" TOTAL_2="77" VAR="5.2865305816744" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.363027925909612" CI_END="1.7321642065942804" CI_START="0.8776725519902797" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2329935034978166" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.23858906010479772" LOG_CI_START="-0.05666748339749131" LOG_EFFECT_SIZE="0.09096078835365319" METHOD="PETO" NO="8" P_CHI2="0.5005542315240132" P_Q="0.5005542315240132" P_Z="0.22719083731164602" Q="2.363027925909612" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1236" TOTAL_2="1256" WEIGHT="400.0" Z="1.2076268797554934">
<NAME>Withdrawals before end of treatment due to an adverse event</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.477999815978266" CI_START="0.05714841211671996" DF="0" EFFECT_SIZE="0.5595167477912006" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.7386220133287449" LOG_CI_START="-1.2429958320845669" LOG_EFFECT_SIZE="-0.25218690937791094" NO="1" P_CHI2="1.0" P_Z="0.6178763668096404" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="77" WEIGHT="100.00000000000001" Z="0.49886234209813474">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="5.477999815978266" CI_START="0.05714841211671996" EFFECT_SIZE="0.5595167477912006" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7386220133287449" LOG_CI_START="-1.2429958320845669" LOG_EFFECT_SIZE="-0.25218690937791094" ORDER="4917" O_E="-0.4285714285714286" SE="1.1640121315623142" STUDY_ID="STD-Branconnier-1988" TOTAL_1="70" TOTAL_2="77" VAR="0.7380486441151803" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0018901096286625" CI_START="0.7346190388551244" DF="0" EFFECT_SIZE="1.2126939383987154" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="0.3014402339366326" LOG_CI_START="-0.13393782039233695" LOG_EFFECT_SIZE="0.08375120677214778" NO="2" P_CHI2="1.0" P_Z="0.4508166178635159" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="551" WEIGHT="100.0" Z="0.7540543089071104">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="2.0018901096286625" CI_START="0.7346190388551244" EFFECT_SIZE="1.2126939383987154" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" LOG_CI_END="0.3014402339366326" LOG_CI_START="-0.13393782039233695" LOG_EFFECT_SIZE="0.08375120677214778" ORDER="4918" O_E="2.9484820607175735" SE="0.2557432242689636" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="15.28944523085028" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.858435473756433" CI_START="0.81023120720316" DF="0" EFFECT_SIZE="3.099689418222808" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-002.08.03" LOG_CI_END="1.074027394767321" LOG_CI_START="-0.09139103336285277" LOG_EFFECT_SIZE="0.491318180702234" NO="3" P_CHI2="1.0" P_Z="0.09841904632345705" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="77" WEIGHT="100.0" Z="1.6525668650548586">
<NAME>nimodipine 180 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="11.858435473756433" CI_START="0.81023120720316" EFFECT_SIZE="3.099689418222808" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.074027394767321" LOG_CI_START="-0.09139103336285277" LOG_EFFECT_SIZE="0.491318180702234" ORDER="4919" O_E="2.4140127388535033" SE="0.684572553597923" STUDY_ID="STD-Branconnier-1988" TOTAL_1="80" TOTAL_2="77" VAR="2.1338359802394855" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8949203213381969" CI_START="0.690641260937287" DF="0" EFFECT_SIZE="1.1439887062837208" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" I2="0.0" ID="CMP-002.08.04" LOG_CI_END="0.2775909532325025" LOG_CI_START="-0.16074747918365043" LOG_EFFECT_SIZE="0.058421737024426046" NO="4" P_CHI2="1.0" P_Z="0.6013585028506248" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="0.5224479170169417">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.8949203213381969" CI_START="0.690641260937287" EFFECT_SIZE="1.1439887062837208" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" LOG_CI_END="0.2775909532325025" LOG_CI_START="-0.16074747918365043" LOG_EFFECT_SIZE="0.058421737024426046" ORDER="4920" O_E="2.029064486830155" SE="0.2574821650114829" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="15.083623920455436" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.975787132640905E-5" CI_END="0.9454787318497742" CI_START="0.6567426907381784" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7879950801818126" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="362" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-0.024348235982526657" LOG_CI_START="-0.1826047520245576" LOG_EFFECT_SIZE="-0.10347649400354211" METHOD="PETO" MODIFIED="2008-10-13 14:45:39 +0100" MODIFIED_BY="Helen Collins" NO="9" P_CHI2="0.9964534285984646" P_Q="0.9964534285984646" P_Z="0.010375514208858575" Q="1.975787132640905E-5" RANDOM="NO" SCALE="2.161292143466225" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1086" TOTAL_2="1102" WEIGHT="200.0" Z="2.5630565687362106">
<NAME>number of patients with at least one adverse event by end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0199996095828634" CI_START="0.6082552111779392" DF="0" EFFECT_SIZE="0.7876674919839208" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="181" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="0.00860000553050529" LOG_CI_START="-0.21591416159791932" LOG_EFFECT_SIZE="-0.10365707803370706" NO="1" P_CHI2="1.0" P_Z="0.0703250531030977" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="551" WEIGHT="100.0" Z="1.8098113120185564">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.0199996095828634" CI_START="0.6082552111779392" EFFECT_SIZE="0.7876674919839208" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="181" LOG_CI_END="0.00860000553050529" LOG_CI_START="-0.21591416159791932" LOG_EFFECT_SIZE="-0.10365707803370706" ORDER="4921" O_E="-13.723091076356951" SE="0.13188073313428772" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="57.49595533823134" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0191933263106379" CI_START="0.6097433936322632" DF="0" EFFECT_SIZE="0.7883187157184605" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="181" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="0.008256571235434261" LOG_CI_START="-0.214852896425624" LOG_EFFECT_SIZE="-0.10329816259509488" NO="2" P_CHI2="1.0" P_Z="0.06953928968220807" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="1.8148999276276456">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.0191933263106379" CI_START="0.6097433936322632" EFFECT_SIZE="0.7883187157184605" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="181" LOG_CI_END="0.008256571235434261" LOG_CI_START="-0.214852896425624" LOG_EFFECT_SIZE="-0.10329816259509488" ORDER="4922" O_E="-13.848319709355138" SE="0.1310556057137822" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="58.22222469705932" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.120808388766101" CI_END="2.8258213371549545" CI_START="1.3411775265248647" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9467737596769346" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="40" I2="3.871060754674076" I2_Q="3.871060754674076" ID="CMP-002.10" LOG_CI_END="0.45114470006718843" LOG_CI_START="0.1274862675512853" LOG_EFFECT_SIZE="0.2893154838092369" METHOD="PETO" NO="10" P_CHI2="0.37337163647305405" P_Q="0.37337163647305405" P_Z="4.583428566694291E-4" Q="3.120808388766101" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1236" TOTAL_2="1256" WEIGHT="400.0" Z="3.5039898329114174">
<NAME>number of patients with at least one serious adverse event before end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.877216094799277" CI_START="0.0545570753123135" DF="0" EFFECT_SIZE="0.3961975456432873" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.4589724810264141" LOG_CI_START="-1.2631489193224101" LOG_EFFECT_SIZE="-0.40208821914799797" NO="1" P_CHI2="1.0" P_Z="0.36006490885013276" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="77" WEIGHT="100.0" Z="0.915241431850618">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="2.8772160947992784" CI_START="0.05455707531231348" EFFECT_SIZE="0.3961975456432873" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4589724810264143" LOG_CI_START="-1.2631489193224104" LOG_EFFECT_SIZE="-0.40208821914799797" ORDER="4923" O_E="-0.9047619047619047" SE="1.0115826352033148" STUDY_ID="STD-Branconnier-1988" TOTAL_1="70" TOTAL_2="77" VAR="0.9772310750784331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9553245942607265" CI_START="1.337134256688934" DF="0" EFFECT_SIZE="2.2997391180980236" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="17" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.5971821297330107" LOG_CI_START="0.12617501534865075" LOG_EFFECT_SIZE="0.3616785725408307" NO="2" P_CHI2="1.0" P_Z="0.002612065348661385" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="551" WEIGHT="100.0" Z="3.0100478507057744">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="3.9553245942607265" CI_START="1.337134256688934" EFFECT_SIZE="2.2997391180980236" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="17" LOG_CI_END="0.5971821297330107" LOG_CI_START="0.12617501534865075" LOG_EFFECT_SIZE="0.3616785725408307" ORDER="4924" O_E="10.879484820607175" SE="0.27667191051219153" STUDY_ID="STD-Morich-1996" TOTAL_1="536" TOTAL_2="551" VAR="13.063810195740807" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.863240344859335" CI_START="0.2854412334933232" DF="0" EFFECT_SIZE="1.2936810102588916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.10.03" LOG_CI_END="0.7681376970684339" LOG_CI_START="-0.5444832905586436" LOG_EFFECT_SIZE="0.11182720325489523" NO="3" P_CHI2="1.0" P_Z="0.7384145283346378" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="77" WEIGHT="100.0" Z="0.33395365903398816">
<NAME>nimodipine 180 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="5.863240344859335" CI_START="0.2854412334933232" EFFECT_SIZE="1.2936810102588916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7681376970684339" LOG_CI_START="-0.5444832905586436" LOG_EFFECT_SIZE="0.11182720325489523" ORDER="4925" O_E="0.43312101910828016" SE="0.7710400657108257" STUDY_ID="STD-Branconnier-1988" TOTAL_1="80" TOTAL_2="77" VAR="1.6820779123509455" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4517362759383925" CI_START="1.110269386493788" DF="0" EFFECT_SIZE="1.9576407018205542" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" I2="0.0" ID="CMP-002.10.04" LOG_CI_END="0.5380376067766672" LOG_CI_START="0.04542836515917347" LOG_EFFECT_SIZE="0.29173298596792036" NO="4" P_CHI2="1.0" P_Z="0.0202620697985021" STUDIES="1" TAU2="0.0" TOTAL_1="550" TOTAL_2="551" WEIGHT="100.0" Z="2.3214592715393643">
<NAME>nimodipine 180 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="3.4517362759383925" CI_START="1.110269386493788" EFFECT_SIZE="1.9576407018205542" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5380376067766672" LOG_CI_START="0.04542836515917347" LOG_EFFECT_SIZE="0.29173298596792036" ORDER="4926" O_E="8.022706630336057" SE="0.2893611069811888" STUDY_ID="STD-Morich-1996" TOTAL_1="550" TOTAL_2="551" VAR="11.943171965705357" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-10-13 14:46:22 +0100" MODIFIED_BY="Helen Collins" NO="3">
<NAME>Nimodipine vs placebo (vascular dementia)</NAME>
<CONT_OUTCOME CHI2="42.36420267648351" CI_END="-1.61284158918403" CI_START="-3.2739746759931094" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.4434081325885697" ESTIMABLE="YES" I2="95.27903306649459" I2_Q="95.64721442675878" ID="CMP-003.01" MODIFIED="2008-10-13 14:45:58 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="6.320367562651086E-10" P_Q="1.6422721355047187E-6" P_Z="8.120679769754433E-9" Q="22.973794210022746" RANDOM="NO" SCALE="31.067855869525317" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="158" TOTAL_2="123" UNITS="" WEIGHT="199.99999999999994" Z="5.7659340813025235">
<NAME>SCAG - change from baseline</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="19.390408466460762" CI_END="-7.853424401647108" CI_START="-15.641908364665042" DF="1" EFFECT_SIZE="-11.747666383156075" ESTIMABLE="YES" I2="94.8428110643998" ID="CMP-003.01.01" NO="1" P_CHI2="1.0654223337791535E-5" P_Z="3.367976571338942E-9" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="67" WEIGHT="99.99999999999997" Z="5.912576342894837">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="-17.298841609610715" CI_START="-30.701158390389285" EFFECT_SIZE="-24.0" ESTIMABLE="YES" MEAN_1="-29.3" MEAN_2="-5.3" ORDER="4927" SD_1="12.9" SD_2="15.2" SE="3.419021187760167" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="34" WEIGHT="33.77116963868148"/>
<CONT_DATA CI_END="-0.7148077386204665" CI_START="-10.285192261379533" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="0.0" ORDER="4928" SD_1="8.5" SD_2="10.7" SE="2.441469485727554" STUDY_ID="STD-Fischhof-1989" TOTAL_1="29" TOTAL_2="33" WEIGHT="66.2288303613185"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.1498728555625437" CI_START="-2.850127144437457" DF="0" EFFECT_SIZE="-2.0000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="1.0" P_Z="4.007553479417905E-6" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="55" WEIGHT="99.99999999999999" Z="4.610990243905211">
<NAME>nimodipine 90 mg/day, 52 week assessment per protocol</NAME>
<CONT_DATA CI_END="-1.1498728555625437" CI_START="-2.850127144437457" EFFECT_SIZE="-2.0000000000000004" ESTIMABLE="YES" MEAN_1="-4.9" MEAN_2="-2.9" ORDER="4929" SD_1="2.16" SD_2="2.76" SE="0.4337463091889194" STUDY_ID="STD-Pantoni-2005" TOTAL_1="94" TOTAL_2="55" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>nimodipine 90 mg/day, 52 week assessment ITT analysis</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="4930" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Pantoni-2005" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.94724664639078" CI_END="0.3764846129857564" CI_START="0.014088590033437515" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.19528660150959695" ESTIMABLE="YES" I2="19.14694605092785" I2_Q="58.691942553381715" ID="CMP-003.02" NO="2" P_CHI2="0.29275333570232975" P_Q="0.11973128612477124" P_Z="0.034655926487118245" Q="2.4208352118525145" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="229" TOTAL_2="245" UNITS="" WEIGHT="200.0" Z="2.112355993886805">
<NAME>Cognitive function - change from baseline</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1267269073773192" CI_END="0.6456870413172412" CI_START="0.08476299755456052" DF="2" EFFECT_SIZE="0.36522501943590086" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="0.5692912087487126" P_Z="0.010700921943283766" STUDIES="3" TAU2="0.0" TOTAL_1="96" TOTAL_2="104" WEIGHT="99.99999999999999" Z="2.5523166364755223">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="0.9841391291254156" CI_START="0.048412287335832416" EFFECT_SIZE="0.516275708230624" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="5.7" ORDER="4931" SD_1="7.9" SD_2="6.7" SE="0.23871021334332596" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="39" WEIGHT="35.9343618961624"/>
<CONT_DATA CI_END="0.9161119319390761" CI_START="-0.09280421140611106" EFFECT_SIZE="0.41165386026648254" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="1.0" ORDER="4932" SD_1="5.5" SD_2="6.4" SE="0.2573812966216188" STUDY_ID="STD-Fischhof-1989" TOTAL_1="29" TOTAL_2="33" WEIGHT="30.909926353457667"/>
<CONT_DATA CI_END="0.6453052857061329" CI_START="-0.3288425693345166" EFFECT_SIZE="0.1582313581858081" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.3" ORDER="4933" SD_1="5.7" SD_2="2.3" SE="0.24851167233801322" STUDY_ID="STD-Tobares-1989" TOTAL_1="33" TOTAL_2="32" WEIGHT="33.15571175037993"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3996845271609464" CI_END="0.3109266791059755" CI_START="-0.16386208801336147" DF="1" EFFECT_SIZE="0.07353229554630702" ESTIMABLE="YES" I2="28.55532939066259" ID="CMP-003.02.02" NO="2" P_CHI2="0.2367766144411998" P_Z="0.5437886885840086" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="141" WEIGHT="100.0" Z="0.6070937686488798">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.26553372052211854" CI_START="-0.27726514445923345" EFFECT_SIZE="-0.005865711968557435" ESTIMABLE="YES" MEAN_1="-0.68" MEAN_2="-0.66" ORDER="4934" SD_1="3.49" SD_2="3.31" SE="0.13847164265845704" STUDY_ID="STD-Pantoni-2000" TOTAL_1="100" TOTAL_2="109" WEIGHT="76.51084693704338"/>
<CONT_DATA CI_END="0.8219744487890968" CI_START="-0.15766610831190025" EFFECT_SIZE="0.3321541702385983" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="0.3" ORDER="4935" SD_1="5.3" SD_2="2.5" SE="0.24991289759104676" STUDY_ID="STD-Tobares-1989" TOTAL_1="33" TOTAL_2="32" WEIGHT="23.489153062956614"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="60.86619361380298" CI_START="4.888797579294003" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="17.25" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="1.7843761431492633" LOG_CI_START="0.6892020556693227" LOG_EFFECT_SIZE="1.236789099409293" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="9.563828545677876E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="29" TOTAL_2="33" WEIGHT="100.0" Z="4.426806877602175">
<NAME>CGI - Numbers improved compared with baseline</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="60.86619361380298" CI_START="4.888797579294003" DF="0" EFFECT_SIZE="17.25" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="1.7843761431492633" LOG_CI_START="0.6892020556693227" LOG_EFFECT_SIZE="1.236789099409293" NO="1" P_CHI2="1.0" P_Z="9.563828545677876E-6" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="33" WEIGHT="100.0" Z="4.426806877602175">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="60.86619361380298" CI_START="4.888797579294003" EFFECT_SIZE="17.25" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="1.7843761431492633" LOG_CI_START="0.6892020556693227" LOG_EFFECT_SIZE="1.236789099409293" ORDER="4936" O_E="0.0" SE="0.643310680184882" STUDY_ID="STD-Fischhof-1989" TOTAL_1="29" TOTAL_2="33" VAR="0.4138486312399356" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="25.93281845489807" CI_END="-0.16814694095787514" CI_START="-0.6184378956875503" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.39329241832271267" ESTIMABLE="YES" I2="96.14388230982613" I2_Q="96.14388230982613" ID="CMP-003.04" MODIFIED="2008-10-13 14:46:22 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="3.5351387051019145E-7" P_Q="3.5351387051019145E-7" P_Z="6.176629176095396E-4" Q="25.93281845489807" RANDOM="NO" SCALE="1.8095267385696576" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="129" TOTAL_2="142" UNITS="" WEIGHT="200.0" Z="3.423737328980719">
<NAME>Clinical Global Impression - global</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8914633460952499" CI_START="-1.7285366539047493" DF="0" EFFECT_SIZE="-1.3099999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="8.537647051083668E-10" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="33" WEIGHT="100.0" Z="6.134594893406378">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="-0.8914633460952499" CI_START="-1.7285366539047493" EFFECT_SIZE="-1.3099999999999996" ESTIMABLE="YES" MEAN_1="2.75" MEAN_2="4.06" ORDER="4937" SD_1="0.91" SD_2="0.75" SE="0.2135430330384198" STUDY_ID="STD-Fischhof-1989" TOTAL_1="29" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.24708080157453033" CI_START="-0.28708080157453036" DF="0" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="1.0" P_Z="0.8833140658902475" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="109" WEIGHT="100.0" Z="0.14676936514982844">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.24708080157453033" CI_START="-0.28708080157453036" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="3.97" MEAN_2="3.99" ORDER="4938" SD_1="0.94" SD_2="1.03" SE="0.13626821904954867" STUDY_ID="STD-Pantoni-2000" TOTAL_1="100" TOTAL_2="109" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.08328790417604127" CI_START="-0.22328790417604127" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.3707703426324237" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="109" UNITS="" WEIGHT="100.0" Z="0.8950313441577316">
<NAME>Clinical Global Impression - Severity of disease</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.08328790417604127" CI_START="-0.22328790417604127" DF="0" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" NO="1" P_CHI2="1.0" P_Z="0.3707703426324237" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="109" WEIGHT="100.0" Z="0.8950313441577316">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.08328790417604127" CI_START="-0.22328790417604127" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="-0.11" ORDER="4939" SD_1="0.56" SD_2="0.57" SE="0.07820955149439311" STUDY_ID="STD-Pantoni-2000" TOTAL_1="100" TOTAL_2="109" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.06240695846585366" CI_END="-0.0025848169202836724" CI_START="-0.4299529504882911" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21626888370428737" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.969278325238884" P_Q="0.8091333566546821" P_Z="0.04729235276889213" Q="0.058343606401853716" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="166" TOTAL_2="173" UNITS="" WEIGHT="200.0" Z="1.9836725752021118">
<NAME>Activities of Daily Living</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3247947789875315" CI_START="-0.6494377465100641" DF="0" EFFECT_SIZE="-0.16232148376126632" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" NO="1" P_CHI2="1.0" P_Z="0.5136803944144557" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.6531177183325736">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<CONT_DATA CI_END="0.32479477898753145" CI_START="-0.649437746510064" EFFECT_SIZE="-0.16232148376126632" ESTIMABLE="YES" MEAN_1="-0.43" MEAN_2="-0.19" ORDER="4940" SD_1="1.17" SD_2="1.71" SE="0.2485332723412821" STUDY_ID="STD-Tobares-1989" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.004063352063999943" CI_END="0.008660244240842108" CI_START="-0.46690793886166604" DF="1" EFFECT_SIZE="-0.22912384731041197" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" NO="2" P_CHI2="0.949173728493708" P_Z="0.05894801106199179" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="141" WEIGHT="100.0" Z="1.8885808793935426">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<CONT_DATA CI_END="0.038895805398314776" CI_START="-0.5057793896950962" EFFECT_SIZE="-0.23344179214839073" ESTIMABLE="YES" MEAN_1="0.07" MEAN_2="0.15" ORDER="4941" SD_1="0.32" SD_2="0.36" SE="0.13895030709485975" STUDY_ID="STD-Pantoni-2000" TOTAL_1="100" TOTAL_2="109" WEIGHT="76.23429483357464"/>
<CONT_DATA CI_END="0.27248843015231416" CI_START="-0.7030344026867573" EFFECT_SIZE="-0.2152729862672216" ESTIMABLE="YES" MEAN_1="-0.63" MEAN_2="-0.24" ORDER="4942" SD_1="1.62" SD_2="1.95" SE="0.24886243842587696" STUDY_ID="STD-Tobares-1989" TOTAL_1="33" TOTAL_2="32" WEIGHT="23.76570516642537"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.7063528685496245" CI_END="4.139078946714646" CI_START="0.366824214839106" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2321990037269444" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="73.01929860792445" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.6169037099947573" LOG_CI_START="-0.4355420033621791" LOG_EFFECT_SIZE="0.09068085331628915" METHOD="PETO" NO="7" P_CHI2="0.05420594861806238" P_Q="1.0" P_Z="0.7355523992806551" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="138" TOTAL_2="141" WEIGHT="100.0" Z="0.33774892962485525">
<NAME>Withdrawals before end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7063528685496245" CI_END="4.139078946714646" CI_START="0.366824214839106" DF="1" EFFECT_SIZE="1.2321990037269444" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="73.01929860792445" ID="CMP-003.07.01" LOG_CI_END="0.6169037099947573" LOG_CI_START="-0.4355420033621791" LOG_EFFECT_SIZE="0.09068085331628915" NO="1" P_CHI2="0.05420594861806238" P_Z="0.7355523992806551" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="141" WEIGHT="100.0" Z="0.33774892962485525">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="102.29824003226075" CI_START="0.8544440687358337" EFFECT_SIZE="9.349231221746512" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0098681620518235" LOG_CI_START="-0.06831636060199149" LOG_EFFECT_SIZE="0.9707759007249159" ORDER="4943" O_E="1.5" SE="1.2207358757861475" STUDY_ID="STD-Besson-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.6710526315789473" WEIGHT="25.64668247630351"/>
<DICH_DATA CI_END="2.4967568977372" CI_START="0.15025995434777928" EFFECT_SIZE="0.6125051652610733" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3973762583661568" LOG_CI_START="-0.8231567474442884" LOG_EFFECT_SIZE="-0.21289024453906571" ORDER="4944" O_E="-0.9536679536679538" SE="0.7169471293488741" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="1.9454753821279818" WEIGHT="74.35331752369649"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5012552335159948" CI_END="1.2785533094403376" CI_START="0.5022472184003439" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8013425255425821" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.10671884070267698" LOG_CI_START="-0.2990824598295424" LOG_EFFECT_SIZE="-0.0961818095634327" METHOD="PETO" MODIFIED="2008-10-10 17:05:12 +0100" MODIFIED_BY="Helen Collins" NO="8" P_CHI2="0.47894915551534745" P_Q="0.47894915551534745" P_Z="0.3528426679594653" Q="0.5012552335159948" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="162" TOTAL_2="165" WEIGHT="200.0" Z="0.9290895936754198">
<NAME>number of patients with at least one adverse event by end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.179805752398698" CI_START="0.31980000654930724" DF="0" EFFECT_SIZE="1.2870516359265634" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.7143134735979066" LOG_CI_START="-0.4951215316957004" LOG_EFFECT_SIZE="0.1095959709511031" NO="1" P_CHI2="1.0" P_Z="0.7224292371594836" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="100.0" Z="0.35521405445464743">
<NAME>nimodipine 90 mg/day, 12 week assessment</NAME>
<DICH_DATA CI_END="5.179805752398698" CI_START="0.31980000654930724" EFFECT_SIZE="1.2870516359265634" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7143134735979066" LOG_CI_START="-0.4951215316957004" LOG_EFFECT_SIZE="0.1095959709511031" ORDER="4945" O_E="0.5" SE="0.7104281089092949" STUDY_ID="STD-Dorn-1985" TOTAL_1="34" TOTAL_2="34" VAR="1.9813432835820894" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2390802540384844" CI_START="0.4595428891987057" DF="0" EFFECT_SIZE="0.7545929498013557" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="57" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="0.0930994361236934" LOG_CI_START="-0.33767394962477904" LOG_EFFECT_SIZE="-0.12228725675054282" NO="2" P_CHI2="1.0" P_Z="0.2658017185187551" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="1.112782854877735">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.2390802540384847" CI_START="0.4595428891987057" EFFECT_SIZE="0.7545929498013557" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="57" LOG_CI_END="0.09309943612369348" LOG_CI_START="-0.33767394962477904" LOG_EFFECT_SIZE="-0.12228725675054282" ORDER="4946" O_E="-4.3976833976833944" SE="0.25303841915130254" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="15.618059342581208" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.412631103317777" CI_START="0.35744453037235835" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7105893760216297" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.1500287643182129" LOG_CI_START="-0.44679134413507676" LOG_EFFECT_SIZE="-0.14838128990843197" METHOD="PETO" MODIFIED="2008-10-10 17:05:12 +0100" MODIFIED_BY="Helen Collins" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.3297727856867698" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="0.974571667679942">
<NAME>number of patients with at least one serious adverse event before end of treatment</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.412631103317777" CI_START="0.35744453037235835" DF="0" EFFECT_SIZE="0.7105893760216297" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.1500287643182129" LOG_CI_START="-0.44679134413507676" LOG_EFFECT_SIZE="-0.14838128990843197" NO="1" P_CHI2="1.0" P_Z="0.3297727856867698" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="0.974571667679942">
<NAME>nimodipine 90 mg/day, 24 week assessment</NAME>
<DICH_DATA CI_END="1.412631103317777" CI_START="0.35744453037235835" EFFECT_SIZE="0.7105893760216297" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.1500287643182129" LOG_CI_START="-0.44679134413507676" LOG_EFFECT_SIZE="-0.14838128990843197" ORDER="4947" O_E="-2.7799227799227815" SE="0.35057508601264564" STUDY_ID="STD-Pantoni-2000" TOTAL_1="128" TOTAL_2="131" VAR="8.13650510911892" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-05-19 15:52:31 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-05-19 15:47:32 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-05-19 15:35:30 +0100" MODIFIED_BY="[Empty name]">Update search: March 2010</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-19 15:47:32 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="12">
<TR>
<TH>
<P>Source</P>
</TH>
<TH>
<P>Search strategy</P>
</TH>
<TH>
<P>Hits</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>MEDLINE In-process and other non-indexed citations and MEDLINE 1950-present (Ovid SP)</B>
</P>
</TD>
<TD>
<P>1. exp Dementia/</P>
<P>2. Delirium/</P>
<P>3. Wernicke Encephalopathy/</P>
<P>4. Delirium, Dementia, Amnestic, Cognitive Disorders/</P>
<P>5. dement*.mp.</P>
<P>6. alzheimer*.mp.</P>
<P>7. (lewy* adj2 bod*).mp.</P>
<P>8. deliri*.mp.</P>
<P>9. (chronic adj2 cerebrovascular).mp.</P>
<P>10. ("organic brain disease" or "organic brain syndrome").mp.</P>
<P>11. ("normal pressure hydrocephalus" and "shunt*").mp.</P>
<P>12. "benign senescent forgetfulness".mp.</P>
<P>13. (cerebr* adj2 deteriorat*).mp.</P>
<P>14. (cerebral* adj2 insufficient*).mp.</P>
<P>15. (pick* adj2 disease).mp.</P>
<P>16. (creutzfeldt or jcd or cjd).mp.</P>
<P>17. huntington*.mp.</P>
<P>18. binswanger*.mp.</P>
<P>19. korsako*.mp.</P>
<P>20. or/1-19</P>
<P>21. Nimodipine/</P>
<P>22. nimodipin*.mp.</P>
<P>23. nimotop*.mp.</P>
<P>24. or/21-23</P>
<P>25. 20 and 24</P>
<P>26. randomized controlled trial.pt.</P>
<P>27. controlled clinical trial.pt.</P>
<P>28. random*.ab.</P>
<P>29. placebo.ab.</P>
<P>30. drug therapy.fs.</P>
<P>31. trial.ab.</P>
<P>32. groups.ab.</P>
<P>33. or/26-32</P>
<P>34. (animals not (humans and animals)).sh.</P>
<P>35. 33 not 34</P>
<P>36. 25 and 35</P>
<P>37. 2008*.ed.</P>
<P>38. 2009*.ed.</P>
<P>39. 2010*.ed.</P>
<P>40. or/37-39</P>
<P>41. 36 and 40</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>EMBASE</B>
</P>
<P>
<B>1980-2010 week 5 (Ovid SP)</B>
</P>
</TD>
<TD>
<P>1. exp dementia/</P>
<P>2. Lewy body/</P>
<P>3. delirium/</P>
<P>4. Wernicke encephalopathy/</P>
<P>5. cognitive defect/</P>
<P>6. dement*.mp.</P>
<P>7. alzheimer*.mp.</P>
<P>8. (lewy* adj2 bod*).mp.</P>
<P>9. deliri*.mp.</P>
<P>10. (chronic adj2 cerebrovascular).mp.</P>
<P>11. ("organic brain disease" or "organic brain syndrome").mp.</P>
<P>12. "supranuclear palsy".mp.</P>
<P>13. ("normal pressure hydrocephalus" and "shunt*").mp.</P>
<P>14. "benign senescent forgetfulness".mp.</P>
<P>15. (cerebr* adj2 deteriorat*).mp.</P>
<P>16. (cerebral* adj2 insufficient*).mp.</P>
<P>17. (pick* adj2 disease).mp.</P>
<P>18. (creutzfeldt or jcd or cjd).mp.</P>
<P>19. huntington*.mp.</P>
<P>20. binswanger*.mp.</P>
<P>21. korsako*.mp.</P>
<P>22. CADASIL.mp.</P>
<P>23. or/1-22</P>
<P>24. nimodipine/</P>
<P>25. nimodipin*.mp.</P>
<P>26. nimotop*.mp.</P>
<P>27. or/24-26</P>
<P>28. 23 and 27</P>
<P>29. 2008*.em.</P>
<P>30. 2009*.em.</P>
<P>31. 2010*.em.</P>
<P>32. or/29-31</P>
<P>33. 32 and 28</P>
<P>34. randomized controlled trial/</P>
<P>35. controlled clinical trial/</P>
<P>36. random*.mp.</P>
<P>37. placebo.ab.</P>
<P>38. trial.ab.</P>
<P>39. groups.ab.</P>
<P>40. "control group".ab.</P>
<P>41. or/34-40</P>
<P>42. 33 and 41</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>PSYCINFO</B>
</P>
<P>
<B>1806-February week 1 2010 (Ovid SP)</B>
</P>
</TD>
<TD>
<P>1. exp Dementia/</P>
<P>2. exp Delirium/</P>
<P>3. exp Huntingtons Disease/</P>
<P>4. exp Kluver Bucy Syndrome/</P>
<P>5. exp Wernickes Syndrome/</P>
<P>6. exp Cognitive Impairment/</P>
<P>7. dement*.mp.</P>
<P>8. alzheimer*.mp.</P>
<P>9. (lewy* adj2 bod*).mp.</P>
<P>10. deliri*.mp.</P>
<P>11. (chronic adj2 cerebrovascular).mp.</P>
<P>12. ("organic brain disease" or "organic brain syndrome").mp.</P>
<P>13. "supranuclear palsy".mp.</P>
<P>14. ("normal pressure hydrocephalus" and "shunt*").mp.</P>
<P>15. "benign senescent forgetfulness".mp.</P>
<P>16. (cerebr* adj2 deteriorat*).mp.</P>
<P>17. (cerebral* adj2 insufficient*).mp.</P>
<P>18. (pick* adj2 disease).mp.</P>
<P>19. (creutzfeldt or jcd or cjd).mp.</P>
<P>20. huntington*.mp.</P>
<P>21. binswanger*.mp.</P>
<P>22. korsako*.mp.</P>
<P>23. ("parkinson* disease dementia" or PDD or "parkinson* dementia").mp.</P>
<P>24. or/1-23</P>
<P>25. nimodipin*.mp.</P>
<P>26. nimotop*.mp.</P>
<P>27. or/25-26</P>
<P>28. 24 and 27</P>
<P>29. 2008*.up.</P>
<P>30. 2009*.up.</P>
<P>31. 2010*.up.</P>
<P>32. or/29-31</P>
<P>33. 28 and 32</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>CINAHL (EbscoHOST)</B>
</P>
</TD>
<TD>
<P>S1 <B> </B>(MH "Dementia+")  </P>
<P>S2  (MH "Delirium")  </P>
<P>S3  (MH "Wernicke's Encephalopathy")  </P>
<P>S4  TX dement*</P>
<P>S5  TX alzheimer*</P>
<P>S6  TX lewy* N2 bod*</P>
<P>S7  TX deliri*</P>
<P>S8  TX chronic N2 cerebrovascular  </P>
<P>S9  TX "organic brain disease" or "organic brain syndrome" </P>
<P>S10  TX "normal pressure hydrocephalus" and "shunt*"  </P>
<P>S11  TX "benign senescent forgetfulness" </P>
<P>S12  TX cerebr* N2 deteriorat* </P>
<P>S13  TX cerebral* N2 insufficient*  </P>
<P>S14  TX pick* N2 disease  </P>
<P>S15  TX creutzfeldt or jcd or cjd  </P>
<P>S16  TX huntington*</P>
<P>S17  TX binswanger*</P>
<P>S18  TX korsako* </P>
<P>S19  S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18  </P>
<P>S20  (MH "Nimodipine")</P>
<P>S21  TX nimodipin* </P>
<P>S22  TX nimotop*</P>
<P>S23  S20 or S21 or S22  </P>
<P>S24  S19 and S23  </P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Web of Science with Conference Proceedings (1945 to present) (ISI Web of Knowledge)</B>
</P>
</TD>
<TD>
<P>Topic=(dement* OR alzheimer* OR "lew* bod*" OR cognit*) AND Topic=(nimodipin* OR nimotp) AND Topic=(random* OR placebo* OR group* OR trial OR study)</P>
<P>Timespan=2008-2010. Databases=SCI-EXPANDED, SSCI, CPCI-S.</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>LILACS (BIREME)</B>
</P>
</TD>
<TD>
<P>dement$ OR demenc$ OR alzheimer$ OR cognit$ [Words] and nimodipine OR nimotop$ [Words]</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>ALOIS (www.medicine.ox.ac.uk/alois)</B>
</P>
</TD>
<TD>
<P>Advanced search: [Study aim: Treatment dementia] AND [Study design: RCT] AND [Intervention: starts with: nimo]</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Umin (Clinical Trial register of Japan)</B>
</P>
</TD>
<TD>
<P>Nimodipine OR nimotop</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>CENTRAL (<I>The Cochrane Library</I>)</B>
</P>
</TD>
<TD>
<P>#1MeSH descriptor Dementia explode all trees</P>
<P>#2 MeSH descriptor Delirium explode all trees</P>
<P>#3 MeSH descriptor Wernicke Encephalopathy explode all trees</P>
<P>#4 MeSH descriptor Delirium, Dementia, Amnestic, Cognitive Disorders explode all trees</P>
<P>#5 dement*</P>
<P>#6 alzheimer*</P>
<P>#7 lewy* adj2 bod*</P>
<P>#8 deliri*</P>
<P>#9 chronic adj2 cerebrovascular</P>
<P>#10 "organic brain disease" or "organic brain syndrome"</P>
<P>#11 "normal pressure hydrocephalus" and "shunt*"</P>
<P>#12 "benign senescent forgetfulness"</P>
<P>#13 cerebr* adj2 deteriorat*</P>
<P>#14 cerebral* adj2 insufficient*</P>
<P>#15 pick* adj2 disease</P>
<P>#16 creutzfeldt or jcd or cjd</P>
<P>#17 huntington*</P>
<P>#18 binswanger*</P>
<P>#19 korsako*</P>
<P>#20 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19)</P>
<P>#21 MeSH descriptor Nimodipine explode all trees</P>
<P>#22 nimodipin*</P>
<P>#23 nimotop*</P>
<P>#24 (#21 OR #22 OR #23)</P>
<P>#25 (#20 AND #24), from 2008 to 2010</P>
<P>#26 (#20 AND #24), from 2008 to 2010</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Clinicaltrials.gov</B>
</P>
</TD>
<TD>
<P>Keyword search: nimodipine OR nimotop</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>ICTRP Search Portal</B>
</P>
</TD>
<TD>
<P>nimodipine OR nimotop</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-05-19 15:52:31 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-05-19 15:49:01 +0100" MODIFIED_BY="[Empty name]">Update search: January 2008</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-19 15:52:31 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P>Source</P>
</TH>
<TH>
<P>Search strategy</P>
</TH>
<TH>
<P>Hits</P>
</TH>
</TR>
<TR>
<TD>
<P>CDCIG SR (now ALOIS)</P>
</TD>
<TD>
<P>nimodipin*</P>
</TD>
<TD>
<P>103</P>
</TD>
</TR>
<TR>
<TD>
<P>PubMed</P>
</TD>
<TD>
<P>nimodipin* (ti, ab, Mesh)</P>
<P>AND</P>
<P>(((Dementia  OR  Alzheimer$ OR (Lewy body) OR arteriosclerosis OR (Huntington disease) OR (Kluver Bucy) OR (Pick disease) OR delirium OR (cerebrovascular disorder$) OR (Wernicke encephalopathy) OR (Korsakoff psychosis) OR ((cognit$ or memory$ or mental$) AND (declin$ or impair$ or los$ or deteriorat$)) OR (cerebr$ deteriorat$) OR (cerebr$ insufficien$)</P>
</TD>
<TD>
<P>18</P>
</TD>
</TR>
<TR>
<TD>
<P>Embase, CENTRAL,PsycINFO, CINAHL (Ovid SP)</P>
</TD>
<TD>
<P>nimodipin*</P>
<P>  AND</P>
<P>Phases 1-3 of the Highly sensitive search strategies for identifying reports of randomized controlled trials in Medline (APPENDIX 5b, Cochrane Handbook, 2006), all terms searched as Title, abstract, keyword, Publication type.</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>LILACS (BIREME)</P>
</TD>
<TD>
<P>nimodipin*</P>
<P>AND (Alzheimer$ OR dementia OR vascular OR vascular cognitive impairment OR multi-infarct )</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>